
<html lang="en"     class="pb-page"  data-request-id="799b8b5d-a311-4190-b200-f09390f6251a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.9b01348;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms" /></meta><meta name="dc.Creator" content="Tao  Yang" /></meta><meta name="dc.Creator" content="Mengshi  Hu" /></meta><meta name="dc.Creator" content="Wenyan  Qi" /></meta><meta name="dc.Creator" content="Zhuang  Yang" /></meta><meta name="dc.Creator" content="Minghai  Tang" /></meta><meta name="dc.Creator" content="Jun  He" /></meta><meta name="dc.Creator" content="Yong  Chen" /></meta><meta name="dc.Creator" content="Peng  Bai" /></meta><meta name="dc.Creator" content="Xue  Yuan" /></meta><meta name="dc.Creator" content="Chufeng  Zhang" /></meta><meta name="dc.Creator" content="Kongjun  Liu" /></meta><meta name="dc.Creator" content="Yulin  Lu" /></meta><meta name="dc.Creator" content="Mingli  Xiang" /></meta><meta name="dc.Creator" content="Lijuan  Chen" /></meta><meta name="dc.Description" content="Herein, we describe the design, synthesis, and structure–activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivatives that selectively inhibit Janus kinase 2 (JAK2..." /></meta><meta name="Description" content="Herein, we describe the design, synthesis, and structure–activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivatives that selectively inhibit Janus kinase 2 (JAK2..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 31, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01348" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01348" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01348" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01348" /></link>
        
    
    

<title>Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01348" /></meta><meta property="og:title" content="Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0018.jpeg" /></meta><meta property="og:description" content="Herein, we describe the design, synthesis, and structure–activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivatives that selectively inhibit Janus kinase 2 (JAK2) and FLT3 kinases. These screening cascades revealed that 18e was a preferred compound, with IC50 values of 0.7 and 4 nM for JAK2 and FLT3, respectively. Moreover, 18e was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, respectively, and possessed an excellent selectivity profile over the other 100 representative kinases. In a series of cytokine-stimulated cell-based assays, 18e exhibited a higher JAK2 selectivity over other JAK isoforms. The oral administration of 60 mg/kg of 18e could significantly inhibit tumor growth, with a tumor growth inhibition rate of 93 and 85% in MV4-11 and SET-2 xenograft models, respectively. Additionally, 18e showed an excellent bioavailability (F = 58%), a suitable half-life time (T1/2 = 4.1 h), a satisfactory metabolic stability, and a weak CYP3A4 inhibitory activity, suggesting that 18e might be a potential drug candidate for JAK2-driven myeloproliferative neoplasms and FLT3-internal tandem duplication-driven acute myelogenous leukemia." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Herein, we describe the design, synthesis, and structure–activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivatives that selectively inhibit Janus kinase 2 (JAK2) and FLT3 kinases. These screening cascades revealed that 18e was a preferred compound, with IC50 values of 0.7 and 4 nM for JAK2 and FLT3, respectively. Moreover, 18e was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, respectively, and possessed an excellent selectivity profile over the other 100 representative kinases. In a series of cytokine-stimulated cell-based assays, 18e exhibited a higher JAK2 selectivity over other JAK isoforms. The oral administration of 60 mg/kg of 18e could significantly inhibit tumor growth, with a tumor growth inhibition rate of 93 and 85% in MV4-11 and SET-2 xenograft models, respectively. Additionally, 18e showed an excellent bioavailability (F = 58%), a suitable half-life time (T1/2 = 4.1 h), a satisfactory metabolic stability, and a weak CYP3A4 inhibitory activity, suggesting that 18e might be a potential drug candidate for JAK2-driven myeloproliferative neoplasms and FLT3-internal tandem duplication-driven acute myelogenous leukemia." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0018.jpeg" /></meta><meta name="twitter:title" content="Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01348"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01348">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01348&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01348&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01348&amp;href=/doi/10.1021/acs.jmedchem.9b01348" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 10305-10320</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01344" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01382" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.0c00025"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Tao Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tao Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Yang">Tao Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mengshi Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mengshi Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mengshi++Hu">Mengshi Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenyan Qi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenyan Qi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenyan++Qi">Wenyan Qi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhuang Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhuang Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhuang++Yang">Zhuang Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Minghai Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Minghai Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Minghai++Tang">Minghai Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jun He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jun He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jun++He">Jun He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yong Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Chen">Yong Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peng Bai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peng Bai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peng++Bai">Peng Bai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xue Yuan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xue Yuan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xue++Yuan">Xue Yuan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chufeng Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chufeng Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chufeng++Zhang">Chufeng Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kongjun Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kongjun Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kongjun++Liu">Kongjun Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yulin Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yulin Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yulin++Lu">Yulin Lu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mingli Xiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingli Xiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingli++Xiang">Mingli Xiang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Lijuan Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lijuan Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#dbb8b3beb5b7b2b1aebab5eae9ee9beaede8f5b8b4b6"><span class="__cf_email__" data-cfemail="6b08030e050702011e0a055a595e2b5a5d5845080406">[email protected]</span></a>. Phone: +86-28-85164063.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lijuan++Chen">Lijuan Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8076-163X" title="Orcid link">http://orcid.org/0000-0002-8076-163X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01348&amp;href=/doi/10.1021%2Facs.jmedchem.9b01348" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 10305–10320</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 31, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 August 2019</li><li><span class="item_label"><b>Published</b> online</span>31 October 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 November 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01348" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01348</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10305%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTao%2BYang%252C%2BMengshi%2BHu%252C%2BWenyan%2BQi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D22%26contentID%3Dacs.jmedchem.9b01348%26title%3DDiscovery%2Bof%2BPotent%2Band%2BOrally%2BEffective%2BDual%2BJanus%2BKinase%2B2%252FFLT3%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BAcute%2BMyelogenous%2BLeukemia%2Band%2BMyeloproliferative%2BNeoplasms%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10320%26publicationDate%3DNovember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01348"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2055</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01348" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Mengshi&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Wenyan&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Zhuang&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Minghai&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Peng&quot;,&quot;last_name&quot;:&quot;Bai&quot;},{&quot;first_name&quot;:&quot;Xue&quot;,&quot;last_name&quot;:&quot;Yuan&quot;},{&quot;first_name&quot;:&quot;Chufeng&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Kongjun&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Yulin&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Mingli&quot;,&quot;last_name&quot;:&quot;Xiang&quot;},{&quot;first_name&quot;:&quot;Lijuan&quot;,&quot;last_name&quot;:&quot;Chen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;10305-10320&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01348&quot;},&quot;abstract&quot;:&quot;Herein, we describe the design, synthesis, and structure–activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivatives that selectively inhibit Janus kinase 2 (JAK2) and FLT3 kinases. These screening cascades revealed that 18e was a preferred compound, with IC50 values of 0.7 and 4 nM for JAK2 and FLT3, respectively. Moreover, 18e was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, respectively, and possessed an excellent selectivity profile over the other 100 representative kinases. In a series of cytokine-stimulated cell-based assays, 18e exhibited a higher JAK2 selectivity over other JAK isoforms. The oral administration of 60 mg/kg of 18e could significantly inhibit tumor growth, with a tumor growth inhibition rate of 93 and 85% in MV4-11 and SET-2 xenograft models, respectively. Additionally, 18e showed an excellent bioavailability (F = 58%), a suitable half-life time (T1/2 = 4.1 h), a satisfactory metabolic stability, and a weak CYP3A4 in&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01348&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01348" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01348&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01348" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01348&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01348" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01348&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01348&amp;href=/doi/10.1021/acs.jmedchem.9b01348" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01348" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01348" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01348%26sid%3Dliteratum%253Aachs%26pmid%3D31670517%26genre%3Darticle%26aulast%3DYang%26date%3D2019%26atitle%3DDiscovery%2Bof%2BPotent%2Band%2BOrally%2BEffective%2BDual%2BJanus%2BKinase%2B2%252FFLT3%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BAcute%2BMyelogenous%2BLeukemia%2Band%2BMyeloproliferative%2BNeoplasms%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D22%26spage%3D10305%26epage%3D10320%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (8)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=290969" title="Cell and molecular biology">Cell and molecular biology</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/22" title="Go to Volume 62, Issue 22"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/jmcmar.2019.62.issue-22/20191127/jmcmar.2019.62.issue-22.largecover.jpg" alt="Go to Volume 62, Issue 22"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein, we describe the design, synthesis, and structure–activity relationships of a series of unique 4-(1<i>H</i>-pyrazol-4-yl)-pyrimidin-2-amine derivatives that selectively inhibit Janus kinase 2 (JAK2) and FLT3 kinases. These screening cascades revealed that <b>18e</b> was a preferred compound, with IC<sub>50</sub> values of 0.7 and 4 nM for JAK2 and FLT3, respectively. Moreover, <b>18e</b> was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, respectively, and possessed an excellent selectivity profile over the other 100 representative kinases. In a series of cytokine-stimulated cell-based assays, <b>18e</b> exhibited a higher JAK2 selectivity over other JAK isoforms. The oral administration of 60 mg/kg of <b>18e</b> could significantly inhibit tumor growth, with a tumor growth inhibition rate of 93 and 85% in MV4-11 and SET-2 xenograft models, respectively. Additionally, <b>18e</b> showed an excellent bioavailability (<i>F</i> = 58%), a suitable half-life time (<i>T</i><sub>1/2</sub> = 4.1 h), a satisfactory metabolic stability, and a weak CYP3A4 inhibitory activity, suggesting that <b>18e</b> might be a potential drug candidate for JAK2-driven myeloproliferative neoplasms and FLT3-internal tandem duplication-driven acute myelogenous leukemia.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Janus kinase 2 (JAK2) is an intracellular nonreceptor tyrosine kinase that belongs to the JAK family of kinases (JAK1, JAK2, JAK3, and TYK2). The JAK-signal transducer and activator of the transcription (JAK–STAT) pathway mediates signaling by cytokines, which controls the survival, proliferation, and differentiation of a variety of cells.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> JAK2 phosphorylation, downstream STAT phosphorylation, and activation of gene transcription ultimately result in increased proliferation, differentiation, and survival of erythroid and myeloid cells.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Among the four JAK subtypes, JAK2 was proven to be critical for the growth and progression of hematologic malignancies, especially for myeloproliferative neoplasms (MPNs).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Activating JAK2 fusion proteins has been also described in chronic myelogenous leukemia,<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> acute myelocytic leukemia (AML),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and acute lymphoblastic leukemia.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Currently, a number of pan JAK and selective JAK inhibitors, such as ruxolitinib, a JAK1/2 inhibitor, used for myelofibrosis,<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> tofacitinib, a JAK1/JAK3 inhibitor used for rheumatoid arthritis,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and fedratinib, a JAK2/FLT3 inhibitor used for myelofibrosis in Aug 2019,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> have been used clinically.</div><div class="NLM_p">FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that plays a crucial role in the development of hematopoietic progenitor cells.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Up to 20–30% of patients with AML have been shown to have an activated FLT3 internal tandem duplication (ITD) mutation, which is a high-risk factor for disease relapse.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> To date, several small-molecule inhibitors against FLT3,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> such as midostaurin (PKC412, approved for AML by the FDA),<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> quizartinib (AC220, approved for AML in Japan in 2019),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and gilteritinib (ASP2215, approved for AML by the FDA in 2018) have been developed.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Although positive outcomes were obtained for these FLT3 inhibitors during clinical trials, most patients experienced rapid drug-resistant relapse, which has become a major challenge in treating AML.<a onclick="showRef(event, 'ref20 ref24'); return false;" href="javascript:void(0);" class="ref ref20 ref24">(20,24)</a> The phosphorylation of JAK2 was already found to increase in primary samples of AML, and in vitro studies have shown that the negative regulators of the JAK signal are downregulated in FLT3-TKI (FLT3 tyrosine kinase inhibitor)-resistant AML cells with FLT3-ITD.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a> These discoveries indicate that targeting JAK2 may provide an opportunity to prevent the formation of leukemic cells and eliminate FLT3 monoinhibition, which may improve treatment outcomes in AML patients. Pacritinib, a dual FLT3/JAK2 inhibitor, has been used in clinical trials to treat AML (phase 1), myelofibrosis (phase 3), and lymphoma (phase 2).<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> However, pacritinib is a macrocycle compound with a moderate enzymatic activity for JAK2 and FLT3 (IC<sub>50</sub> values = 23 and 22 nM, respectively) and a poor oral bioavailability (<i>F</i> = 10% in rats).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> As both JAK2 and FLT3 play vital functions in hematologic neoplasms and the existing development is still unable to meet medical needs, the development of better candidate drugs is urgently needed.</div><div class="NLM_p">Through extensive studies on the binding mode of pacritinib with JAK2 and FLT3, we found that it was crucial to keep the 4-substituent pyrimidine-2-amine pharmacophore of pacritinib to maintain the ATP domain binding group for JAK2 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> For the hydrophobic group of pacritinib, we designed pyrazol instead of phenyl to increase the enzymatic activity for JAK2 and FLT3. Then, we introduced a series of hydrophile groups in the benzene ring to improve the oral bioavailability. Accordingly, we used computer-aided drug design to simulate the shape of the designed compound (named molecule A) in the JAK2 and FLT3 proteins (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B,C). The docking results clearly indicated that the pyrazol and hydrophile groups formed hydrogen bonds with the surrounding amino acid residues such as Leu932, Cys694, and Asp939, suggesting increased protein affinity. Based on our hypothesis, a series of compounds were synthesized and their cell inhibition activities and enzymatic inhibition activities were evaluated. Herein, we report the design and synthesis of a 4-(1<i>H</i>-pyrazol-4-yl)-pyrimidin-2-amine derivatives as potent JAK2 and FLT3 inhibitors. A series of structure modifications led to the discovery of 2-((1-(2-fluoro-4-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)phenyl)piperidin-4-yl)(methyl)amino)ethan-1-ol (<b>18e</b>). <b>18e</b> showed good cell potency, excellent kinase activity, good pharmacokinetic profiles, and favorable safety. More importantly, <b>18e</b> could significantly inhibit the tumor growth without obvious death in both the MV4-11 and SET-2 xenograft tumor models. In this paper, we described our efforts toward identifying potent, highly selective, and metabolically stable dual JAK2/FLT3 inhibitors for the treatment of AML and MPNs.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A). Schematic showing plans for splitting the loop of pacritinib; (B) docking result of the designed compound (molecule A) in the JAK2 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>); (C) docking result of the designed compound (molecule A) in the FLT3 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86221" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86221" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> In Vitro Structure–Activity Analysis</h3><div class="NLM_p">In the beginning, compounds <b>12a–q</b> were synthesized. These compounds were tested to determine their ability to inhibit the recombinant FLT3 kinase and JAK2 kinase and antiproliferative activities against the FLT3-ITD positive acute myeloid leukemia cell lines of MV4-11 and Molm-13 were evaluated. It is clear that introduction of an F atom at the C-2 position of R<sup>4</sup> (<b>12a</b>, <b>12c</b>, <b>12f</b>) resulted in significantly decreased inhibitory activities compared to the C-3 position substituted analogues (<b>12b</b>, <b>12d</b>, <b>12g</b>) in the MV4-11 and Molm-13 cells. However, no substitution at the C-3 position of R<sup>4</sup> (<b>12e</b>) exhibited a slight improvement in antitumor activity in the MV4-11 cells compared with <b>12b</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Considering that the electronegativity of the fluorine atom can acidify the NH bridge between the pyrimidine and benzene ring and increase the strength of the hydrogen bond between it and amino acid residues, there is still a substituted F at the C-3 position of R<sup>4</sup>. We next focused on the modification of the extended substituents at the R<sup>1</sup> position of pyrazole (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). High steric resistance rings such as cyclopentyl (<b>12i</b> and <b>12j</b>) resulted in significantly decreased activities against the MV4-11 and Molm-13 cells. In contrast, <b>12k</b> and <b>12l</b> with bipyridyl substituted exhibited an improved activity in the MV4-11 but a decreased activity in the Molm-13 cells. When the R<sup>1</sup> was substituted with an extended side chain, <b>12h</b> retained a moderate activity in both the MV4-11 and Molm-13 cells. Furthermore, when the R<sup>1</sup> substituent was replaced with an isopropyl group, <b>12m</b> exhibited an excellent activity both in JAK kinases and in the MV4-11 cells and a desirable selectivity for JAK1 and JAK3. As the isopropyl group substituent at the R<sup>1</sup> position could retain relatively high inhibitory activities in both kinases and the MV4-11 cells, we further investigated the effect of the R<sup>2</sup> substituent. Compared with <b>12m</b> and <b>12p</b>, when an F atom at the R<sup>2</sup> position was replaced with methyl, <b>12p</b> significantly increased the inhibitory activities toward the Molm-13 cells and possessed a relatively good selectivity for JAK2. Therefore, a methyl group was chosen as the R<sup>2</sup> substituent. However, <b>12p</b> had relatively low inhibitory activities against MV4-11 and Molm-13 cells; more modifications should be investigated.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures and in Vitro Biological Activities of Compounds <b>12a–g</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0011.gif" alt="" id="GRAPHIC-d7e502-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">substituents</th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a>± SEM (nM)</th><th class="rowsep1 colsep0" colspan="4" align="center">% control<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a>@100 nM</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>4</sup></th><th class="colsep0 rowsep0" align="center">R<sup>5</sup></th><th class="colsep0 rowsep0" align="center">MV4-11</th><th class="colsep0 rowsep0" align="center">Molm-13</th><th class="colsep0 rowsep0" align="center">JAK1</th><th class="colsep0 rowsep0" align="center">JAK2</th><th class="colsep0 rowsep0" align="center">JAK3</th><th class="colsep0 rowsep0" align="center">FLT3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left">NCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">8100 ± 128</td><td class="colsep0 rowsep0" align="left">9700 ± 700</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">NCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">57 ± 17</td><td class="colsep0 rowsep0" align="left">490 ± 140</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">69</td><td class="colsep0 rowsep0" align="left">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left">NCH<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">4200 ± 860</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12d</b></td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">NCH<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">61 ± 24</td><td class="colsep0 rowsep0" align="left">410 ± 58</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12e</b></td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="left">NS<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">NCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">27 ± 14</td><td class="colsep0 rowsep0" align="left">540 ± 17</td><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12f</b></td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left">NCH<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">8300 ± 150</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12g</b></td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">NCH<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">27 ± 18</td><td class="colsep0 rowsep0" align="left">410 ± 46</td><td class="colsep0 rowsep0" align="left">57</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">68</td><td class="colsep0 rowsep0" align="left">12</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> = compound concentration required to inhibit tumor cell proliferation by 50%; data are expressed as the mean ± SEM from the dose–response curves of at least three independent experiments.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">% control = kinase activity remained.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">NS = none substituent.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structures and in Vitro Biological Activities of Compounds <b>12h–q</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0012.gif" alt="" id="GRAPHIC-d7e811-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0013.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> = compound concentration required to inhibit tumor cell proliferation by 50%; data are expressed as the mean ± SEM from the dose–response curves of at least three independent experiments.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">% control = kinase activity remained.</p></div></div><div></div></div><div class="NLM_p">We noticed that <b>12o</b> possessing bipyridyl maintained a superior activity against the MV4-11 cells and certain selectivity over JAK1 and JAK3. Therefore, we speculated that moving N out of the piperazine ring might increase the antiproliferative activity. We docked a newly designed compound (molecule B) into the JAK2 and FLT3 protein crystals (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), and the results suggested that the piperidine amino of molecule B could form strong hydrogen bonds with the amino acid residues of Asp939 and Asp829, respectively. Hence, we synthesized compounds <b>18a–d</b>, and the results are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. As expected, <b>18b</b> and <b>18d</b> with the piperidine amine group had good antiproliferative activities and kinase activities, suggesting that the piperidine amine group played a vital role in the cellular activity. <b>18d</b> substituted with a methyl group at the R<sup>2</sup> position increased the MV4-11 cell activity by an order of magnitude than <b>18b</b> with an F atom at the R<sup>2</sup> position, suggesting that the methyl group was the suitable R<sup>2</sup> substituent. However, we noticed that the kinase selectivity of <b>18d</b> over JAK1 and JAK3 was slightly decreased.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Docking result of the designed compound (molecule B) in the JAK2 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>); (B) docking result of the designed compound (molecule B) in the FLT3 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structures and in Vitro Biological Activities of Compounds <b>18a–d</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0014.gif" alt="" id="GRAPHIC-d7e890-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0015.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> = compound concentration required to inhibit tumor cell proliferation by 50%; data are expressed as the mean ± SEM from the dose–response curves of at least three independent experiments.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">% control = kinase activity remained.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structures and in Vitro Biological Activities of Compounds <b>18e–s</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0016.gif" alt="" id="GRAPHIC-d7e914-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0017.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> = compound concentration required to inhibit tumor cell proliferation by 50%; data are expressed as the mean ± SEM from the dose–response curves of at least three independent experiments.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">% control = kinase activity remaining.</p></div></div><div></div></div><div class="NLM_p">Hoping to improve the kinase selectivity toward the JAK family, we continued to modify the piperidine amine structure based on <b>18d</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). At first, the hydrophilic side chains (<b>18e–g</b>) and hydrophobic side chains (<b>18h–j</b>) were introduced to the R<sup>8</sup> position. Obviously, when the side chain length was maintained at 3–4 atoms, <b>18e</b>, <b>18f</b>, and <b>18i</b> had excellent activities in both the cells and kinases. Meanwhile, as the hydroxyl group was alkylated (<b>18k</b>), the kinase selectivity decreased apparently, suggesting that the hydroxyl group played a certain role in the kinase activity. When the R<sup>8</sup> substituent was replaced by a series of heterocycle groups, such as cyclopropane (<b>18l</b>), furan (<b>18m</b>), and morpholine (<b>18n</b>, <b>18q</b>, <b>18r</b>), these compounds almost lost kinase selectivity for JAK2. Interestingly, compounds with hydrophilic substituents such as piperidine (<b>18o</b>) and piperazine (<b>18p</b>) still maintained the kinase selectivity toward JAK2 and had good activities against the MV4-11 and Molm-13 cells. Considering that <b>18p</b> had a better cellular activity and kinase selectivity than <b>18o</b>, we chose <b>18p</b> as one of the candidates in the next study. When the methyl group at the R<sup>7</sup> position was replaced by longer chains (<b>18q–r</b>) or H (<b>18s</b>), the cellular activity decreased sharply. To further investigate the kinase activity and selectivity, <b>18e</b>, <b>18f</b>, <b>18i</b>, and <b>18p</b> were studied to determine the IC<sub>50</sub> values toward the JAK family and FLT3 (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Meanwhile, the pharmacokinetic properties and safety the CYP3A4 activities were also evaluated (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro Profiling of Preferred Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">kinase IC<sub>50</sub><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> (nM)</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">selectivity (fold)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">JAK1</th><th class="colsep0 rowsep0" align="center" char=".">JAK2</th><th class="colsep0 rowsep0" align="center" char=".">JAK3</th><th class="colsep0 rowsep0" align="center" char=".">FLT3</th><th class="colsep0 rowsep0" align="center" char=".">JAK2/JAK1</th><th class="colsep0 rowsep0" align="center" char=".">JAK2/JAK3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18e</b></td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18f</b></td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18i</b></td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">38</td><td class="colsep0 rowsep0" align="char" char=".">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18p</b></td><td class="colsep0 rowsep0" align="char" char=".">121</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">103</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">34</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">The biochemical tests were provided by Eurofins Discovery. All data were obtained by double testing.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vivo Profiling of the Preferred Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">ADME parameter<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>0–<i>t</i></sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th><th class="colsep0 rowsep0" align="center">CYP3A4 IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">clog <i>P</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18e</b></td><td class="colsep0 rowsep0" align="char" char="±">102 ± 34</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">2552 ± 379</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="char" char=".">4.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18f</b></td><td class="colsep0 rowsep0" align="char" char="±">88.9 ± 55.3</td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 3.6</td><td class="colsep0 rowsep0" align="char" char="±">7.8 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">1510 ± 1097</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="char" char=".">4.62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18i</b></td><td class="colsep0 rowsep0" align="char" char="±">56.5 ± 12.9</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">5.9 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">304.8 ± 109</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="char" char=".">6.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18p</b></td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">2265 ± 198</td><td class="colsep0 rowsep0" align="char" char=".">45</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="char" char=".">4.46</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">5 mg/kg po (0.25% DMSO, 1% Tween 80, saline). <i>C</i><sub>max</sub>: peak concentration of the drug <i>t</i><sub>max</sub> (h): time to peak; <i>T</i><sub>1/2</sub>: end elimination half-life; AUC<sub>0–<i>t</i></sub>: area under the concentration–time curve; <i>F</i>: bioavailability.</p></div></div></div><div class="NLM_p last">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, <b>18e</b>, <b>18f</b>, <b>18i</b>, <b>18p</b> all demonstrated potent antiproliferative activities against the MV4-11 and Molm-13 cells (IC<sub>50</sub> < 100 nM), potent inhibitory activities for JAK2 and FLT3, and good selectivity over JAK1 and JAK3. Among the four compounds, <b>18e</b> had the best kinase activities toward JAK2 and FLT3 and a suitable selectivity toward JAK1 and JAK3. Further, in vivo pharmacokinetic studies and CYP3A4 inhibition activities of the four compounds are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, the four compounds showed no inhibition against CYP3A4 even above 100 μM. <b>18e</b> had a high volume of distribution at a steady state with a terminal half-life of 4.1 h and relatively rapid absorption (<i>t</i><sub>max</sub> = 1.5 h). In addition, <b>18e</b> exhibited the best oral bioavailability (<i>F</i> = 58%) among them. Based on the above results, we chose <b>18e</b> as a candidate compound for the next study.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Kinase Selectivity Profiling of <b>18e</b></h3><div class="NLM_p">To further understand the selectivity of <b>18e</b>, we then examined its kinome selectivity profile with Kinase Profile technology developed by Eurofins Discovery. A panel of 100 related kinases was tested at a 0.1 μM concentration of <b>18e</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_001.pdf" class="ext-link">Table S1</a>). <b>18e</b> displayed strong binding affinities with JAK2 and FLT3 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). <b>18e</b> also exhibited a potent inhibitory activity against the FLT3 D835Y mutation with IC<sub>50</sub> values of 4 nM (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). In addition, <b>18e</b> possessed relatively good selectivity in a panel of 100 kinases at 100 nM concentration except for CDK4/6, Lck, and Lyn (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). As the pharmacologic inhibition of the FLT3 ITD led to the downregulation of cyclin D2 and D3, which was followed by retinoblastoma protein (pRb) dephosphorylation and G1 cell-cycle arrest,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> the inhibition of CDK4/6 may contribute synergistically to AML treatment.<a onclick="showRef(event, 'ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33">(31−33)</a> Additionally, Lck and Lyn kinases have been proved as promising targets for treating leukemia.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> Hence, we can conclude that <b>18e</b> is highly selective to JAK2 and FLT3.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinome-wide selectivity profiling of compound <b>18e</b> with the Kinase Profile assay by Eurofins Discovery. Measurements were performed at a concentration of 0.1 μM of the inhibitor in duplicate. The % control means remaining active kinase percentage. The affinity was defined with respect to a dimethyl sulfoxide (DMSO) control. TREEspot image was mapped with the TREEspot software tool provided by DiscoverX Corporation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Data in Enzymatic Assays for <b>18e</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK4/cyclinD3</td><td class="colsep0 rowsep0" align="char" char=".">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK6/cyclinD3</td><td class="colsep0 rowsep0" align="char" char=".">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt1</td><td class="colsep0 rowsep0" align="char" char=".">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt3 (D835Y)</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt3</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt4</td><td class="colsep0 rowsep0" align="char" char=".">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK1</td><td class="colsep0 rowsep0" align="char" char=".">26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="char" char=".">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Lck</td><td class="colsep0 rowsep0" align="char" char=".">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Lyn</td><td class="colsep0 rowsep0" align="char" char=".">17</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">The biochemical tests were provided by Eurofins Discovery. All data were obtained by double testing.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> JAK2 Selectivity of <b>18e</b> in Cell-Based Assays</h3><div class="NLM_p">Because of the complexity of the cooperative property of JAK kinases, the cellular potency and selectivity of <b>18e</b> for each individual kinase were characterized in human peripheral blood mononuclear cells (hPBMCs), which can be stimulated by different cytokines. For instance, IL-2-induced STAT5 phosphorylation is mediated by JAK1 and JAK3,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> IL-6-induced STAT3 phosphorylation is considered to be triggered by JAK1 and JAK2,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and GM-CSF-induced STAT5 phosphorylation is dependent on JAK2.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Accordingly, the potency and selectivity of <b>18e</b> from a cellular context were assessed in total lymphocytes in hPBMCs by flow cytometry. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_001.pdf" class="ext-link">Figure S2</a>, <b>18e</b> inhibited the IL-6-induced phosphorylation of STAT3 and the IL-2-induced phosphorylation of STAT5 with IC<sub>50</sub> values of 94.2 and 112.3 nM, respectively. Meanwhile, <b>18e</b> also inhibited the phosphorylation of STAT5, which was elicited by GM-CSF, with an IC<sub>50</sub> value of 10.4 nM, and demonstrated an acceptable selectivity over the IL-2 and IL-6 stimulated pathway.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Cellular Potency of <b>18e</b> in Total Lymphocytes in hPBMCs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cytokine</th><th class="colsep0 rowsep0" align="center">JAK</th><th class="colsep0 rowsep0" align="center">pSTAT</th><th class="colsep0 rowsep0" align="center">cells</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-2</td><td class="colsep0 rowsep0" align="left">JAK1/JAK3</td><td class="colsep0 rowsep0" align="left">pSTAT5</td><td class="colsep0 rowsep0" align="left">PBMC</td><td class="colsep0 rowsep0" align="char" char=".">112.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-6</td><td class="colsep0 rowsep0" align="left">JAK1</td><td class="colsep0 rowsep0" align="left">pSTAT3</td><td class="colsep0 rowsep0" align="left">PBMC</td><td class="colsep0 rowsep0" align="char" char=".">94.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GM-CSF</td><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="left">pSTAT5</td><td class="colsep0 rowsep0" align="left">PBMC</td><td class="colsep0 rowsep0" align="char" char=".">10.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-6</td><td class="colsep0 rowsep0" align="left">JAK1</td><td class="colsep0 rowsep0" align="left">pSTAT3</td><td class="colsep0 rowsep0" align="left">TF-1</td><td class="colsep0 rowsep0" align="char" char=".">692.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-3</td><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="left">pSTAT5</td><td class="colsep0 rowsep0" align="left">TF-1</td><td class="colsep0 rowsep0" align="char" char=".">269.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-4</td><td class="colsep0 rowsep0" align="left">JAK1/JAK3</td><td class="colsep0 rowsep0" align="left">pSTAT6</td><td class="colsep0 rowsep0" align="left">THP-1</td><td class="colsep0 rowsep0" align="char" char=".">578.4</td></tr></tbody></table></div></div><div class="NLM_p last">To further determine the selectivity of <b>18e</b> for the inhibition of different JAK isotypes within cells, we used a series of cytokine-stimulated cell-based assays. The cell lines were preincubated with <b>18e</b> and treated with different JAK1 heterodimeric or JAK2 homodimeric complexes as signaling cytokines. All the results were obtained by a Western blot and quantified by examining the grayscale intensity levels. To assess JAK2 signaling, we stimulated TF-1 cells via IL-3 and measured the levels of phosphorylated STAT5 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_001.pdf" class="ext-link">Figure S3A</a>). In this system, <b>18e</b> concentration dependence inhibited the phosphorylation of JAK2 with an IC<sub>50</sub> value of 269.9 nM. Compared with the JAK1 and JAK3 assays (IL-6 phosphorylation of STAT3 in TF-1 cells and IL-4 phosphorylation of STAT6, respectively) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_001.pdf" class="ext-link">Figure S3B,C</a>), <b>18e</b> exhibited a relatively weak ability to inhibit STAT and JAK phosphorylation. The data from these in vitro enzyme and cell-based assays indicate that <b>18e</b> inhibits JAK2 rather than JAK1 or JAK3.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Molecular Docking Study of <b>18e</b></h3><div class="NLM_p">To better understand how <b>18e</b> interacted with JAK2 and FLT3, molecular docking was performed. As expected, compound <b>18e</b> docked into the cavity of the JAK2 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>) by independently forming hydrogen bonds between the crucial residues Asp939 and Leu932, and a salt–bridge interaction was found to occur between the methylamine of piperidine and the Asp939 residues. Similarly, a network of hydrogen bonds was found between <b>18e</b> with receptor residues such as Met665 and Asp829 in the FLT3 protein. The benzene ring of <b>18e</b> was found to interact via cation-π stacking interactions with the Phe830 residue (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The 50 ns molecular dynamics simulation result showed that the complex of <b>18e</b> and FLT3 achieved a balance after approximately 10 ns and had an rmsd < 2 Å (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_001.pdf" class="ext-link">Figure S1</a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Molecular docking of <b>18e</b> in the cavity of the JAK2 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>); (B) molecular docking of <b>18e</b> in the cavity of the FLT3 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Pharmacological Safety and in Vivo Anticancer Activity of <b>18e</b></h3><div class="NLM_p"><b>18e</b> was further tested on a panel of tumor cell lines to determine the antiproliferative effects and toxicity to normal cell lines (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_001.pdf" class="ext-link">Tables S2 and S3</a>), and pacritinib was selected as a positive control. As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_001.pdf" class="ext-link">Table S2</a>, <b>18e</b> possessed potent inhibitory activities against Ba/F3-JAK2<sup>V617F</sup> cells and SET-2 cells (over expressing JAK2<sup>V617F</sup>) with IC<sub>50</sub> values of 145 and 270 nM, respectively. In contrast, pacritinib had only IC<sub>50</sub> values of 1061.3 nM for Ba/F3-JAK2<sup>V617F</sup> and 915.7 nM for SET-2 cells. Similar results were obtained in MV4-11 cells, which are FLT3-ITD-positive cells. In addition, <b>18e</b> inhibited the growth of a panel of solid tumors cells (NCl-H460, HCT116, MDA-MB-231, and MDA-MB-453). These results are consistent with the strong in vitro kinase activities of <b>18e</b> to JAK2 and FLT3, and indicated that <b>18e</b> had a potential extra anticancer activity.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The normal human cell lines were not sensitive to <b>18e</b>, indicating its low toxicity to normal cells. <b>18e</b> was further applied to in vitro CYP450 and hERG channel inhibitory screens to assess the potential impact of <b>18e</b> on drug–drug interactions and cardiac responsibility. <b>18e</b> exhibited good safety profile with an IC<sub>50</sub> value of 28 μM against hERG and IC<sub>50</sub> values over 50 μM against six common CYP450 isoforms. Liver microsomal metabolism experiments revealed that metabolism of <b>18e</b> in various liver microsomes was relatively stable (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). Based on the above results, <b>18e</b> was further evaluated in vivo studies.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Biopharmaceutical Profiles of <b>18e</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">inhibition of CYP450 (IC<sub>50</sub>, μM)</td><td class="colsep0 rowsep0" align="left">CYP1A2</td><td class="colsep0 rowsep0" align="left">CYP2C9</td><td class="colsep0 rowsep0" align="left">CYP2C19</td><td class="colsep0 rowsep0" align="left">CYP2D6</td><td class="colsep0 rowsep0" align="left">CYP2E1</td><td class="colsep0 rowsep0" align="left">CYP3A4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">64.4</td><td class="colsep0 rowsep0" align="left">78.1</td><td class="colsep0 rowsep0" align="left">74.7</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver microsomal metabolism</td><td class="colsep0 rowsep0" align="left">species</td><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">mice</td><td class="colsep0 rowsep0" align="left">monkey</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="left">288.8</td><td class="colsep0 rowsep0" align="left">770.0</td><td class="colsep0 rowsep0" align="left">187.3</td><td class="colsep0 rowsep0" align="left">385.0</td><td class="colsep0 rowsep0" align="left">1386.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cl<sub>int</sub> (mg<sup>–1</sup>·mL·min<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">0.0024</td><td class="colsep0 rowsep0" align="left">0.0009</td><td class="colsep0 rowsep0" align="left">0.0037</td><td class="colsep0 rowsep0" align="left">0.0018</td><td class="colsep0 rowsep0" align="left">0.0005</td></tr></tbody></table></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Western Blot of Signaling Pathways for JAK2 and FLT3 Kinase</h3><div class="NLM_p">To evaluate whether the observed antiproliferative activity of <b>18e</b> was derived from the inhibition of JAK2 and FLT3 kinase, we then examined the signaling proteins in the two cell lines expressing endogenous JAK2<sup>V617F</sup> (SET-2) and FLT3-ITD (MV4-11), respectively.<a onclick="showRef(event, 'ref27 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref27 ref40 ref41">(27,40,41)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B, the p-STAT5 and p-JAK2 signal intensities decreased sharply or even vanished at 0.2 μM in MV4-11. <b>18e</b> could also downregulate p-FLT3 in a dose-dependent manner from 0.008 to 1 μM. Similar potencies for the inhibition of JAK2 signaling were achieved in the SET-2 cell line. These results showed that <b>18e</b> was a potent JAK2 and FLT3 dual target inhibitor.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A,B) MV4-11 and SET-2 cells were treated with <b>18e</b> for 2 h at 0.008, 0.04, 0.2, 1 μM, respectively. The cells were harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis with the indicated antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Cell Cycle Analysis and Apoptosis Assays Performed by Flow Cytometry</h3><div class="NLM_p">As JAK2 and FLT3 signaling have key roles in important functional responses such as cell proliferation and survival,<a onclick="showRef(event, 'ref28 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref28 ref42 ref43">(28,42,43)</a> the effects of <b>18e</b> on the cell cycle and apoptosis were investigated.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A, <b>18e</b> strongly induced cell cycle arrest with a G1/G0 percentage of 85% at 100 nM compared to the vehicle in the MV4-11 cell. We next confirmed that the phenotypic observation of cell death induced by <b>18e</b> was due to apoptosis. As exhibited in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B, the treatment with <b>18e</b> had a dose-dependent effect on the induction of apoptosis in the MV4-11 cells. It was evident that <b>18e</b> blocked the tumor cells during G<sub>0</sub>/G<sub>1</sub>-phase progression, which resulted in decreased S-phase and G2-phase populations and induced tumor cell apoptosis.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Cell cycle effects of <b>18e</b> on MV4-11 cells. Cells were treated with increasing concentrations of <b>18e</b> for 24 h, harvested, fixed, and stained with propidium iodide prior to flow cytometric analysis. (B) Effects of <b>18e</b> on the induction of apoptosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> In Vivo Xenograft and Allograft Model Experiments</h3><div class="NLM_p">We then evaluated the antitumor efficacy of <b>18e</b> in the MV4-1 and SET-2 cell-inoculated xenograft NOD/SCID mouse models. The administration, dosing schedules, route, and results are presented in <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>. The oral administration of 30 and 60 mg/kg of <b>18e</b> exhibited significant antitumor effects and the tumor growth inhibition (TGI) rates were 58 and 93%, respectively, in the MV4-11-bearing mice model (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A,B). To further investigate the therapeutic effects of <b>18e</b> on JAK2-driven malignancy in vivo, a xenograft model using the subcutaneous injection of SET-2 cells was established. As expected, the 30 and 60 mg/kg of <b>18e</b>-treated groups significantly inhibited tumor growth with TGI rates of 66 and 85%, respectively (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D,E). In addition, no obvious body weight changes were observed during the treatment period (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C,F).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Tumor volume changes following the treatment of <b>18e</b> at doses of 30 mg/kg (po) and 60 mg/kg; (B) tumor weight of each mouse on day 14; (C) average body weights for <b>18e</b>-treated mice groups; (D) tumor volume changes following the treatment of <b>18e</b> at doses of 30 mg/kg (po) and 60 mg/kg (po) in the SET-2 xenograft model; (E) tumor weight of each mouse on day 18; (F) average body weights for <b>18e</b>-treated mice groups; (H) inhibition of the spleen growth in the Ba/F-JAK2<sup>V617F</sup> allograft model; (I) spleen weight of each mouse on day 25; (G) inhibition of the liver growth in the Ba/F-JAK2<sup>V617F</sup> allograft model; *, <i>P</i> < 0.05 **, <i>P</i> < 0.01 ***, <i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Summary of Tumor Growth Inhibition of Compound <b>18e</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">administration</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">tumor model</th><th class="colsep0 rowsep0" align="center">schedule<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">survivors (day)</th><th class="colsep0 rowsep0" align="center" char=".">inhibition rate (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MV4-11</td><td class="colsep0 rowsep0" align="left">QD × 14</td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="left">6/6</td><td class="colsep0 rowsep0" align="char" char=".">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="left">6/6</td><td class="colsep0 rowsep0" align="char" char=".">93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SET-2</td><td class="colsep0 rowsep0" align="left">QD × 18</td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="left">6/6</td><td class="colsep0 rowsep0" align="char" char=".">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="left">6/6</td><td class="colsep0 rowsep0" align="char" char=".">85</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">QD, every day.</p></div></div></div><div class="NLM_p last">To investigate the effect of <b>18e</b> on MPNs, we further established a Ba/F3-JAK2<sup>V617F</sup> allograft model by tail vein injection. This model represented a JAK2-driven myeloproliferative disease characterized by typical symptoms such as splenomegaly and hepatomegaly. In this model, fedratinib, a dual JAK2 and FLT3 inhibitor, was chosen as a positive control because it was approved for myelofibrosis by the FDA in Aug 2019 and showed much better JAK2/FLT3 inhibitory activities and bioavailability than pacritinib. The treatments started 4 days after the cells were injected and continued for 20 consecutive days at a dose of 60 mg/kg p.o. q.d. At the end of the study, the vehicle control mice exhibited splenomegaly and hepatomegaly (∼7-fold and 1.4-fold, respectively). <b>18e</b> significantly improved the disease symptoms, with a 59.5 and 94.3% normalization of the spleen and liver weight, respectively (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>H,I,G). In comparison, fedratinib had only respectively 24.7 and 69.8% improvement of the spleen and liver weight. These results indicate that <b>18e</b> has a good therapeutic effect, suggesting that <b>18e</b> has potential clinical value in the development of myelofibrosis drug.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51261" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51261" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Based on the progress made in clinical research by combining JAK2 inhibitors with FLT3 inhibitors, our groups designed and synthesized a number of dual target inhibitors for JAK2 and FLT3. We designed 4-substituent pyrimidine-2-amine pharmacophores to append JAK2 and FLT3 inhibition. Among these compounds, <b>18e</b> was the optimal compound and had a potent inhibition activity for JAK2 and FLT3 with an IC<sub>50</sub> of 0.7 and 4 nM, respectively. The kinome profile confirmed that <b>18e</b> had weak inhibition on other kinases, except for JAK2 and FLT3. In addition, the cellular assays also verified that <b>18e</b> possessed a desirable selectivity toward JAK1 and JAK3. Compound <b>18e</b> also exhibited potent inhibition activities for hematologic malignancies cells, such as MV4-11, Molm-13, and SET-2. Furthermore, a Western blot confirmed that the antitumor activities were indeed on-target. Compound <b>18e</b> could also stimulate cell cycle arrest in the G<sub>0</sub>/G<sub>1</sub> phase and induce tumor cell apoptosis. Most importantly, <b>18e</b> possessed excellent pharmacokinetic properties in vivo. In established MV4-11 and SET-2 xenograft models, <b>18e</b> could inhibit tumor growth, and the TGI rates reached 93 and 85% when a 60 mg/kg dose of <b>18e</b> was orally administered. Additionally, in a model of a JAK2<sup>V617F</sup>-driven disease, <b>18e</b> normalized the splenomegaly and hepatomegaly symptoms when administered with a relatively low dosage. We speculated that the potent antitumor activities of <b>18e</b> were due to dual target effects to JAK2 and FLT3. To summarize, <b>18e</b> is a promising dual target inhibitor of JAK2 and FLT3 for treating cancers, especially AML and MPNs.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Chemistry</h3><div class="NLM_p">The syntheses of the 4-(1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine derivatives <b>12a–q</b> and <b>18a–s</b> require the preparation of two pairs of building blocks, that is, 4-(1<i>H</i>-pyrazol-4-yl)pyrimidine and anilines. The route used to synthesize a variety of 4-(1<i>H</i>-pyrazol-4-yl)pyrimidine compounds (<b>3a–g</b> and <b>5a–b</b>) is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Substituted intermediate <b>2a–f</b> was synthesized from commercially available pyrazole-4-boronic acid pinacol ester (<b>1</b>) by an alkylation reaction. Then, compounds <b>3a–g</b> were synthesized using 2,4-dichloro-5-methylpyrimidine or 2,4-dichloro-5-fluoropyrimidine via a Suzuki coupling reaction. The treatment of compound <b>3g</b> with HCl afforded compound <b>4</b>, which was further alkylated to give pyrimidine derivatives <b>5a–b</b>.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Intermediates <b>3a–g</b> and <b>5a–b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate halide, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux; (b) 2,4-dichloropyrimidine derivatives, dioxane/EtOH/water (v/v/v, 7/3/4), 80 °C, 2 h; (c) TFA, DCM; (d) appropriate halide, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, rt.</p></p></figure><div class="NLM_p">The syntheses of a wide range of anilines are depicted in <a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Nitro-compounds <b>6a–b</b> and <b>13</b> were treated with various N-heterocycles to furnish nitro compounds <b>7a–c</b>, <b>14a</b>, and <b>14e</b> in moderate to excellent yields. The secondary amino group of <b>14a</b> was modified by methyl, ethyl, propyl groups to produce intermediates <b>14b–d</b>.</div><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of Compounds <b>12a–q</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate N-heterocycles, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux; (b) 80% hydrazine hydrate, Pd/C 10%, methanol, rt; (c) 2-chloropyrimidine derivatives, dioxane, reflux, 4 h, N<sub>2</sub> atmosphere; (d) TFA, DCM; (e) appropriate halide, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, rt.</p></p></figure><figure id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Syntheses of Compounds <b>18a–s</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate N-heterocycles, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux; (b–d) appropriate halide, NaH, anhydrous DMF, rt; (e) 80% hydrazine hydrate, Pd/C 10%, methanol, rt; (f) 2-chloropyrimidine derivatives, dioxane, reflux, 4 h, N<sub>2</sub> atmosphere; (g) TFA, DCM; (h) appropriate halide, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, rt.</p></p></figure><div class="NLM_p last">Nitro compounds <b>7a–c</b> and <b>14a–e</b> were reduced by hydrazine hydrate to produce respective amines <b>8a–c</b> and <b>15a–e</b> in good to excellent yields. The anilines and pyrimidine intermediates were coupled via a Buchwald–Hartwig reaction. The Boc groups were removed from <b>10a–j</b> and <b>16a–f</b> with trifluoroacetyl (TFA) to produce the corresponding piperazines <b>11a–j</b> and piperidine-4-amines <b>17a–e</b> in quantitative yields. The piperazines <b>11a–j</b> and piperidine-4-amines <b>17a–e</b> were further alkylated to obtain candidate compounds <b>12a–q</b> and <b>18a–s</b>.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75310" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75310" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Synthesis</h3><div class="NLM_p last">All the chemical solvents and reagents, which were purchased from commercial sources and were used as received. Thin-layer chromatography was performed on 0.20 mm Silica Gel 60 F254 plates (Qingdao Haiyang Chemical, China) and visualized under UV light (254 nm). Flash column chromatography was carried out using fritted solid loaders packed with Scharlau silica gel (0.04–0.06 mm) on Biotage FlashMaster Personal + flash chromatography. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker AVANCE 400 spectrometer (Bruker Company, Germany) or Varian spectrometer (Varian, Palo Alto, CA), using TMS as an internal standard. Chemical shifts were given in ppm (parts per million). Mass spectra were recorded on Q-TOF Premier mass spectrometer (Micromass, Manchester, UK). The purity of all final compounds was determined to be ≥95% with a Waters e2695 series LC system (column, Xtimate C18, 4.6 mm × 150 mm, 5 μm; mobile phase, methanol (60%)/H<sub>2</sub>O (40%); low rate, 1.0 mL/min; UV wavelength, 254–400 nM; temperature, 25 °C; injection volume, 10 μL).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> General Synthetic Procedure 1: Arylamine Formation</h3><div class="NLM_p">A solution of 3,4-difluoronitrobenzene or 2,4-difluoronitrobenzene (3.2 g, 20 mmol, 1.0 equiv) in CH<sub>3</sub>CN (50 mL) was added to the heterocyclic secondary amine (<i>N</i>-Boc-piperazine, 5.4 g, 22 mmol, 1.1 equiv) and potassium carbonate (6.9 g, 50 mmol, 2.5 equiv). The reaction mixture was heated at 82 °C for 4 h. The completion of the reaction was checked with thin layer chromatography on silica (silica gel: PE/EA = 5:1). After cooling to room temperature, the reaction mixture was evaporated under reduced pressure. The residue was partitioned between dichloromethane and water (V/V = 1:1). The water phase was extracted twice with dichloromethane. The combined organic phases were washed with water and brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was then used directly without further purification.</div><div class="NLM_p last">The nitro compounds from the previous step (2.4 g, 10 mmol, 1.0 equiv) were hydrogenated under atmospheric pressure in methanol (30 mL) with 10% wt palladium on charcoal (0.5 g, 10% wt). After completion, the reaction mixture was filtered through Celite, washed with methanol, and evaporated under reduced pressure. The crude product was precipitated in acetate ether and the precipitate was filtered to give the desired aromatic amine derivative.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> General Synthetic Procedure 2: Suzuki Reaction</h3><div class="NLM_p last">A solution of pyrazole-4-boronic acid pinacol ester (1.9 g, 10 mmol, 1.3 equiv), substituted pyrimidine (1.7 g, 7.6 mmol, 1.0 equiv), potassium carbonate (3.4 g, 25 mmol, 2.5 equiv) in dioxane/EtOH/H<sub>2</sub>O (70 mL, V/V/V = 7:4:3) was added to PdCl<sub>2</sub>(dppf)DCM (0.75 g, 1.0 mmol, 0.1 equiv). The reaction was heated under an argon atmosphere in a sealed three-necked bottle at 90 °C for 3 h, cooled to room temperature, and concentrated under reduced pressure. The residue was purified by FlashMaster Personal + chromatography (silica gel: PE/EA = 10:1) to give the desired product.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Synthetic Procedure 3: TFA-Mediated Boc Removal</h3><div class="NLM_p last">Boc-protected amine (1.0 equiv) was dissolved in a mixture of TFA (10.0 equiv)/DCM (1:1), and stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure, triturated with diethyl ether, and filtered to give the desired product, which was directly used in the next step without further purification.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Synthetic Procedure 4: Pyrimidine Amine Formation</h3><div class="NLM_p last">A solution of aromatic amine (2.4 g, 10.0 mmol, 1.0 equiv), substituted pyrimidine (3.4 g, 12.0 mmol, 1.2 equiv), cesium carbonate (8.2 g, 25.0 mmol, 2.5 equiv) in dioxane (60 mL) was added to Pd<sub>2</sub>(DBA)<sub>3</sub> (0.45 g, 0.5 mmol, 0.05 equiv) and xantphos (0.9 g, 1.0 mmol, 0.1 equiv). The reaction was heated under an argon atmosphere in a sealed three-necked bottle at 103 °C for 3 h, cooled to room temperature, and concentrated under reduced pressure. The residue was purified by FlashMaster Personal + chromatography (silica gel: EA) to give the desired product.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> General Synthetic Procedure 5: Substitution of Amines with Halide</h3><div class="NLM_p last">A solution of secondary amine (0.45 g, 1.0 mmol, 1.0 equiv), potassium carbonate (0.35 g, 2.5 mmol, 2.5 equiv) in CH<sub>3</sub>CN (20 mL) was added to halide (0.2 g, 1.3 mmol, 1.3 equiv). The reaction mixture was heated at 82 °C for 4 h, cooled to room temperature, and concentrated under reduced pressure. The residue was purified by FlashMaster Personal + chromatography (silica gel: DCM/MeOH = 90:10) to give the desired product.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 2-Chloro-5-fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidine (<b>3a</b>)</h3><div class="NLM_p last">1-Isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole and 2,4-dichloro-5-fluoropyrimidine were coupled according to general procedure 2. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 8.39 (dd, <i>J</i> = 2.5, 1.4 Hz, 1H), 8.24–8.18 (m, 2H), 4.59 (heptd, <i>J</i> = 6.7, 1.2 Hz, 1H), 1.58 (dd, <i>J</i> = 6.8, 1.2 Hz, 6H). HRMS (ESI) <i>m</i>/<i>z</i>: 241.0574 [M + H<sup>+</sup>].</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 2-Chloro-5-fluoro-4-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)pyrimidine (<b>4</b>)</h3><div class="NLM_p last"><i>tert</i>-Butyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate and 2,4-dichloro-5-fluoropyrimidine were coupled according to general procedure 2. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 8.40 (d, <i>J</i> = 2.4 Hz, 1H), 8.21 (dd, <i>J</i> = 3.1, 1.6 Hz, 2H), 4.34 (dddd, <i>J</i> = 19.8, 15.8, 9.9, 5.6 Hz, 3H), 2.92 (t, <i>J</i> = 12.9 Hz, 2H), 2.23–2.15 (m, 3H), 1.97 (qd, <i>J</i> = 12.3, 4.5 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i>: 282.0848 [M + H<sup>+</sup>].</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>tert</i>-Butyl 4-(4-Amino-2-fluorophenyl)piperazine-1-carboxylate (<b>8b</b>)</h3><div class="NLM_p last"><i>tert</i>-Butyl 4-(2-fluoro-4-nitrophenyl)piperazine-1-carboxylate was redacted according to general procedure 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 6.75 (dd, <i>J</i> = 10.0, 8.4 Hz, 1H), 6.39–6.23 (m, 2H), 3.15–3.07 (m, 2H), 2.57–2.46 (m, 2H), 1.84–1.75 (m, 2H), 1.50 (qd, <i>J</i> = 11.9, 3.9 Hz, 2H), 1.49 (s, 9H). HRMS (ESI) <i>m</i>/<i>z</i>: 296.1694 [M + H<sup>+</sup>].</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 5-Fluoro-<i>N</i>-(3-fluoro-4-(piperazin-1-yl)phenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>11c</b>)</h3><div class="NLM_p last">The Boc group was removed from <i>tert</i>-Butyl-4-(2-fluoro-4-((5-fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate according to general procedure 3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.76 (s, 1H), 9.73 (s, 1H), 8.55 (d, <i>J</i> = 3.0 Hz, 1H), 8.48 (d, <i>J</i> = 2.1 Hz, 1H), 8.30–8.20 (m, 2H), 8.17 (d, <i>J</i> = 1.2 Hz, 1H), 7.17–7.03 (m, 2H), 4.68 (hept, <i>J</i> = 6.6 Hz, 1H), 3.53 (d, <i>J</i> = 11.8 Hz, 2H), 3.37–3.19 (m, 4H), 3.10–2.98 (m, 2H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H). HRMS (ESI) <i>m</i>/<i>z</i>: 400.1989 [M + H<sup>+</sup>].</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 5-Fluoro-<i>N</i>-(2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-(1-propyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>12a</b>)</h3><div class="NLM_p last">Yield: 40%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.71 (s, 1H), 8.52 (d, <i>J</i> = 3.0 Hz, 1H), 8.44 (d, <i>J</i> = 2.1 Hz, 1H), 8.27–8.17 (m, 2H), 8.12 (d, <i>J</i> = 1.2 Hz, 1H), 7.14–7.00 (m, 2H), 4.20 (t, <i>J</i> = 7.0 Hz, 2H), 3.37 (dd, <i>J</i> = 12.7, 6.0 Hz, 5H), 3.11 (s, 4H), 2.85 (s, 3H), 2.36 (s, 3H), 1.84 (h, <i>J</i> = 7.3 Hz, 2H), 0.85 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.23, 156.85, 156.64, 156.62, 150.39, 147.90, 147.21, 147.08, 146.46, 146.22, 142.64, 142.56, 139.43, 139.38, 132.33, 132.25, 131.15, 131.12, 121.45, 121.36, 115.64, 115.58, 111.55, 111.33, 108.53, 108.30, 53.59, 53.50, 48.77, 43.05, 23.55, 11.26. HRMS (ESI) <i>m</i>/<i>z</i>: 414.2218 [M + H<sup>+</sup>].</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 5-Fluoro-<i>N</i>-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-(1-propyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>12b</b>)</h3><div class="NLM_p last">Yield: 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.70 (s, 2H), 8.52 (d, <i>J</i> = 2.9 Hz, 1H), 8.41 (d, <i>J</i> = 2.2 Hz, 1H), 8.09 (s, 1H), 7.73 (dd, <i>J</i> = 15.3, 2.4 Hz, 1H), 7.53 (dd, <i>J</i> = 8.9, 2.4 Hz, 1H), 7.10 (t, <i>J</i> = 9.4 Hz, 1H), 4.20 (t, <i>J</i> = 6.9 Hz, 2H), 3.53 (d, <i>J</i> = 12.0 Hz, 2H), 3.43 (d, <i>J</i> = 12.8 Hz, 2H), 3.23 (dd, <i>J</i> = 12.6, 9.5 Hz, 2H), 3.09–2.96 (m, 2H), 2.89 (d, <i>J</i> = 4.6 Hz, 3H), 2.38 (s, 3H), 1.85 (h, <i>J</i> = 7.2 Hz, 2H), 0.86 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 156.62, 156.59, 156.47, 154.06, 150.12, 147.63, 147.13, 147.00, 146.25, 146.02, 139.18, 139.14, 137.66, 137.55, 132.27, 132.25, 132.19, 132.15, 120.56, 120.52, 115.70, 115.64, 114.77, 114.74, 107.00, 106.74, 53.63, 53.22, 48.19, 48.16, 42.76, 23.52, 11.28. HRMS (ESI) <i>m</i>/<i>z</i>: 414.2221 [M + H<sup>+</sup>].</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-(4-(4-Ethylpiperazin-1-yl)-2-fluorophenyl)-5-fluoro-4-(1-propyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>12c</b>)</h3><div class="NLM_p last">Yield: 46%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.49 (s, 1H), 8.52 (d, <i>J</i> = 3.0 Hz, 1H), 8.43 (d, <i>J</i> = 2.1 Hz, 1H), 8.21 (d, <i>J</i> = 8.7 Hz, 2H), 8.12 (s, 1H), 7.16–6.98 (m, 2H), 4.20 (t, <i>J</i> = 6.9 Hz, 2H), 3.56 (s, 2H), 3.23 (s, 6H), 3.03 (s, 2H), 2.33 (s, 3H), 1.84 (h, <i>J</i> = 7.3 Hz, 2H), 1.26 (t, <i>J</i> = 7.4 Hz, 3H), 0.85 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.30, 156.91, 156.69, 150.39, 147.90, 147.20, 147.07, 146.49, 146.26, 142.74, 142.66, 139.43, 139.38, 132.34, 132.26, 131.12, 131.09, 121.74, 115.63, 115.57, 111.52, 111.30, 108.43, 108.20, 53.60, 51.33, 51.26, 48.62, 23.55, 11.27, 9.55. HRMS (ESI) <i>m</i>/<i>z</i>: 428.2375 [M + H<sup>+</sup>].</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i>-(4-(4-Ethylpiperazin-1-yl)-3-fluorophenyl)-5-fluoro-4-(1-propyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>12d</b>)</h3><div class="NLM_p last">Yield: 57%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.70 (s, 1H), 9.44 (s, 1H), 8.52 (d, <i>J</i> = 2.9 Hz, 1H), 8.41 (d, <i>J</i> = 2.2 Hz, 1H), 8.09 (d, <i>J</i> = 1.0 Hz, 1H), 7.73 (dd, <i>J</i> = 15.3, 2.4 Hz, 1H), 7.56–7.49 (m, 1H), 7.10 (dd, <i>J</i> = 10.0, 8.8 Hz, 1H), 4.20 (t, <i>J</i> = 6.9 Hz, 2H), 3.63–3.53 (m, 2H), 3.44 (d, <i>J</i> = 12.7 Hz, 2H), 3.27–3.13 (m, 4H), 3.07–2.97 (m, 2H), 2.34 (s, 3H), 1.85 (h, <i>J</i> = 7.2 Hz, 2H), 1.27 (t, <i>J</i> = 7.3 Hz, 3H), 0.86 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 156.62, 156.60, 156.47, 154.06, 150.12, 147.64, 147.14, 147.01, 146.26, 146.03, 139.16, 137.67, 137.56, 132.27, 132.20, 132.16, 120.50, 115.69, 115.64, 114.77, 107.00, 106.75, 53.63, 51.30, 51.10, 48.17, 23.52, 11.29, 9.41. HRMS (ESI) <i>m</i>/<i>z</i>: 428.2376 [M + H<sup>+</sup>].</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 4-(1-Butyl-1<i>H</i>-pyrazol-4-yl)-5-fluoro-<i>N</i>-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)pyrimidin-2-amine (<b>12e</b>)</h3><div class="NLM_p last">Yield: 42%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.60 (s, 1H), 8.45 (d, <i>J</i> = 39.3 Hz, 2H), 8.07 (s, 1H), 7.56 (dd, <i>J</i> = 75.5, 11.9 Hz, 2H), 7.00 (t, <i>J</i> = 9.4 Hz, 1H), 4.24 (s, 2H), 2.96 (s, 4H), 2.23 (s, 3H), 1.99–1.61 (m, 2H), 1.47–1.15 (m, 2H), 1.08–0.59 (t, <i>J</i> = 7.3 Hz, 3H). MS (ESI), [M + H<sup>+</sup>] <i>m</i>/<i>z</i>: 428.2376.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 4-(1-Cyclopentyl-1<i>H</i>-pyrazol-4-yl)-5-fluoro-<i>N</i>-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)pyrimidin-2-amine (<b>12f</b>)</h3><div class="NLM_p last">Yield: 60%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.61 (s, 1H), 8.44 (dd, <i>J</i> = 48.4, 2.4 Hz, 2H), 8.09 (s, 1H), 7.67 (dd, <i>J</i> = 15.5, 2.4 Hz, 1H), 7.46 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 7.00 (t, <i>J</i> = 9.4 Hz, 1H), 4.87 (p, <i>J</i> = 7.0 Hz, 1H), 2.95 (t, <i>J</i> = 4.8 Hz, 4H), 2.34–2.04 (m, 5H), 1.97 (dq, <i>J</i> = 13.8, 6.9 Hz, 2H), 1.90–1.76 (m, 2H), 1.67 (qq, <i>J</i> = 9.9, 6.7, 5.0 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i>: 440.2377 [M + H<sup>+</sup>].</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 4-(1-Cyclopentyl-1<i>H</i>-pyrazol-4-yl)-<i>N</i>-(4-(4-ethylpiperazin-1-yl)-3-fluorophenyl)-5-fluoropyrimidin-2-amine (<b>12g</b>)</h3><div class="NLM_p last">Yield: 55%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.44 (s, 1H), 8.50 (d, <i>J</i> = 2.9 Hz, 1H), 8.40 (d, <i>J</i> = 1.8 Hz, 1H), 8.10 (d, <i>J</i> = 9.3 Hz, 2H), 7.99 (d, <i>J</i> = 3.0 Hz, 1H), 7.46 (dd, <i>J</i> = 9.2, 3.1 Hz, 1H), 4.87 (p, <i>J</i> = 7.1 Hz, 1H), 3.12 (t, <i>J</i> = 5.0 Hz, 4H), 2.53 (s, 4H), 2.38 (q, <i>J</i> = 7.2 Hz, 2H), 2.13 (dq, <i>J</i> = 12.8, 6.8 Hz, 2H), 1.97 (dq, <i>J</i> = 13.7, 7.0 Hz, 2H), 1.83 (qd, <i>J</i> = 11.5, 9.8, 5.0 Hz, 2H), 1.68 (dtd, <i>J</i> = 12.2, 7.7, 3.5 Hz, 2H), 1.04 (t, <i>J</i> = 7.1 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i>: 437.2567 [M + H<sup>+</sup>].</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 5-Fluoro-<i>N</i>-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-(1-(1-propylpiperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>12h</b>)</h3><div class="NLM_p last">Yield: 48%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.61 (s, 1H), 8.50 (d, <i>J</i> = 2.9 Hz, 1H), 8.39 (d, <i>J</i> = 1.9 Hz, 1H), 8.09 (s, 1H), 7.66 (dd, <i>J</i> = 15.5, 2.5 Hz, 1H), 7.46 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 7.00 (t, <i>J</i> = 9.4 Hz, 1H), 4.30 (h, <i>J</i> = 7.6, 6.4 Hz, 1H), 3.09–2.82 (m, 6H), 2.47 (d, <i>J</i> = 5.0 Hz, 4H), 2.25 (d, <i>J</i> = 21.7 Hz, 5H), 2.03 (t, <i>J</i> = 8.8 Hz, 6H), 1.46 (h, <i>J</i> = 7.3 Hz, 2H), 0.87 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 156.71, 147.57, 147.10, 147.08, 146.23, 138.97, 138.91, 136.53, 136.43, 134.17, 134.08, 130.24, 119.80, 119.79, 115.68, 115.63, 114.74, 107.07, 106.82, 60.05, 59.57, 55.27, 52.44, 50.93, 46.27, 32.40, 20.27, 12.32. HRMS (ESI) <i>m</i>/<i>z</i>: 497.2949 [M + H<sup>+</sup>].</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 4-(1-(1-Butylpiperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)-5-fluoro-<i>N</i>-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)pyrimidin-2-amine (<b>12i</b>)</h3><div class="NLM_p last">Yield: 56%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.61 (s, 1H), 8.45 (d, <i>J</i> = 43.4 Hz, 2H), 8.09 (s, 1H), 7.66 (d, <i>J</i> = 15.4 Hz, 1H), 7.46 (d, <i>J</i> = 8.8 Hz, 1H), 7.00 (s, 0H), 4.30 (s, 0H), 3.18–2.72 (m, 6H), 2.47 (s, 5H), 2.31 (t, <i>J</i> = 7.3 Hz, 2H), 2.22 (s, 2H), 2.01 (d, <i>J</i> = 7.3 Hz, 6H), 1.43 (p, <i>J</i> = 7.4 Hz, 2H), 1.31 (p, <i>J</i> = 7.2 Hz, 2H), 0.89 (t, <i>J</i> = 7.0 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i>: 511.3107 [M + H<sup>+</sup>].</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 5-Fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-<i>N</i>-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidin-2-amine (<b>12j</b>)</h3><div class="NLM_p last">Yield: 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.31 (s, 1H), 8.43 (d, <i>J</i> = 3.0 Hz, 1H), 8.36 (d, <i>J</i> = 1.9 Hz, 1H), 8.07 (d, <i>J</i> = 1.4 Hz, 1H), 7.65–7.53 (m, 2H), 6.97–6.85 (m, 2H), 4.67 (hept, <i>J</i> = 6.7 Hz, 1H), 3.07 (t, <i>J</i> = 5.0 Hz, 4H), 2.48 (d, <i>J</i> = 5.1 Hz, 4H), 2.24 (s, 3H), 1.47 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 156.84, 156.82, 150.28, 147.80, 147.62, 147.49, 147.11, 145.27, 145.03, 139.57, 139.51, 132.61, 128.29, 128.21, 120.82, 117.02, 116.25, 116.19, 55.14, 54.33, 49.81, 46.05, 22.83. HRMS (ESI) <i>m</i>/<i>z</i>: 396.2313 [M + H<sup>+</sup>].</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 5-Fluoro-<i>N</i>-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>12k</b>)</h3><div class="NLM_p last">Yield: 49%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.70 (s, 2H), 8.52 (d, <i>J</i> = 2.9 Hz, 1H), 8.40 (d, <i>J</i> = 2.0 Hz, 1H), 8.10 (s, 1H), 7.74 (dd, <i>J</i> = 15.3, 2.4 Hz, 1H), 7.51 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 7.10 (t, <i>J</i> = 9.4 Hz, 1H), 4.67 (hept, <i>J</i> = 6.7 Hz, 1H), 3.60–2.96 (m, 9H), 2.35 (s, 3H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 156.62, 156.60, 150.13, 147.64, 147.21, 147.08, 146.20, 145.97, 138.91, 138.87, 137.67, 132.25, 132.15, 129.96, 129.88, 120.53, 120.50, 115.58, 115.53, 114.76, 106.98, 106.73, 54.03, 53.24, 48.21, 48.18, 42.80, 22.96. HRMS (ESI) <i>m</i>/<i>z</i>: 414.2218 [M + H<sup>+</sup>].</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>N</i>-(4-(4-Ethylpiperazin-1-yl)-2-fluorophenyl)-5-fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>12l</b>)</h3><div class="NLM_p last">Yield: 62%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.47 (s, 1H), 8.52 (d, <i>J</i> = 3.0 Hz, 1H), 8.41 (d, <i>J</i> = 2.0 Hz, 1H), 8.24 (s, 1H), 8.19 (dd, <i>J</i> = 9.0, 6.1 Hz, 1H), 8.12 (d, <i>J</i> = 1.3 Hz, 1H), 7.12–7.01 (m, 2H), 4.67 (hept, <i>J</i> = 6.6 Hz, 1H), 3.57 (d, <i>J</i> = 11.1 Hz, 2H), 3.30–3.16 (m, 6H), 3.02 (t, <i>J</i> = 12.2 Hz, 2H), 2.35 (s, 5H), 1.47 (d, <i>J</i> = 6.7 Hz, 6H), 1.26 (t, <i>J</i> = 7.3 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i>: 428.2373 [M + H<sup>+</sup>].</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-(4-(4-Ethylpiperazin-1-yl)-3-fluorophenyl)-5-fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>12m</b>)</h3><div class="NLM_p last">Yield: 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.71 (s, 1H), 9.46 (s, 1H), 8.52 (d, <i>J</i> = 2.9 Hz, 1H), 8.40 (d, <i>J</i> = 2.0 Hz, 1H), 8.10 (d, <i>J</i> = 1.1 Hz, 1H), 7.75 (dd, <i>J</i> = 15.3, 2.4 Hz, 1H), 7.55–7.49 (m, 1H), 7.10 (dd, <i>J</i> = 10.0, 8.8 Hz, 1H), 4.67 (hept, <i>J</i> = 6.7 Hz, 1H), 3.64–3.52 (m, 2H), 3.44 (d, <i>J</i> = 12.6 Hz, 2H), 3.20 (ddt, <i>J</i> = 18.0, 12.4, 8.5 Hz, 4H), 3.10–2.96 (m, 2H), 2.39–2.31 (m, 3H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H), 1.27 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 156.59, 156.57, 156.46, 154.06, 150.12, 147.63, 147.24, 147.11, 146.14, 145.90, 138.93, 138.88, 137.65, 137.55, 132.26, 132.16, 129.97, 129.88, 120.45, 120.42, 115.58, 115.53, 114.80, 114.77, 107.01, 106.75, 54.03, 51.31, 51.09, 48.15, 48.12, 22.95, 9.38. HRMS (ESI) <i>m</i>/<i>z</i>: 428.2371 [M + H<sup>+</sup>].</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 5-Fluoro-<i>N</i>-(3-fluoro-4-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)phenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>12n</b>)</h3><div class="NLM_p last">Yield: 44%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.60 (s, 1H), 8.50 (d, <i>J</i> = 2.9 Hz, 1H), 8.38 (d, <i>J</i> = 1.9 Hz, 1H), 8.08 (s, 1H), 7.66 (dd, <i>J</i> = 15.4, 2.5 Hz, 1H), 7.44 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H), 6.99 (t, <i>J</i> = 9.4 Hz, 1H), 4.67 (hept, <i>J</i> = 6.7 Hz, 1H), 3.28 (s, 1H), 2.65–2.56 (m, 2H), 2.36–2.19 (m, 4H), 2.14 (s, 3H), 1.82 (d, <i>J</i> = 12.1 Hz, 2H), 1.70–1.34 (m, 8H). HRMS (ESI) <i>m</i>/<i>z</i>: 497.2951 [M + H<sup>+</sup>].</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-(4-([1,4′-Bipiperidin]-1′-yl)-3-fluorophenyl)-5-fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>12o</b>)</h3><div class="NLM_p last">Yield: 38%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.60 (s, 1H), 8.50 (d, <i>J</i> = 2.9 Hz, 1H), 8.38 (d, <i>J</i> = 1.9 Hz, 1H), 8.08 (d, <i>J</i> = 1.2 Hz, 1H), 7.67 (dd, <i>J</i> = 15.4, 2.4 Hz, 1H), 7.44 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.00 (t, <i>J</i> = 9.4 Hz, 1H), 4.67 (hept, <i>J</i> = 6.6 Hz, 1H), 3.30 (s, 2H), 2.66–2.53 (m, 5H), 2.42 (s, 1H), 1.82 (d, <i>J</i> = 12.0 Hz, 2H), 1.63 (dt, <i>J</i> = 12.1, 6.7 Hz, 2H), 1.52 (d, <i>J</i> = 5.6 Hz, 4H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H), 1.41 (d, <i>J</i> = 6.0 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 156.68, 150.05, 147.56, 147.16, 145.85, 145.62, 138.88, 136.50, 129.47, 119.83, 115.75, 114.58, 107.06, 106.81, 62.40, 54.02, 51.05, 50.04, 27.90, 22.94. HRMS (ESI) <i>m</i>/<i>z</i>: 482.2840 [M + H<sup>+</sup>].</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-(3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>12p</b>)</h3><div class="NLM_p last">Yield: 47%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.37 (s, 1H), 8.30 (d, <i>J</i> = 18.4 Hz, 2H), 8.08 (s, 1H), 7.76 (dd, <i>J</i> = 15.7, 2.4 Hz, 1H), 7.45 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 7.05–6.94 (m, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 3.57 (s, 1H), 2.94 (t, <i>J</i> = 4.8 Hz, 4H), 2.46 (t, <i>J</i> = 4.9 Hz, 4H), 2.31 (s, 3H), 2.22 (s, 3H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 159.50, 158.43, 158.02, 156.93, 154.51, 139.41, 135.80, 135.69, 134.52, 134.43, 128.10, 121.08, 119.18, 119.13, 116.79, 114.50, 114.47, 107.90, 107.64, 55.26, 54.20, 50.95, 50.92, 46.15, 22.81, 17.31, 17.24. HRMS (ESI) <i>m</i>/<i>z</i>: 410.2462 [M + H<sup>+</sup>].</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N</i>-(4-(4-Ethylpiperazin-1-yl)-3-fluorophenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>12q</b>)</h3><div class="NLM_p last">Yield: 45%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.09 (s, 1H), 8.32 (d, <i>J</i> = 21.5 Hz, 2H), 8.17 (d, <i>J</i> = 9.1 Hz, 1H), 8.10 (s, 1H), 7.98 (d, <i>J</i> = 3.0 Hz, 1H), 7.46 (dd, <i>J</i> = 9.1, 3.0 Hz, 1H), 4.64 (p, <i>J</i> = 6.6 Hz, 1H), 3.11 (t, <i>J</i> = 4.9 Hz, 4H), 2.35 (d, <i>J</i> = 19.3 Hz, 5H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H), 1.04 (t, <i>J</i> = 7.2 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i>: 407.2667 [M + H<sup>+</sup>].</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> <i>N</i>-(3-Fluoro-4-(4-(methylamino)piperidin-1-yl)phenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>17b</b>)</h3><div class="NLM_p last"><i>tert</i>-Butyl-(1-(2-fluoro-4-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)phenyl)piperidin-4-yl)carbamate was removed Boc group according to general procedure 3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.66 (s, 1H), 9.65 (t, <i>J</i> = 5.7 Hz, 2H), 8.55 (s, 1H), 8.44 (s, 1H), 8.18 (s, 1H), 7.80–7.70 (m, 1H), 7.52–7.42 (m, 2H), 4.69 (hept, <i>J</i> = 6.6 Hz, 1H), 3.65–3.52 (m, 2H), 3.25 (q, <i>J</i> = 9.1, 7.3 Hz, 1H), 3.16–3.05 (m, 2H), 2.39 (s, 3H), 2.33–2.22 (m, 2H), 2.05 (tt, <i>J</i> = 12.3, 6.3 Hz, 2H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). HRMS (ESI) <i>m</i>/<i>z</i>: 424.2545 [M + H<sup>+</sup>].</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 4-(1-Cyclopentyl-1<i>H</i>-pyrazol-4-yl)-<i>N</i>-(4-(4-(dimethylamino)piperidin-1-yl)-3-fluorophenyl)-5-fluoropyrimidin-2-amine (<b>18a</b>)</h3><div class="NLM_p last">Yield: 67%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.40 (s, 1H), 8.51 (d, <i>J</i> = 3.0 Hz, 1H), 8.41 (d, <i>J</i> = 1.9 Hz, 1H), 8.10 (d, <i>J</i> = 9.5 Hz, 2H), 7.99 (d, <i>J</i> = 3.0 Hz, 1H), 7.47 (dd, <i>J</i> = 9.2, 3.0 Hz, 1H), 4.68 (p, <i>J</i> = 6.6 Hz, 1H), 3.12 (t, <i>J</i> = 5.0 Hz, 4H), 2.38 (q, <i>J</i> = 7.2 Hz, 3H), 1.48 (dd, <i>J</i> = 6.8, 4.1 Hz, 9H), 1.26 (d, <i>J</i> = 7.1 Hz, 7H), 1.04 (t, <i>J</i> = 7.2 Hz, 3H), 0.86 (t, <i>J</i> = 6.6 Hz, 4H). HRMS (ESI) <i>m</i>/<i>z</i>: 411.2417 [M + H<sup>+</sup>].</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>N</i>-(4-(4-(Dimethylamino)piperidin-1-yl)-3-fluorophenyl)-5-fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>18b</b>)</h3><div class="NLM_p last">Yield: 60%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.61 (s, 1H), 8.44 (d, <i>J</i> = 46.7 Hz, 2H), 8.09 (s, 1H), 7.67 (d, <i>J</i> = 15.3 Hz, 1H), 7.45 (d, <i>J</i> = 8.6 Hz, 1H), 7.00 (t, <i>J</i> = 9.3 Hz, 1H), 4.67 (dt, <i>J</i> = 13.5, 6.5 Hz, 1H), 3.40 (s, 4H), 2.61 (t, <i>J</i> = 11.5 Hz, 2H), 2.26 (s, 6H), 1.98–1.76 (m, 2H), 1.52 (dd, <i>J</i> = 30.1, 7.1 Hz, 7H). HRMS (ESI) <i>m</i>/<i>z</i>: 442.2528 [M + H<sup>+</sup>].</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (1-(2-Fluoro-4-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)phenyl)piperidin-4-yl)methanol (<b>18c</b>)</h3><div class="NLM_p last">Yield: 62%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.35 (s, 1H), 8.30 (d, <i>J</i> = 18.8 Hz, 2H), 8.08 (s, 1H), 7.74 (dd, <i>J</i> = 15.4, 2.4 Hz, 1H), 7.51–7.37 (m, 1H), 6.99 (t, <i>J</i> = 9.4 Hz, 1H), 4.63 (hept, <i>J</i> = 6.9 Hz, 1H), 4.46 (t, <i>J</i> = 5.2 Hz, 1H), 3.31 (d, <i>J</i> = 4.9 Hz, 2H), 3.26 (d, <i>J</i> = 11.4 Hz, 2H), 2.58 (t, <i>J</i> = 11.5 Hz, 2H), 2.31 (s, 3H), 1.83–1.67 (m, 2H), 1.48 (d, <i>J</i> = 6.7 Hz, 7H), 1.30 (qd, <i>J</i> = 12.4, 4.2 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.82, 158.75, 157.78, 154.16, 139.32, 136.88, 134.62, 129.42, 120.58, 120.04, 116.67, 114.57, 106.95, 66.39, 53.83, 51.67, 38.58, 29.48, 23.02, 17.14. HRMS (ESI) <i>m</i>/<i>z</i>: 425.2467 [M + H<sup>+</sup>].</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>N</i>-(4-(4-(Dimethylamino)piperidin-1-yl)-3-fluorophenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>18d</b>)</h3><div class="NLM_p last">Yield: 68%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.36 (s, 1H), 8.30 (d, <i>J</i> = 18.9 Hz, 2H), 8.08 (s, 1H), 7.75 (dd, <i>J</i> = 15.6, 2.4 Hz, 1H), 7.43 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 7.03–6.93 (m, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 3.31–3.21 (m, 2H), 2.60 (td, <i>J</i> = 11.8, 2.3 Hz, 2H), 2.31 (s, 3H), 2.19 (s, 7H), 1.89–1.76 (m, 2H), 1.60–1.43 (m, 8H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 159.54, 158.42, 158.04, 156.99, 154.56, 139.41, 135.59, 135.48, 135.03, 134.94, 128.10, 121.10, 119.44, 119.40, 116.81, 114.41, 114.38, 107.87, 107.61, 62.01, 54.22, 51.13, 51.11, 41.62, 29.69, 28.54, 22.83, 17.24. HRMS (ESI) <i>m</i>/<i>z</i>: 438.2738 [M + H<sup>+</sup>].</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 2-((1-(2-Fluoro-4-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)phenyl)piperidin-4-yl)(methyl)amino)ethan-1-ol (<b>18e</b>)</h3><div class="NLM_p last">Yield: 58%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.38 (s, 1H), 8.31 (d, <i>J</i> = 20.6 Hz, 2H), 8.08 (s, 1H), 7.75 (dd, <i>J</i> = 15.5, 2.4 Hz, 1H), 7.47–7.40 (m, 1H), 6.99 (dd, <i>J</i> = 10.1, 8.8 Hz, 1H), 4.63 (p, <i>J</i> = 6.7 Hz, 1H), 4.33 (s, 1H), 3.45 (t, <i>J</i> = 6.5 Hz, 2H), 3.30 (d, <i>J</i> = 11.7 Hz, 2H), 2.65–2.55 (m, 2H), 2.43 (td, <i>J</i> = 11.6, 5.9 Hz, 1H), 2.31 (s, 3H), 2.24 (s, 3H), 1.81–1.72 (m, 2H), 1.58 (qd, <i>J</i> = 12.2, 3.9 Hz, 2H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.84, 158.69, 157.80, 154.10, 139.32, 137.47, 133.13, 129.49, 120.53, 120.38, 116.84, 114.60, 106.91, 62.48, 55.93, 54.69, 53.84, 50.14, 37.25, 26.45, 23.03, 17.14. HRMS (ESI) <i>m</i>/<i>z</i>: 468.2881 [M + H<sup>+</sup>].</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 3-((1-(2-Fluoro-4-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)phenyl)piperidin-4-yl)(methyl)amino)propan-1-ol (<b>18f</b>)</h3><div class="NLM_p last">Yield: 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.36 (s, 1H), 8.31 (d, <i>J</i> = 19.0 Hz, 2H), 8.08 (s, 1H), 7.75 (dd, <i>J</i> = 15.5, 2.5 Hz, 1H), 7.44 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 7.04–6.93 (m, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 2H), 3.46 (t, <i>J</i> = 6.2 Hz, 2H), 3.32 (s, 2H), 3.29 (s, 2H), 2.67–2.56 (m, 2H), 2.47–2.39 (m, 1H), 2.32 (s, 3H), 2.21 (s, 3H), 1.76 (d, <i>J</i> = 12.1 Hz, 2H), 1.67–1.52 (m, 4H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.82, 158.69, 157.83, 154.12, 139.32, 137.47, 133.13, 129.49, 120.53, 120.40, 116.84, 114.60, 106.91, 62.48, 55.93, 54.69, 53.84, 50.14, 37.25, 28.37, 26.45, 23.03, 17.14. HRMS (ESI) <i>m</i>/<i>z</i>: 482.3043 [M + H<sup>+</sup>].</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 5-((1-(2-Fluoro-4-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)phenyl)piperidin-4-yl)(methyl)amino)pentan-1-ol (<b>18g</b>)</h3><div class="NLM_p last">Yield: 65%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.42 (s, 1H), 8.32 (d, <i>J</i> = 20.1 Hz, 2H), 8.09 (s, 1H), 7.80 (dd, <i>J</i> = 15.5, 2.4 Hz, 1H), 7.47 (dd, <i>J</i> = 8.9, 2.4 Hz, 1H), 7.25 (d, <i>J</i> = 51.1 Hz, 1H), 7.07–6.99 (m, 1H), 4.64 (hept, <i>J</i> = 6.7 Hz, 1H), 3.73 (m, 1H), 3.42 (tt, <i>J</i> = 9.5, 6.4, 5.5 Hz, 6H), 2.96 (s, 3H), 2.76 (t, <i>J</i> = 11.6 Hz, 2H), 2.32 (s, 3H), 2.18 (d, <i>J</i> = 11.7 Hz, 2H), 1.97–1.75 (m, 6H), 1.58 (dq, <i>J</i> = 23.6, 7.3, 6.8 Hz, 2H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). HRMS (ESI) <i>m</i>/<i>z</i>: 492.2878 [M + H<sup>+</sup>].</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>N</i>-(3-Fluoro-4-(4-(methyl(propyl)amino)piperidin-1-yl)phenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>18h</b>)</h3><div class="NLM_p last">Yield: 66%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.36 (s, 1H), 8.30 (d, <i>J</i> = 19.1 Hz, 2H), 8.08 (s, 1H), 7.75 (dd, <i>J</i> = 15.6, 2.5 Hz, 1H), 7.44 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 6.98 (dd, <i>J</i> = 10.1, 8.8 Hz, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 3.30 (d, <i>J</i> = 15.1 Hz, 5H), 2.68–2.56 (m, 2H), 2.39 (q, <i>J</i> = 7.4, 6.8 Hz, 3H), 2.32 (s, 3H), 2.20 (s, 3H), 1.75 (d, <i>J</i> = 12.1 Hz, 2H), 1.59 (tt, <i>J</i> = 11.8, 5.5 Hz, 2H), 1.53–1.34 (m, 8H), 0.85 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.81, 158.74, 157.78, 154.09, 139.32, 136.97, 134.17, 129.42, 120.58, 120.00, 116.67, 114.51, 106.93, 60.62, 55.53, 53.83, 51.33, 37.76, 28.35, 23.02, 20.85, 17.14, 12.19. HRMS (ESI) <i>m</i>/<i>z</i>: 466.3088 [M + H<sup>+</sup>].</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> <i>N</i>-(4-(4-(Butyl(methyl)amino)piperidin-1-yl)-3-fluorophenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>18i</b>)</h3><div class="NLM_p last">Yield: 55%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.36 (s, 1H), 8.31 (dd, <i>J</i> = 19.0, 0.7 Hz, 2H), 8.11–8.06 (m, 1H), 7.75 (dd, <i>J</i> = 15.6, 2.4 Hz, 1H), 7.47–7.40 (m, 1H), 6.99 (dd, <i>J</i> = 10.1, 8.8 Hz, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 2.61 (td, <i>J</i> = 11.8, 2.3 Hz, 2H), 2.41 (t, <i>J</i> = 7.1 Hz, 3H), 2.32 (s, 3H), 2.19 (s, 3H), 1.80–1.68 (m, 2H), 1.59 (qd, <i>J</i> = 11.8, 3.7 Hz, 2H), 1.49 (d, <i>J</i> = 6.7 Hz, 6H), 1.38 (ddt, <i>J</i> = 12.4, 10.0, 5.8 Hz, 2H), 1.28 (qd, <i>J</i> = 7.6, 5.8 Hz, 2H), 0.89 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.82, 158.74, 157.78, 156.49, 154.09, 139.32, 136.96, 134.18, 129.42, 120.58, 116.68, 114.53, 106.92, 60.62, 53.83, 53.22, 51.36, 37.80, 29.93, 28.37, 23.02, 20.48, 17.14, 14.40. HRMS (ESI) <i>m</i>/<i>z</i>: 480.3251 [M + H<sup>+</sup>].</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> <i>N</i>-(3-Fluoro-4-(4-(hexyl(methyl)amino)piperidin-1-yl)phenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>18j</b>)</h3><div class="NLM_p last">Yield: 66%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.36 (s, 1H), 8.31 (d, <i>J</i> = 19.0 Hz, 2H), 8.08 (s, 1H), 7.75 (dd, <i>J</i> = 15.6, 2.4 Hz, 1H), 7.43 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.04–6.94 (m, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 2.66–2.55 (m, 2H), 2.40 (d, <i>J</i> = 7.6 Hz, 3H), 2.32 (s, 3H), 2.20 (s, 3H), 1.75 (d, <i>J</i> = 12.1 Hz, 2H), 1.60 (td, <i>J</i> = 11.9, 3.7 Hz, 2H), 1.54 (s, 6H), 1.39 (q, <i>J</i> = 6.7 Hz, 2H), 1.27 (s, 6H), 0.87 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.80, 158.74, 157.77, 154.09, 139.32, 136.98, 134.15, 129.40, 120.59, 119.98, 116.65, 114.51, 106.92, 60.65, 53.83, 53.54, 51.34, 37.76, 31.75, 28.35, 27.66, 27.01, 23.01, 22.64, 17.15, 14.40. HRMS (ESI) <i>m</i>/<i>z</i>: 508.3566 [M + H<sup>+</sup>].</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> <i>N</i>-(4-(4-((2-Ethoxyethyl) (methyl)amino)piperidin-1-yl)-3-fluorophenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>18k</b>)</h3><div class="NLM_p last">Yield: 48%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.36 (s, 1H), 8.37–8.24 (m, 2H), 8.08 (s, 1H), 7.75 (dd, <i>J</i> = 15.6, 2.5 Hz, 1H), 7.48–7.40 (m, 1H), 6.99 (dd, <i>J</i> = 10.1, 8.8 Hz, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 3.44 (t, <i>J</i> = 6.9 Hz, 4H), 2.60 (dq, <i>J</i> = 9.7, 4.8, 3.2 Hz, 4H), 2.48–2.39 (m, 1H), 2.32 (s, 3H), 2.24 (s, 3H), 1.82–1.71 (m, 2H), 1.58 (qd, <i>J</i> = 11.8, 3.5 Hz, 2H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H), 1.11 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.82, 158.74, 157.78, 154.09, 139.32, 136.96, 134.16, 129.42, 120.58, 120.01, 116.68, 114.54, 106.93, 69.34, 65.87, 60.92, 53.83, 53.24, 51.29, 38.51, 28.45, 23.02, 17.14, 15.65. HRMS (ESI) <i>m</i>/<i>z</i>: 496.3199 [M + H<sup>+</sup>].</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> <i>N</i>-(4-(4-((Cyclopropylmethyl)(methyl)amino)piperidin-1-yl)-3-fluorophenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>18l</b>)</h3><div class="NLM_p last">Yield: 52%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.36 (s, 1H), 8.31 (d, <i>J</i> = 19.0 Hz, 2H), 8.08 (s, 1H), 7.75 (dd, <i>J</i> = 15.6, 2.5 Hz, 1H), 7.44 (dd, <i>J</i> = 8.9, 2.4 Hz, 1H), 6.99 (dd, <i>J</i> = 10.1, 8.8 Hz, 1H), 5.82 (ddt, <i>J</i> = 17.0, 10.2, 6.7 Hz, 1H), 5.07 (dq, <i>J</i> = 17.2, 1.7 Hz, 1H), 4.98 (ddt, <i>J</i> = 10.2, 2.4, 1.2 Hz, 1H), 4.64 (h, <i>J</i> = 6.7 Hz, 1H), 3.32 (s, 4H), 2.61 (td, <i>J</i> = 11.9, 2.3 Hz, 2H), 2.45 (s, 1H), 2.32 (s, 3H), 2.23 (s, 3H), 2.20–2.11 (m, 2H), 1.81–1.69 (m, 2H), 1.59 (qd, <i>J</i> = 11.9, 3.7 Hz, 2H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). HRMS (ESI) <i>m</i>/<i>z</i>: 478.3091 [M + H<sup>+</sup>].</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>N</i>-(3-Fluoro-4-(4-(methyl((tetrahydrofuran-2-yl)methyl)amino)piperidin-1-yl)phenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>18m</b>)</h3><div class="NLM_p last">Yield: 48%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.35 (s, 1H), 8.29 (d, <i>J</i> = 19.3 Hz, 2H), 8.08 (s, 1H), 7.75 (dd, <i>J</i> = 15.5, 2.4 Hz, 1H), 7.51–7.36 (m, 1H), 6.96 (t, <i>J</i> = 9.4 Hz, 1H), 4.62 (hept, <i>J</i> = 6.8 Hz, 1H), 3.86 (p, <i>J</i> = 6.4 Hz, 1H), 3.73 (q, <i>J</i> = 7.1 Hz, 1H), 3.59 (q, <i>J</i> = 7.4 Hz, 1H), 3.28 (d, <i>J</i> = 11.3 Hz, 2H), 2.58 (t, <i>J</i> = 11.8 Hz, 2H), 2.45 (d, <i>J</i> = 6.0 Hz, 3H), 2.28 (d, <i>J</i> = 21.6 Hz, 6H), 1.89 (tt, <i>J</i> = 11.9, 6.1 Hz, 1H), 1.77 (dq, <i>J</i> = 20.7, 13.7, 10.5 Hz, 4H), 1.62–1.39 (m, 9H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.81, 158.74, 157.78, 154.09, 139.32, 136.99, 134.12, 129.41, 120.59, 120.02, 116.67, 114.53, 106.92, 77.97, 67.51, 61.30, 58.01, 53.83, 51.32, 30.06, 28.58, 28.00, 25.41, 23.02, 17.14. HRMS (ESI) <i>m</i>/<i>z</i>: 508.3198 [M + H<sup>+</sup>].</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> <i>N</i>-(3-Fluoro-4-(4-(methyl(2-morpholinoethyl)amino)piperidin-1-yl)phenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>18n</b>)</h3><div class="NLM_p last">Yield: 66%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.36 (s, 1H), 8.30 (d, <i>J</i> = 19.0 Hz, 2H), 8.08 (s, 1H), 7.75 (dd, <i>J</i> = 15.6, 2.5 Hz, 1H), 7.47–7.39 (m, 1H), 6.98 (dd, <i>J</i> = 10.1, 8.8 Hz, 1H), 4.63 (hept, <i>J</i> = 6.6 Hz, 1H), 3.56 (t, <i>J</i> = 4.6 Hz, 4H), 2.67–2.53 (m, 4H), 2.46–2.27 (m, 10H), 2.22 (s, 3H), 1.76 (d, <i>J</i> = 11.9 Hz, 2H), 1.58 (qd, <i>J</i> = 12.1, 11.7, 3.5 Hz, 2H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.79, 158.74, 157.77, 154.10, 139.33, 136.99, 134.12, 129.37, 120.60, 119.97, 116.65, 114.53, 114.50, 106.93, 66.70, 60.95, 57.31, 54.18, 53.83, 51.30, 50.96, 38.23, 28.37, 23.01, 17.15. HRMS (ESI) <i>m</i>/<i>z</i>: 537.3463 [M + H<sup>+</sup>].</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> N-(3-Fluoro-4-(4-(methyl(2-(piperidin-1-yl)ethyl)amino)piperidin-1-yl)phenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>18o</b>)</h3><div class="NLM_p last">Yield: 54%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.36 (s, 1H), 8.30 (d, <i>J</i> = 19.0 Hz, 2H), 8.08 (s, 1H), 7.75 (dd, <i>J</i> = 15.5, 2.5 Hz, 1H), 7.43 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 6.98 (t, <i>J</i> = 9.5 Hz, 1H), 4.63 (hept, <i>J</i> = 6.6 Hz, 1H), 3.28 (s, 2H), 2.65–2.57 (m, 2H), 2.54 (dd, <i>J</i> = 8.5, 5.7 Hz, 2H), 2.48–2.29 (m, 10H), 2.22 (s, 3H), 1.76 (d, <i>J</i> = 12.0 Hz, 2H), 1.59 (td, <i>J</i> = 11.7, 3.6 Hz, 2H), 1.48 (t, <i>J</i> = 5.9 Hz, 10H), 1.37 (q, <i>J</i> = 6.2 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.81, 158.74, 157.78, 154.09, 139.32, 136.97, 134.16, 129.42, 120.58, 120.02, 116.67, 114.54, 106.93, 60.88, 57.77, 54.92, 53.83, 51.40, 51.33, 38.30, 28.44, 26.08, 24.55, 23.03, 17.15. HRMS (ESI) <i>m</i>/<i>z</i>: 535.3671 [M + H<sup>+</sup>].</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> <i>N</i>-(3-Fluoro-4-(4-(methyl(2-(4-methylpiperazin-1-yl)ethyl)amino)piperidin-1-yl)phenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>18p</b>)</h3><div class="NLM_p last">Yield: 53%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.35 (s, 1H), 8.30 (d, <i>J</i> = 18.6 Hz, 2H), 8.08 (s, 1H), 7.74 (dd, <i>J</i> = 15.5, 2.5 Hz, 1H), 7.43 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 6.97 (t, <i>J</i> = 9.4 Hz, 1H), 4.63 (p, <i>J</i> = 6.6 Hz, 1H), 3.29 (d, <i>J</i> = 11.0 Hz, 2H), 2.58 (ddd, <i>J</i> = 23.0, 10.6, 2.5 Hz, 4H), 2.47–2.08 (m, 20H), 1.75 (d, <i>J</i> = 12.0 Hz, 2H), 1.57 (qd, <i>J</i> = 12.0, 3.8 Hz, 2H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.78, 158.75, 157.77, 154.10, 139.33, 136.98, 134.15, 129.35, 120.62, 119.90, 116.63, 114.52, 106.94, 60.90, 57.09, 55.29, 53.83, 53.57, 51.34, 46.22, 38.29, 28.45, 23.01, 17.16. HRMS (ESI) <i>m</i>/<i>z</i>: 550.3781 [M + H<sup>+</sup>].</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> <i>N</i>-(4-(4-(Ethyl(2-morpholinoethyl)amino)piperidin-1-yl)-3-fluorophenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>18q</b>)</h3><div class="NLM_p last">Yield: 62%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.36 (s, 1H), 8.33 (s, 1H), 8.28 (s, 1H), 8.08 (s, 1H), 7.75 (dd, <i>J</i> = 15.5, 2.4 Hz, 1H), 7.43 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.03–6.95 (m, 1H), 4.63 (p, <i>J</i> = 6.6 Hz, 1H), 3.59–3.53 (m, 5H), 2.69–2.52 (m, 6H), 2.43–2.27 (m, 11H), 1.75 (d, <i>J</i> = 11.9 Hz, 2H), 1.65–1.54 (m, 2H), 1.49 (d, <i>J</i> = 6.7 Hz, 6H), 0.99 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.81, 158.73, 157.77, 154.08, 139.32, 136.97, 134.16, 129.40, 120.58, 120.00, 116.67, 114.54, 106.92, 66.70, 66.66, 58.43, 54.27, 53.83, 51.51, 47.36, 44.84, 28.97, 23.02, 17.14, 14.44. HRMS (ESI) <i>m</i>/<i>z</i>: 551.3630 [M + H<sup>+</sup>].</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> <i>N</i>-(3-Fluoro-4-(4-((2-morpholinoethyl)(propyl)amino)piperidin-1-yl)phenyl)-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine (<b>18r</b>)</h3><div class="NLM_p last">Yield: 66%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.36 (s, 1H), 8.33 (s, 1H), 8.28 (s, 1H), 8.08 (s, 1H), 7.74 (dd, <i>J</i> = 15.5, 2.4 Hz, 1H), 7.43 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 6.99 (dd, <i>J</i> = 10.1, 8.7 Hz, 1H), 4.63 (p, <i>J</i> = 6.6 Hz, 1H), 3.56 (t, <i>J</i> = 4.6 Hz, 4H), 2.68–2.53 (m, 5H), 2.48–2.27 (m, 11H), 1.74 (d, <i>J</i> = 11.9 Hz, 2H), 1.49 (d, <i>J</i> = 6.6 Hz, 8H), 1.39 (q, <i>J</i> = 7.3 Hz, 2H), 0.85 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.80, 158.74, 157.77, 154.09, 139.32, 136.97, 134.18, 129.39, 120.59, 120.00, 116.65, 114.50, 106.92, 66.71, 58.93, 58.65, 54.28, 53.83, 53.02, 51.60, 48.08, 28.82, 23.02, 22.20, 17.15, 12.12. HRMS (ESI) <i>m</i>/<i>z</i>: 565.3771 [M + H<sup>+</sup>].</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 2-((1-(2-Fluoro-4-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)phenyl)piperidin-4-yl)amino)ethan-1-ol (<b>18s</b>)</h3><div class="NLM_p last">Yield: 40% <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.38 (s, 1H), 8.31 (d, <i>J</i> = 20.3 Hz, 2H), 8.08 (s, 1H), 7.74 (dd, <i>J</i> = 15.6, 2.5 Hz, 1H), 7.43 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 6.99 (dd, <i>J</i> = 10.1, 8.8 Hz, 1H), 4.64 (h, <i>J</i> = 6.7 Hz, 1H), 4.49 (t, <i>J</i> = 5.3 Hz, 1H), 3.46 (q, <i>J</i> = 5.4 Hz, 2H), 3.27–3.17 (m, 2H), 2.70–2.57 (m, 4H), 2.31 (s, 3H), 1.94–1.83 (m, 2H), 1.53–1.29 (m, 8H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.83, 158.74, 157.79, 154.09, 139.32, 136.88, 134.35, 129.44, 120.57, 120.02, 116.69, 114.56, 114.53, 106.94, 61.17, 54.48, 53.84, 50.37, 49.17, 33.01, 23.03, 17.14. HRMS (ESI) <i>m</i>/<i>z</i>: 454.2730 [M + H<sup>+</sup>].</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i75"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01348" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74335" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74335" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b01348" class="ext-link">10.1021/acs.jmedchem.9b01348</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Binding affinities of <b>18e</b> with 100 protein kinases; antiproliferative activity of <b>18e</b> against a panel of human tumor cell lines; antiproliferative activity of <b>18e</b> against a panel of human normal cell lines; 50 ns molecular dynamics simulation result of <b>18e</b>; histogram data of flow cytometry after cytokine stimulation in the presence of <b>18e</b>; western blot analysis of STAT phosophorylation after treatment with <b>18e</b> in different cells (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Details of various compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a> was used for modeling docking in JAK2 of <b>18e</b>. The authors will release the atomic coordinates and experimental data upon article publication (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a> was used for modeling docking in FLT3 of <b>18e</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecule A-FLT3-4RT7 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecule A-JAK2-2XA4 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_006.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecule B-FLT3-4RT7 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_007.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecule B-JAK2-2XA4 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_008.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_001.pdf">jm9b01348_si_001.pdf (819.59 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_002.csv">jm9b01348_si_002.csv (4.32 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_003.pdb">jm9b01348_si_003.pdb (504.91 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_004.pdb">jm9b01348_si_004.pdb (742.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_005.pdb">jm9b01348_si_005.pdb (502.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_006.pdb">jm9b01348_si_006.pdb (736.61 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_007.pdb">jm9b01348_si_007.pdb (502.99 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_008.pdb">jm9b01348_si_008.pdb (741.02 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01348" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04760" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04760" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lijuan Chen</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8076-163X" title="Orcid link">http://orcid.org/0000-0002-8076-163X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e88b808d868481829d8986d9dadda8d9dedbc68b8785"><span class="__cf_email__" data-cfemail="482b202d262421223d2926797a7d08797e7b662b2725">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Yang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mengshi Hu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenyan Qi</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhuang Yang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minghai Tang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun He</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Chen</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peng Bai</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xue Yuan</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chufeng Zhang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kongjun Liu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yulin Lu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingli Xiang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>T.Y., M.H., W.Q., and Z.Y. contributed equally and should be considered as co-first authors. The paper was written through contributions of all the authors. All the authors have given approval to the final version of the paper.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83044" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83044" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors greatly appreciate the financial support from the National Natural Science Foundation of China (81673289, 81703344) and the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University. Thanks to West China College of Pharmacy Sichuan University for providing Schrodinger software and technical support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">Fms-like tyrosine receptor kinase 3</p></td></tr><tr><td class="NLM_term">ITD</td><td class="NLM_def"><p class="first last">internal tandem duplications</p></td></tr><tr><td class="NLM_term">JAK1</td><td class="NLM_def"><p class="first last">Janus kinase 1</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">JAK3</td><td class="NLM_def"><p class="first last">Janus kinase 3</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">PE</td><td class="NLM_def"><p class="first last">petroleum ether</p></td></tr><tr><td class="NLM_term">EA</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i79">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14612" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14612" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 45 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, I. M.</span></span> <span> </span><span class="NLM_article-title">Jaks and stats in signaling by the cytokine receptor superfamily</span>. <i>Trends Genet.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/s0168-9525(00)89000-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1016%2Fs0168-9525%2800%2989000-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=7716810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADyaK2MXjvFeit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1995&pages=69-74&author=J.+N.+Ihleauthor=I.+M.+Kerr&title=Jaks+and+stats+in+signaling+by+the+cytokine+receptor+superfamily&doi=10.1016%2Fs0168-9525%2800%2989000-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Jaks and Stats in signaling by the cytokine receptor superfamily</span></div><div class="casAuthors">Ihle, James N.; Kerr, Ian M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Genetics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-74</span>CODEN:
                <span class="NLM_cas:coden">TRGEE2</span>;
        ISSN:<span class="NLM_cas:issn">0168-9525</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 67 refs.  Many cytokines mediate their biol. effects through interaction with a distinct family of receptors termed the cytokine receptor superfamily.  Although members of this family lack catalytic domains, they couple ligand binding to tyrosine phosphorylation.  Recent studies have shown that a novel family of cytoplasmic protein tyrosine kinases, termed the Janus kinases (Jaks), assoc. with the cytokine receptors and are catalytically activated after ligand binding.  The activated Jaks phosphorylate and activate members of a novel family of transcription factors termed signal transducers and activators of transcription (Stats).  In addn., many cytokines induce the phosphorylation of SHC, Vav and the p85 subunit of PI-3 kinase.  The region of the receptors proximal to the cytoplasmic membrane is required for Jak assocn., mitogenesis, Stat activation and Vav phosphorylation.  The membrane-distal region, which contains the major sites of tyrosine phosphorylation, is required for phosphorylation of SHC and p85, not for mitogenesis, thus allowing functional dissection of the signaling pathways activated by cytokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohCPhhcjNDsrVg90H21EOLACvtfcHk0li4FiU4o6E36g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjvFeit7s%253D&md5=005308d2c15a703a93e01a711d7da802</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fs0168-9525%2800%2989000-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0168-9525%252800%252989000-9%26sid%3Dliteratum%253Aachs%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26aulast%3DKerr%26aufirst%3DI.%2BM.%26atitle%3DJaks%2520and%2520stats%2520in%2520signaling%2520by%2520the%2520cytokine%2520receptor%2520superfamily%26jtitle%3DTrends%2520Genet.%26date%3D1995%26volume%3D11%26spage%3D69%26epage%3D74%26doi%3D10.1016%2Fs0168-9525%2800%2989000-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, J.</span></span> <span> </span><span class="NLM_article-title">TheJanusprotein tyrosine kinases in hematopoietic cytokine signaling</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1006/smim.1995.0029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1006%2Fsmim.1995.0029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=8520029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADyaK2MXotFegsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1995&pages=247-254&author=J.+Ihle&title=TheJanusprotein+tyrosine+kinases+in+hematopoietic+cytokine+signaling&doi=10.1006%2Fsmim.1995.0029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus protein tyrosine kinases in hematopoietic cytokine signaling</span></div><div class="casAuthors">Ihle, James N.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">247-54</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A review, with 57 refs.  Cytokines regulate cellular functions through their interaction with members of the cytokine receptor superfamily.  These receptors couple ligand binding to induction of tyrosine phosphorylation through their assocn. with the Janus protein tyrosine kinases (Jaks).  Receptor dimerization induces Jak homo- or hetero-assocns., autophosphorylation and activation of Jak catalytic activity.  The activated Jaks are hypothesized to phosphorylate the receptors as well as a no. of proteins involved in cellular signaling including SHC, the p85 subunit of PI 3-kinase, Vav and members of the Signal Transducers and Activators of Transcription (Stats) family of transcription factors.  Receptor phosphorylation also allows assocn. of hematopoietic cell phosphatase with the receptor complex, resulting in its down-regulation.  Receptor mutants have allowed the identification of specific domains that are required for each function and their correlation with biol. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0h0L8HCyoGrVg90H21EOLACvtfcHk0lidlfsS00geAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotFegsbk%253D&md5=a8c59be585bea4be3217663cc618f815</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1006%2Fsmim.1995.0029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsmim.1995.0029%26sid%3Dliteratum%253Aachs%26aulast%3DIhle%26aufirst%3DJ.%26atitle%3DTheJanusprotein%2520tyrosine%2520kinases%2520in%2520hematopoietic%2520cytokine%2520signaling%26jtitle%3DSemin.%2520Immunol.%26date%3D1995%26volume%3D7%26spage%3D247%26epage%3D254%26doi%3D10.1006%2Fsmim.1995.0029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Regulation of JAK-STAT signalling in the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+signalling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lidlfsS00geAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signalling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">STATs in cancer inflammation and immunity: a leading role for STAT3</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1038/nrc2734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fnrc2734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=19851315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=798-809&author=H.+Yuauthor=D.+Pardollauthor=R.+Jove&title=STATs+in+cancer+inflammation+and+immunity%3A+a+leading+role+for+STAT3&doi=10.1038%2Fnrc2734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">STATs in cancer inflammation and immunity: a leading role for STAT3</span></div><div class="casAuthors">Yu, Hua; Pardoll, Drew; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">798-809</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Commensurate with their roles in regulating cytokine-dependent inflammation and immunity, signal transducer and activator of transcription (STAT) proteins are central in detg. whether immune responses in the tumor microenvironment promote or inhibit cancer.  Persistently activated STAT3 and, to some extent, STAT5 increase tumor cell proliferation, survival and invasion while suppressing anti-tumor immunity.  The persistent activation of STAT3 also mediates tumor-promoting inflammation.  STAT3 has this dual role in tumor inflammation and immunity by promoting pro-oncogenic inflammatory pathways, including nuclear factor-κB (NF-κB) and interleukin-6 (IL-6)-GP130-Janus kinase (JAK) pathways, and by opposing STAT1- and NF-κB-mediated T helper 1 anti-tumor immune responses.  Consequently, STAT3 is a promising target to redirect inflammation for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYvEMN5YrxbbVg90H21EOLACvtfcHk0lidlfsS00geAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP&md5=e431d0bd9eabd8f1ef703211be3d5cc9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc2734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2734%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DPardoll%26aufirst%3DD.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DSTATs%2520in%2520cancer%2520inflammation%2520and%2520immunity%253A%2520a%2520leading%2520role%2520for%2520STAT3%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D798%26epage%3D809%26doi%3D10.1038%2Fnrc2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taoka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinsmore, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenstein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczak, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugay-Murphy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-amino-5<i>H</i>-pyrido[4,3-b]indol-4-carboxamide inhibitors of janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7334</span>– <span class="NLM_lpage">7349</span>, <span class="refDoi"> DOI: 10.1021/jm200909u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200909u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WksL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7334-7349&author=J.+Limauthor=B.+Taokaauthor=R.+D.+Otteauthor=K.+Spencerauthor=C.+J.+Dinsmoreauthor=M.+D.+Altmanauthor=G.+Chanauthor=C.+Rosensteinauthor=S.+Sharmaauthor=H.-P.+Suauthor=A.+A.+Szewczakauthor=L.+Xuauthor=H.+Yinauthor=J.+Zugay-Murphyauthor=C.+G.+Marshallauthor=J.+R.+Young&title=Discovery+of+1-amino-5H-pyrido%5B4%2C3-b%5Dindol-4-carboxamide+inhibitors+of+janus+kinase+2+%28JAK2%29+for+the+treatment+of+myeloproliferative+disorders&doi=10.1021%2Fjm200909u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-Amino-5H-pyrido[4,3-b]indol-4-carboxamide Inhibitors of Janus Kinase 2 (JAK2) for the Treatment of Myeloproliferative Disorders</span></div><div class="casAuthors">Lim, Jongwon; Taoka, Brandon; Otte, Ryan D.; Spencer, Kerrie; Dinsmore, Christopher J.; Altman, Michael D.; Chan, Grace; Rosenstein, Craig; Sharma, Sujata; Su, Hua-Poo; Szewczak, Alexander A.; Xu, Lin; Yin, Hong; Zugay-Murphy, Joan; Marshall, C. Gary; Young, Jonathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7334-7349</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The JAK-STAT pathway mediates signaling by cytokines, which control survival, proliferation, and differentiation of a variety of cells.  In recent years, a single point mutation (V617F) in the tyrosine kinase JAK2 was found to be present with a high incidence in myeloproliferative disorders (MPDs).  This mutation led to hyperactivation of JAK2, cytokine-independent signaling, and subsequent activation of downstream signaling networks.  The genetic, biol., and physiol. evidence suggests that JAK2 inhibitors could be effective in treating MPDs.  De novo design efforts of new scaffolds identified 1-amino-5H-pyrido[4,3-b]indol-4-carboxamides as a new viable lead series.  Subsequent optimization of cell potency, metabolic stability, and off-target activities of the leads led to the discovery of 7-(2-aminopyrimidin-5-yl)-1-{[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b]indole-4-carboxamide (65).  Compd. 65 is a potent, orally active inhibitor of JAK2 with excellent selectivity, PK profile, and in vivo efficacy in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3NgzLh6I6LLVg90H21EOLACvtfcHk0liPEDu6pg9Egw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WksL3E&md5=e80e29f1d8794a31602925559c6ebe09</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm200909u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200909u%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DTaoka%26aufirst%3DB.%26aulast%3DOtte%26aufirst%3DR.%2BD.%26aulast%3DSpencer%26aufirst%3DK.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DH.-P.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DZugay-Murphy%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26atitle%3DDiscovery%2520of%25201-amino-5H-pyrido%255B4%252C3-b%255Dindol-4-carboxamide%2520inhibitors%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7334%26epage%3D7349%26doi%3D10.1021%2Fjm200909u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F. H.</span></span> <span> </span><span class="NLM_article-title">Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">854</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.3390/cells8080854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.3390%2Fcells8080854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslWntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=854-872&author=F.+Pernerauthor=C.+Pernerauthor=T.+Ernstauthor=F.+H.+Heidel&title=Roles+of+JAK2+in+aging%2C+inflammation%2C+hematopoiesis+and+malignant+transformation&doi=10.3390%2Fcells8080854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation</span></div><div class="casAuthors">Perner, Florian; Perner, Caroline; Ernst, Thomas; Heidel, Florian H.</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">854</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Clonal alterations in hematopoietic cells occur during aging and are often assocd. with the establishment of a subclin. inflammatory environment.  Several age-related conditions and diseases may be initiated or promoted by these alterations.  JAK2 mutations are among the most frequently mutated genes in blood cells during aging.  The most common mutation within the JAK2 gene is JAK2-V617F that leads to constitutive activation of the kinase and thereby aberrant engagement of downstream signaling pathways.  JAK2 mutations can act as central drivers of myeloproliferative neoplasia, a pre-leukemic and age-related malignancy.  Likewise, hyperactive JAK-signaling is a hallmark of immune diseases and critically influences inflammation, coagulation and thrombosis.  In this review we aim to summarize the current knowledge on JAK2 in clonal hematopoiesis during aging, the role of JAK-signaling in inflammation and lymphocyte biol. and JAK2 function in age-related diseases and malignant transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfbCzDy7BOo7Vg90H21EOLACvtfcHk0lgYy4MGPYviWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslWntbw%253D&md5=8433e74cbd00a65cd218101e5ca62d79</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fcells8080854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8080854%26sid%3Dliteratum%253Aachs%26aulast%3DPerner%26aufirst%3DF.%26aulast%3DPerner%26aufirst%3DC.%26aulast%3DErnst%26aufirst%3DT.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26atitle%3DRoles%2520of%2520JAK2%2520in%2520aging%252C%2520inflammation%252C%2520hematopoiesis%2520and%2520malignant%2520transformation%26jtitle%3DCells%26date%3D2019%26volume%3D8%26spage%3D854%26epage%3D872%26doi%3D10.3390%2Fcells8080854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valent, P.</span></span> <span> </span><span class="NLM_article-title">Targeting the JAK2-STAT5 pathway in CML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1386</span>– <span class="NLM_lpage">1388</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-07-585943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2014-07-585943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=25170113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOksbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=1386-1388&author=P.+Valent&title=Targeting+the+JAK2-STAT5+pathway+in+CML&doi=10.1182%2Fblood-2014-07-585943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the JAK2-STAT5 pathway in CML</span></div><div class="casAuthors">Valent, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1386-1388</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">In this issue of Blood, Gallipoli et al show that combined targeting of BCR/ABL1 and Janus kinase 2 (JAK2) by 2 established kinase inhibitors, nilotinib (NI) and the JAK1/2 kinase inhibitor ruxolitinib (RUX), results in synergistic growth inhibition in immature CD34+ stem and progenitor cells obtained from patients with chronic myeloid leukemia (CML).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI_uUIq_U9uLVg90H21EOLACvtfcHk0lgYy4MGPYviWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOksbrF&md5=f8ca828c5ee6fff8870a69784baf60e9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-07-585943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-07-585943%26sid%3Dliteratum%253Aachs%26aulast%3DValent%26aufirst%3DP.%26atitle%3DTargeting%2520the%2520JAK2-STAT5%2520pathway%2520in%2520CML%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D1386%26epage%3D1388%26doi%3D10.1182%2Fblood-2014-07-585943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallipoli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopcroft, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheadon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whetton, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jørgensen, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holyoake, T. L.</span></span> <span> </span><span class="NLM_article-title">JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1492</span>– <span class="NLM_lpage">1501</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-12-545640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2013-12-545640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=24957147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOksbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=1492-1501&author=P.+Gallipoliauthor=A.+Cookauthor=S.+Rhodesauthor=L.+Hopcroftauthor=H.+Wheadonauthor=A.+D.+Whettonauthor=H.+G.+J%C3%B8rgensenauthor=R.+Bhatiaauthor=T.+L.+Holyoake&title=JAK2%2FSTAT5+inhibition+by+nilotinib+with+ruxolitinib+contributes+to+the+elimination+of+CML+CD34%2B+cells+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2013-12-545640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo</span></div><div class="casAuthors">Gallipoli, Paolo; Cook, Amy; Rhodes, Susan; Hopcroft, Lisa; Wheadon, Helen; Whetton, Anthony D.; Jorgensen, Heather G.; Bhatia, Ravi; Holyoake, Tessa L.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1492-1501</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Chronic myeloid leukemia (CML) stem cell survival is not dependent on BCR-ABL protein kinase and treatment with ABL tyrosine kinase inhibitors cures only a minority of CML patients, thus highlighting the need for novel therapeutic targets.  The Janus kinase (JAK)2/signal transducer and activator of transcription (STAT)5 pathway has recently been explored for providing putative survival signals to CML stem/progenitor cells (SPCs) with contradictory results.  We investigated the role of this pathway using the JAK2 inhibitor, ruxolitinib (RUX).  We demonstrated that the combination of RUX, at clin. achievable concns., with the specific and potent tyrosine kinase inhibitor nilotinib, reduced the activity of the JAK2/STAT5 pathway in vitro relative to either single agent alone.  These effects correlated with increased apoptosis of CML SPCs in vitro and a redn. in primitive quiescent CML stem cells, including NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ mice repopulating cells, induced by combination treatment.  A degree of toxicity toward normal SPCs was obsd. with the combination treatment, although this related to mature B-cell engraftment in NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ mice with minimal effects on primitive CD34+ cells.  These results support the JAK2/STAT5 pathway as a relevant therapeutic target in CML SPCs and endorse the current use of nilotinib in combination with RUX in clin. trials to eradicate persistent disease in CML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSb66kAP82FrVg90H21EOLACvtfcHk0lgYy4MGPYviWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOksbjI&md5=e641197ed6514b5a8ef62321ef65a69d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-12-545640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-12-545640%26sid%3Dliteratum%253Aachs%26aulast%3DGallipoli%26aufirst%3DP.%26aulast%3DCook%26aufirst%3DA.%26aulast%3DRhodes%26aufirst%3DS.%26aulast%3DHopcroft%26aufirst%3DL.%26aulast%3DWheadon%26aufirst%3DH.%26aulast%3DWhetton%26aufirst%3DA.%2BD.%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DH.%2BG.%26aulast%3DBhatia%26aufirst%3DR.%26aulast%3DHolyoake%26aufirst%3DT.%2BL.%26atitle%3DJAK2%252FSTAT5%2520inhibition%2520by%2520nilotinib%2520with%2520ruxolitinib%2520contributes%2520to%2520the%2520elimination%2520of%2520CML%2520CD34%252B%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D1492%26epage%3D1501%26doi%3D10.1182%2Fblood-2013-12-545640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span> <span> </span><span class="NLM_article-title">JAK/STAT signaling in hematological malignancies</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2601</span>– <span class="NLM_lpage">2613</span>, <span class="refDoi"> DOI: 10.1038/onc.2012.347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fonc.2012.347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=22869151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=2601-2613&author=W.+Vainchenkerauthor=S.+N.+Constantinescu&title=JAK%2FSTAT+signaling+in+hematological+malignancies&doi=10.1038%2Fonc.2012.347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">JAK/STAT signaling in hematological malignancies</span></div><div class="casAuthors">Vainchenker, W.; Constantinescu, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2601-2613</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is crit. in blood formation and immune response.  Many of those receptors transmit anti-apoptotic, proliferative and differentiation signals, and their expression and functions are crit. for the formation of blood lineages.  Several cancers, including blood malignancies, have been assocd. with constitutive activation of members of the STAT family, which normally require JAK-mediated tyrosine phosphorylation for transcriptional activation.  More recently, human myeloproliferative neoplasms were discovered to be assocd. with a unique acquired somatic mutation in JAK2 (JAK2 V617F), rare exon 12 JAK2 mutations, or thrombopoietin receptor mutations that constitutively activate wild-type JAK2.  Prompted by these observations, many studies have explored the possibility that JAKs, cytokine receptors, or other components of the JAK/STAT pathway are mutated or upregulated in several hematol. malignancies.  This has been obsd. in certain pediatric acute lymphoblastic leukemias and adult T-cell lymphoblastic leukemias, and overexpression of JAK2 seems to be important in Hodgkin lymphoma.  Here we discuss the nature and resp. contribution of mutations dysregulating the JAK/STAT pathway in hematol. malignancies and present examples in which such mutations drive the disease, contribute to the phenotype, or provide a survival and proliferative advantage.  JAK inhibitors are making their way into the therapeutic arsenal (for example, in myelofibrosis), and we discuss the possibility that other hematol. diseases might benefit from treatment with these inhibitors in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwfhpAymyJbVg90H21EOLACvtfcHk0lj1GbNcR8E5vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN&md5=f491a126765e10fbfbb73f6e04fd64e6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.347%26sid%3Dliteratum%253Aachs%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DJAK%252FSTAT%2520signaling%2520in%2520hematological%2520malignancies%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D2601%26epage%3D2613%26doi%3D10.1038%2Fonc.2012.347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopp, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christodoulou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Bodegom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Zwet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layer, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tivey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadleigh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andraos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dölemeyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zender, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallan, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baffert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangrevelinghe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radimerski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, D. M.</span></span> <span> </span><span class="NLM_article-title">Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1016%2Fj.ccell.2015.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=26175414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1GrtL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=29-41&author=S.-C.+Wuauthor=L.+S.+Liauthor=N.+Koppauthor=J.+Monteroauthor=B.+Chapuyauthor=A.+Yodaauthor=A.+L.+Christieauthor=H.+Liuauthor=A.+Christodoulouauthor=D.+van+Bodegomauthor=J.+van+der+Zwetauthor=J.+V.+Layerauthor=T.+Tiveyauthor=A.+A.+Laneauthor=J.+A.+Ryanauthor=S.+Y.+Ngauthor=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=D.+Steensmaauthor=M.+Wadleighauthor=M.+Harrisauthor=E.+Mandonauthor=N.+Ebelauthor=R.+Andraosauthor=V.+Romanetauthor=A.+D%C3%B6lemeyerauthor=D.+Sterkerauthor=M.+Zenderauthor=S.+J.+Rodigauthor=M.+Murakamiauthor=F.+Hofmannauthor=F.+Kuoauthor=M.+J.+Eckauthor=L.+B.+Silvermanauthor=S.+E.+Sallanauthor=A.+Letaiauthor=F.+Baffertauthor=E.+Vangrevelingheauthor=T.+Radimerskiauthor=C.+Gaulauthor=D.+M.+Weinstock&title=Activity+of+the+type+II+JAK2+inhibitor+CHZ868+in+B+cell+acute+lymphoblastic+leukemia&doi=10.1016%2Fj.ccell.2015.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia</span></div><div class="casAuthors">Wu, Shuo-Chieh; Li, Loretta S.; Kopp, Nadja; Montero, Joan; Chapuy, Bjoern; Yoda, Akinori; Christie, Amanda L.; Liu, Huiyun; Christodoulou, Alexandra; van Bodegom, Diederik; van der Zwet, Jordy; Layer, Jacob V.; Tivey, Trevor; Lane, Andrew A.; Ryan, Jeremy A.; Ng, Samuel Y.; DeAngelo, Daniel J.; Stone, Richard M.; Steensma, David; Wadleigh, Martha; Harris, Marian; Mandon, Emeline; Ebel, Nicolas; Andraos, Rita; Romanet, Vincent; Dolemeyer, Arno; Sterker, Dario; Zender, Michael; Rodig, Scott J.; Murakami, Masato; Hofmann, Francesco; Kuo, Frank; Eck, Michael J.; Silverman, Lewis B.; Sallan, Stephen E.; Letai, Anthony; Baffert, Fabienne; Vangrevelinghe, Eric; Radimerski, Thomas; Gaul, Christoph; Weinstock, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-41</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A variety of cancers depend on JAK2 signaling, including the high-risk subset of B cell acute lymphoblastic leukemias (B-ALLs) with CRLF2 rearrangements.  Type I JAK2 inhibitors induce paradoxical JAK2 hyperphosphorylation in these leukemias and have limited activity.  To improve the efficacy of JAK2 inhibition in B-ALL, we developed the type II inhibitor CHZ868, which stabilizes JAK2 in an inactive conformation.  CHZ868 potently suppressed the growth of CRLF2-rearranged human B-ALL cells, abrogated JAK2 signaling, and improved survival in mice with human or murine B-ALL.  CHZ868 and dexamethasone synergistically induced apoptosis in JAK2-dependent B-ALLs and further improved in vivo survival compared to CHZ868 alone.  These data support the testing of type II JAK2 inhibition in patients with JAK2-dependent leukemias and other disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSNPgN7ef4crVg90H21EOLACvtfcHk0lj1GbNcR8E5vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1GrtL7O&md5=18fd3585f9615ab0cf4cf41e2493b71a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DS.-C.%26aulast%3DLi%26aufirst%3DL.%2BS.%26aulast%3DKopp%26aufirst%3DN.%26aulast%3DMontero%26aufirst%3DJ.%26aulast%3DChapuy%26aufirst%3DB.%26aulast%3DYoda%26aufirst%3DA.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DChristodoulou%26aufirst%3DA.%26aulast%3Dvan%2BBodegom%26aufirst%3DD.%26aulast%3Dvan%2Bder%2BZwet%26aufirst%3DJ.%26aulast%3DLayer%26aufirst%3DJ.%2BV.%26aulast%3DTivey%26aufirst%3DT.%26aulast%3DLane%26aufirst%3DA.%2BA.%26aulast%3DRyan%26aufirst%3DJ.%2BA.%26aulast%3DNg%26aufirst%3DS.%2BY.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DSteensma%26aufirst%3DD.%26aulast%3DWadleigh%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DM.%26aulast%3DMandon%26aufirst%3DE.%26aulast%3DEbel%26aufirst%3DN.%26aulast%3DAndraos%26aufirst%3DR.%26aulast%3DRomanet%26aufirst%3DV.%26aulast%3DD%25C3%25B6lemeyer%26aufirst%3DA.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DZender%26aufirst%3DM.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DKuo%26aufirst%3DF.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSilverman%26aufirst%3DL.%2BB.%26aulast%3DSallan%26aufirst%3DS.%2BE.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DBaffert%26aufirst%3DF.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DRadimerski%26aufirst%3DT.%26aulast%3DGaul%26aufirst%3DC.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26atitle%3DActivity%2520of%2520the%2520type%2520II%2520JAK2%2520inhibitor%2520CHZ868%2520in%2520B%2520cell%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D29%26epage%3D41%26doi%3D10.1016%2Fj.ccell.2015.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plosker, G. L.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib: a review of its use in patients with myelofibrosis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0351-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1007%2Fs40265-015-0351-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=25601187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=297-308&author=G.+L.+Plosker&title=Ruxolitinib%3A+a+review+of+its+use+in+patients+with+myelofibrosis&doi=10.1007%2Fs40265-015-0351-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis</span></div><div class="casAuthors">Plosker, Greg L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-308</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib (Jakavi, Jakafi) is an orally administered inhibitor of Janus kinases (JAK) 1 and 2 used in the management of patients with myelofibrosis.  Clin. trials with ruxolitinib, notably the phase III COMFORT-I and -II studies and their extensions, have demonstrated marked and durable clin. benefits in terms of redns. in splenomegaly and disease-related symptoms in patients with intermediate-2 or high-risk myelofibrosis.  Ruxolitinib was also assocd. with improvements in health-related quality of life and functioning.  Despite the crossover of patients in control groups to ruxolitinib, results of the COMFORT studies and their extensions indicate a survival advantage for patients randomized to ruxolitinib.  The beneficial effects of ruxolitinib were obsd. across subgroups of myelofibrosis patients, including those not harbouring the JAK2V617F mutation.  Improvements in splenomegaly and disease-related symptoms were also obsd. in a trial in Japanese/Asian patients with myelofibrosis and in myelofibrosis patients with a low baseline platelet count.  Dose-related anemia and thrombocytopenia were common in clin. trials with ruxolitinib, but rarely led to discontinuation of therapy and were managed with dosage modifications and/or transfusions of packed red blood cells.  In addn. to the USA and EU, ruxolitinib is now approved in a no. of other countries, including Japan, and remains the only approved drug for the treatment of myelofibrosis, although various other agents are undergoing investigation.  Appropriate monitoring and dosage titrn. are important to achieve optimal clin. benefits of ruxolitinib.  Further research, including studies evaluating ruxolitinib-based combination therapy, may also help to optimize treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjqinnNMi_PLVg90H21EOLACvtfcHk0li8_b45SEZZeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeisrg%253D&md5=58970b22ffdaab2e4a3d8ee7dffdb72f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0351-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0351-8%26sid%3Dliteratum%253Aachs%26aulast%3DPlosker%26aufirst%3DG.%2BL.%26atitle%3DRuxolitinib%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520patients%2520with%2520myelofibrosis%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D297%26epage%3D308%26doi%3D10.1007%2Fs40265-015-0351-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingua::EN::Titlecase, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ali, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gisslinger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoops, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuitty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalbovskaya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalakrishna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbui, T.</span></span> <span> </span><span class="NLM_article-title">Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1707</span>, <span class="refDoi"> DOI: 10.1038/leu.2016.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fleu.2016.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=27211272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWlsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1701-1707&author=C.+N.+Harrisonauthor=A.+M.+Lingua%3A%3AEN%3A%3ATitlecaseauthor=A.+M.+Vannucchiauthor=J.-J.+Kiladjianauthor=H.+K.+Al-Aliauthor=H.+Gisslingerauthor=L.+Knoopsauthor=F.+Cervantesauthor=M.+M.+Jonesauthor=K.+Sunauthor=M.+McQuittyauthor=V.+Stalbovskayaauthor=P.+Gopalakrishnaauthor=T.+Barbui&title=Long-term+findings+from+COMFORT-II%2C+a+phase+3+study+of+ruxolitinib+vs+best+available+therapy+for+myelofibrosis&doi=10.1038%2Fleu.2016.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis</span></div><div class="casAuthors">Harrison, C. N.; Vannucchi, A. M.; Kiladjian, J.-J.; Al-Ali, H. K.; Gisslinger, H.; Knoops, L.; Cervantes, F.; Jones, M. M.; Sun, K.; McQuitty, M.; Stalbovskaya, V.; Gopalakrishna, P.; Barbui, T.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1701-1707</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies.  COMFORT-II was a randomized (2:1), open-label phase 3 study in patients with myelofibrosis; patients randomized to BAT could crossover to ruxolitinib upon protocol-defined disease progression or after the primary end point, confounding long-term comparisons.  At week 48, 28% (41/146) of patients randomized to ruxolitinib achieved ≥35% decrease in spleen vol. (primary end point) compared with no patients on BAT (P<0.001).  Among the 78 patients (53.4%) in the ruxolitinib arm who achieved ≥35% redns. in spleen vol. at any time, the probability of maintaining response was 0.48 (95% confidence interval (CI), 0.35-0.60) at 5 years (median, 3.2 years).  Median overall survival was not reached in the ruxolitinib arm and was 4.1 years in the BAT arm.  There was a 33% redn. in risk of death with ruxolitinib compared with BAT by intent-to-treat anal. (hazard ratio (HR)=0.67; 95% CI, 0.44-1.02; P=0.06); the crossover-cor. HR was 0.44 (95% CI, 0.18-1.04; P=0.06).  There was no unexpected increased incidence of adverse events with longer exposure.  This final anal. showed that spleen vol. redns. with ruxolitinib were maintained with continued therapy and may be assocd. with survival benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwVXL4Oxo3bVg90H21EOLACvtfcHk0li8_b45SEZZeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWlsbvE&md5=d3265028a6e4617b1ee1c214f09b34ab</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.148%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26aulast%3DLingua%253A%253AEN%253A%253ATitlecase%26aufirst%3DA.%2BM.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26aulast%3DAl-Ali%26aufirst%3DH.%2BK.%26aulast%3DGisslinger%26aufirst%3DH.%26aulast%3DKnoops%26aufirst%3DL.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DJones%26aufirst%3DM.%2BM.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DMcQuitty%26aufirst%3DM.%26aulast%3DStalbovskaya%26aufirst%3DV.%26aulast%3DGopalakrishna%26aufirst%3DP.%26aulast%3DBarbui%26aufirst%3DT.%26atitle%3DLong-term%2520findings%2520from%2520COMFORT-II%252C%2520a%2520phase%25203%2520study%2520of%2520ruxolitinib%2520vs%2520best%2520available%2520therapy%2520for%2520myelofibrosis%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D1701%26epage%3D1707%26doi%3D10.1038%2Fleu.2016.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariette, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winthrop, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charles-Schoeman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thirunavukkarasu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenhaupt, J.</span></span> <span> </span><span class="NLM_article-title">Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1253</span>– <span class="NLM_lpage">1262</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2016-210457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1136%2Fannrheumdis-2016-210457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=28143815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOitr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=1253-1262&author=S.+B.+Cohenauthor=Y.+Tanakaauthor=X.+Marietteauthor=J.+R.+Curtisauthor=E.+B.+Leeauthor=P.+Nashauthor=K.+L.+Winthropauthor=C.+Charles-Schoemanauthor=K.+Thirunavukkarasuauthor=R.+DeMasiauthor=J.+Geierauthor=K.+Kwokauthor=L.+Wangauthor=R.+Rieseauthor=J.+Wollenhaupt&title=Long-term+safety+of+tofacitinib+for+the+treatment+of+rheumatoid+arthritis+up+to+8.5+years%3A+integrated+analysis+of+data+from+the+global+clinical+trials&doi=10.1136%2Fannrheumdis-2016-210457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials</span></div><div class="casAuthors">Cohen, Stanley B.; Tanaka, Yoshiya; Mariette, Xavier; Curtis, Jeffrey R.; Lee, Eun Bong; Nash, Peter; Winthrop, Kevin L.; Charles-Schoeman, Christina; Thirunavukkarasu, Krishan; DeMasi, Ryan; Geier, Jamie; Kwok, Kenneth; Wang, Lisy; Riese, Richard; Wollenhaupt, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1253-1262</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).  We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA.  Methods: Data were pooled for all tofacitinib-treated patients (data cut-off: 31 March 2015).  Incidence rates (IRs; patients with event/100 patient-years) and 95% CIs are reported for adverse events (AEs) of interest.  Results: 6194 patients received tofacitinib for a total 19 406 patient-years' exposure; median exposure was 3.4 patient-years.  IR (95% CI) for serious AEs was 9.4 (9.0 to 9.9); IR for serious infections was 2.7 (2.5 to 3.0).  IR for (all) herpes zoster was 3.9 (3.6 to 4.2); IR for disseminated or multidermatomal herpes zoster was 0.3 (0.2 to 0.4).  IR for opportunistic infections (excluding tuberculosis) was 0.3 (0.2 to 0.4) and was 0.2 (0.1 to 0.3) for tuberculosis.  IR for malignancies (excluding nonmelanoma skin cancer (NMSC)) was 0.9 (0.8 to 1.0); NMSC IR was 0.6 (0.5 to 0.7).  IR for gastrointestinal perforations was 0.1 (0.1 to 0.2).  Anal. of IR for serious infections, herpes zoster and malignancies by 6-mo intervals did not reveal any notable increase in IR with longer-duration tofacitinib exposure.  Conclusion: This anal. of tofacitinib exposure up to 8.5 years allowed estn. of safety events with improved precision vs. previous tofacitinib reports.  AEs were generally stable over time; no new safety signals were obsd. compared with previous tofacitinib reports.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI4-zQlojJALVg90H21EOLACvtfcHk0li8_b45SEZZeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOitr%252FK&md5=4bd429b9deebee6bf0151e89dbf76f49</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2016-210457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2016-210457%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DMariette%26aufirst%3DX.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DNash%26aufirst%3DP.%26aulast%3DWinthrop%26aufirst%3DK.%2BL.%26aulast%3DCharles-Schoeman%26aufirst%3DC.%26aulast%3DThirunavukkarasu%26aufirst%3DK.%26aulast%3DDeMasi%26aufirst%3DR.%26aulast%3DGeier%26aufirst%3DJ.%26aulast%3DKwok%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRiese%26aufirst%3DR.%26aulast%3DWollenhaupt%26aufirst%3DJ.%26atitle%3DLong-term%2520safety%2520of%2520tofacitinib%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520up%2520to%25208.5%2520years%253A%2520integrated%2520analysis%2520of%2520data%2520from%2520the%2520global%2520clinical%2520trials%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2017%26volume%3D76%26spage%3D1253%26epage%3D1262%26doi%3D10.1136%2Fannrheumdis-2016-210457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Fedratinib: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1725</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01205-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1007%2Fs40265-019-01205-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=31571162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOlu7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1719-1725&author=H.+A.+Blair&title=Fedratinib%3A+First+Approval&doi=10.1007%2Fs40265-019-01205-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Fedratinib: First approval for treating myelofibrosis</span></div><div class="casAuthors">Blair, Hannah A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1719-1725</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Fedratinib (INREBIC) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis.  In August 2019, fedratinib received its first global approval in the USA for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.  Phase III clin. development for myelofibrosis is ongoing worldwide.  This article summarizes the milestones in the development of fedratinib leading to this first approval for myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0phtMTwbye7Vg90H21EOLACvtfcHk0lg990zginJr9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOlu7rP&md5=36fa843febf45050d5dd2d1044b715c8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01205-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01205-x%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DFedratinib%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1719%26epage%3D1725%26doi%3D10.1007%2Fs40265-019-01205-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirewalt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span> <span> </span><span class="NLM_article-title">The role of FLT3 in haematopoietic malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1038/nrc1169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fnrc1169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=12951584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=650-665&author=D.+L.+Stirewaltauthor=J.+P.+Radich&title=The+role+of+FLT3+in+haematopoietic+malignancies&doi=10.1038%2Fnrc1169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The role of FLT3 in hematopoietic malignancies</span></div><div class="casAuthors">Stirewalt, Derek L.; Radich, Jerald P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">650-665</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Normal haematopoietic cells use complex systems to control proliferation, differentiation and cell death.  The control of proliferation is, in part, accomplished through the ligand-induced stimulation of receptor tyrosine kinases, which signal to downstream effectors through the RAS pathway.  Recently, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, which encodes a receptor tyrosine kinase, have been found to be the most common genetic lesion in acute myeloid leukemia (AML), occurring in ∼25% of cases.  Exploring the mechanism by which these FLT3 mutations cause uncontrolled proliferation might lead to a better understanding of how cells become cancerous and provide insights for the development of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRONPQkpemorVg90H21EOLACvtfcHk0lg990zginJr9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D&md5=97183b7a6087fafe20bfc695f403825b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrc1169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1169%26sid%3Dliteratum%253Aachs%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520role%2520of%2520FLT3%2520in%2520haematopoietic%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D650%26epage%3D665%26doi%3D10.1038%2Fnrc1169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermaat, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, W.</span></span> <span> </span><span class="NLM_article-title">Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi"> DOI: 10.1186/1756-8722-2-23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1186%2F1756-8722-2-23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=19490647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A280%3ADC%252BD1MvjsFWqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=23&author=T.+K.+Gregoryauthor=D.+Waldauthor=Y.+Chenauthor=J.+M.+Vermaatauthor=Y.+Xiongauthor=W.+Tse&title=Molecular+prognostic+markers+for+adult+acute+myeloid+leukemia+with+normal+cytogenetics&doi=10.1186%2F1756-8722-2-23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics</span></div><div class="casAuthors">Gregory Tara K; Wald David; Chen Yichu; Vermaat Johanna M; Xiong Yin; Tse William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the differentiation of hematopoietic progenitor cells along with uncontrolled proliferation.  In approximately 60% of cases, specific recurrent chromosomal aberrations can be identified by modern cytogenetic techniques.  This cytogenetic information is the single most important tool to classify patients at their initial diagnosis into three prognostic categories: favorable, intermediate, and poor risk.  Currently, favorable risk AML patients are usually treated with contemporary chemotherapy while poor risk AML patients receive allogeneic stem cell transplantation if suitable stem cell donors exist.  The largest subgroup of AML patients (aproximately 40%) have no identifiable cytogenetic abnormalities and are classified as intermediate risk.  The optimal therapeutic strategies for these patients are still largely unclear.  Recently, it is becoming increasingly evident that it is possible to identify a subgroup of poorer risk patients among those with normal cytogenic AML (NC-AML).  Molecular risk stratification for NC-AML patients may be possible due to mutations of NPM1, FLT3, MLL, and CEBPalpha as well as alterations in expression levels of BAALC, MN1, ERG, and AF1q.  Further prospective studies are needed to confirm if poorer risk NC-AML patients have improved clinical outcomes after more aggressive therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTfW9d1-8T8SM8MEzWGjS9fW6udTcc2eYbpS9tURmz77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvjsFWqsg%253D%253D&md5=64980fe9c46b79baedc8eca3635c818a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-2-23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-2-23%26sid%3Dliteratum%253Aachs%26aulast%3DGregory%26aufirst%3DT.%2BK.%26aulast%3DWald%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DVermaat%26aufirst%3DJ.%2BM.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DTse%26aufirst%3DW.%26atitle%3DMolecular%2520prognostic%2520markers%2520for%2520adult%2520acute%2520myeloid%2520leukemia%2520with%2520normal%2520cytogenetics%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2009%26volume%3D2%26spage%3D23%26doi%3D10.1186%2F1756-8722-2-23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span> <span> </span><span class="NLM_article-title">Current findings for recurring mutations in acute myeloid leukemia</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">36</span>, <span class="refDoi"> DOI: 10.1186/1756-8722-4-36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1186%2F1756-8722-4-36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=21917154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yqsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=36&author=S.+Takahashi&title=Current+findings+for+recurring+mutations+in+acute+myeloid+leukemia&doi=10.1186%2F1756-8722-4-36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Current findings for recurring mutations in acute myeloid leukemia</span></div><div class="casAuthors">Takahashi, Shinichiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of acute myeloid leukemia (AML) is a multistep process that requires at least two genetic abnormalities for the development of the disease.  The identification of genetic mutations in AML has greatly advanced our understanding of leukemogenesis.  Recently, the use of novel technologies, such as massively parallel DNA sequencing or high-resoln. single-nucleotide polymorphism arrays, has allowed the identification of several novel recurrent gene mutations in AML.  The aim of this review is to summarize the current findings for the identification of these gene mutations (Dnmt, TET2, IDH1/2, NPM1, ASXL1, etc.), most of which are frequently found in cytogenetically normal AML.  The cooperative interactions of these mol. aberrations and their interactions with class I/II mutations are presented.  The prognostic and predictive significances of these aberrations are also reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB0uxjzh73P7Vg90H21EOLACvtfcHk0lg990zginJr9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yqsLnN&md5=7152c049fe2c2cf80934c232a3070676</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-4-36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-4-36%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DS.%26atitle%3DCurrent%2520findings%2520for%2520recurring%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2011%26volume%3D4%26spage%3D36%26doi%3D10.1186%2F1756-8722-4-36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringhoffer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salih, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachbaur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamparter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidzik, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleanu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Späth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">German-Austrian, A. M. L. S. G.</span></span> <span> </span><span class="NLM_article-title">Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3441</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-05-578070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2014-05-578070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=25270908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2nsbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3441-3449&author=R.+F.+Schlenkauthor=S.+Kayserauthor=L.+Bullingerauthor=G.+Kobbeauthor=J.+Casperauthor=M.+Ringhofferauthor=G.+Heldauthor=P.+Brossartauthor=M.+L%C3%BCbbertauthor=H.+R.+Salihauthor=T.+Kindlerauthor=H.+A.+Horstauthor=G.+Wulfauthor=D.+Nachbaurauthor=K.+G%C3%B6tzeauthor=A.+Lamparterauthor=P.+Paschkaauthor=V.+I.+Gaidzikauthor=V.+Teleanuauthor=D.+Sp%C3%A4thauthor=A.+Bennerauthor=J.+Krauterauthor=A.+Ganserauthor=H.+D%C3%B6hnerauthor=K.+D%C3%B6hnerauthor=A.+M.+L.+S.+G.+German-Austrian&title=Differential+impact+of+allelic+ratio+and+insertion+site+in+FLT3-ITD-positive+AML+with+respect+to+allogeneic+transplantation&doi=10.1182%2Fblood-2014-05-578070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation</span></div><div class="casAuthors">Schlenk, Richard F.; Kayser, Sabine; Bullinger, Lars; Kobbe, Guido; Casper, Jochen; Ringhoffer, Mark; Held, Gerhard; Brossart, Peter; Luebbert, Michael; Salih, Helmut R.; Kindler, Thomas; Horst, Heinz A.; Wulf, Gerald; Nachbaur, David; Goetze, Katharina; Lamparter, Alexander; Paschka, Peter; Gaidzik, Verena I.; Teleanu, Veronica; Spaeth, Daniela; Benner, Axel; Krauter, Juergen; Ganser, Arnold; Doehner, Hartmut; Doehner, Konstanze</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3441-3449</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The objective was to evaluate the prognostic and predictive impact of allelic ratio and insertion site (IS) of internal tandem duplications (ITDs), as well as concurrent gene mutations, with regard to postremission therapy in 323 patients with FLT3-ITD-pos. acute myeloid leukemia (AML).  Increasing FLT3-ITD allelic ratio (P = .004) and IS in the tyrosine kinase domain 1 (TKD1, P = .06) were assocd. with low complete remission (CR) rates.  After postremission therapy including intensive chemotherapy (n = 121) or autologous hematopoietic stem cell transplantation (HSCT, n = 17), an allelic ratio ≥ 0.51 was assocd. with an unfavorable relapse-free (RFS, P = .0008) and overall survival (OS, P = .004); after allogeneic HSCT (n = 93), outcome was significantly improved in patients with a high allelic ratio (RFS, P = .02; OS, P = .03), whereas no benefit was seen in patients with a low allelic ratio (RFS, P = .38; OS, P = .64).  Multivariable analyses revealed a high allelic ratio as a predictive factor for the beneficial effect of allogeneic HSCT; ITD IS in TKD1 remained an unfavorable factor, whereas no prognostic impact of concurrent gene mutations was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-3OpzDAfbwLVg90H21EOLACvtfcHk0liSJDk5PVwUzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2nsbbN&md5=d505ffab0eb1820edec6d5657d17db41</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-05-578070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-05-578070%26sid%3Dliteratum%253Aachs%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DKayser%26aufirst%3DS.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DKobbe%26aufirst%3DG.%26aulast%3DCasper%26aufirst%3DJ.%26aulast%3DRinghoffer%26aufirst%3DM.%26aulast%3DHeld%26aufirst%3DG.%26aulast%3DBrossart%26aufirst%3DP.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26aulast%3DSalih%26aufirst%3DH.%2BR.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DHorst%26aufirst%3DH.%2BA.%26aulast%3DWulf%26aufirst%3DG.%26aulast%3DNachbaur%26aufirst%3DD.%26aulast%3DG%25C3%25B6tze%26aufirst%3DK.%26aulast%3DLamparter%26aufirst%3DA.%26aulast%3DPaschka%26aufirst%3DP.%26aulast%3DGaidzik%26aufirst%3DV.%2BI.%26aulast%3DTeleanu%26aufirst%3DV.%26aulast%3DSp%25C3%25A4th%26aufirst%3DD.%26aulast%3DBenner%26aufirst%3DA.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DGerman-Austrian%26aufirst%3DA.%2BM.%2BL.%2BS.%2BG.%26atitle%3DDifferential%2520impact%2520of%2520allelic%2520ratio%2520and%2520insertion%2520site%2520in%2520FLT3-ITD-positive%2520AML%2520with%2520respect%2520to%2520allogeneic%2520transplantation%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D3441%26epage%3D3449%26doi%3D10.1182%2Fblood-2014-05-578070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01594</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01594" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKitbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=875-892&author=X.+Liangauthor=B.+Wangauthor=C.+Chenauthor=A.+Wangauthor=C.+Huauthor=F.+Zouauthor=K.+Yuauthor=Q.+Liuauthor=F.+Liauthor=Z.+Huauthor=T.+Luauthor=J.+Wangauthor=L.+Wangauthor=E.+L.+Weisbergauthor=L.+Liauthor=R.+Xiaauthor=W.+Wangauthor=T.+Renauthor=J.+Geauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+N-%284-%286-Acetamidopyrimidin-4-yloxy%29phenyl%29-2-%282-%28trifluoromethyl%29phenyl%29acetamide+%28CHMFL-FLT3-335%29+as+a+Potent+FMS-like+Tyrosine+Kinase+3+Internal+Tandem+Duplication+%28FLT3-ITD%29+Mutant+Selective+Inhibitor+for+Acute+Myeloid+Leukemia&doi=10.1021%2Facs.jmedchem.8b01594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a potent FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutant selective inhibitor for acute myeloid leukemia</span></div><div class="casAuthors">Liang, Xiaofei; Wang, Beilei; Chen, Cheng; Wang, Aoli; Hu, Chen; Zou, Fengming; Yu, Kailin; Liu, Qingwang; Li, Feng; Hu, Zhenquan; Lu, Tingting; Wang, Junjie; Wang, Li; Weisberg, Ellen L.; Li, Lili; Xia, Ruixiang; Wang, Wenchao; Ren, Tao; Ge, Jian; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">875-892</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most of the current FMS-like tyrosine kinase 3 (FLT3) inhibitors lack selectivity between FLT3 kinase and cKIT kinase as well as the FLT3 wt and internal tandem duplication (ITD) mutants.  We report a new compd. I, which displays GI50 values of 30-80 nM against different ITD mutants and achieves selectivity over both FLT3 wt (8-fold) and cKIT kinase in the transformed BaF3 cells (>300-fold). I potently inhibits the proliferation of the FLT3-ITD-pos. acute myeloid leukemia cancer lines through suppression of the phosphorylation of FLT3 kinase and downstream signaling pathways, induction of apoptosis, and arresting the cell cycle into the G0/G1 phase. I also displays potent antiproliferative effect against FLT3-ITD-pos. patient primary cells, whereas it does not apparently affect FLT3 wt primary cells.  In addn., it also exhibits a good therapeutic window to PBMC compared to PKC412.  In the in vivo studies, I demonstrates favorable PK profiles and suppresses the tumor growth in the MV4-11 cell inoculated mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdi_MAkOsXkLVg90H21EOLACvtfcHk0liSJDk5PVwUzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKitbnE&md5=b802859e517d8156353481f41128f7a1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01594%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520N-%25284-%25286-Acetamidopyrimidin-4-yloxy%2529phenyl%2529-2-%25282-%2528trifluoromethyl%2529phenyl%2529acetamide%2520%2528CHMFL-FLT3-335%2529%2520as%2520a%2520Potent%2520FMS-like%2520Tyrosine%2520Kinase%25203%2520Internal%2520Tandem%2520Duplication%2520%2528FLT3-ITD%2529%2520Mutant%2520Selective%2520Inhibitor%2520for%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D875%26epage%3D892%26doi%3D10.1021%2Facs.jmedchem.8b01594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimek, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-03-0891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2004-03-0891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=15345597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD2MXis1GksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=54-60&author=R.+M.+Stoneauthor=D.+J.+DeAngeloauthor=V.+Klimekauthor=I.+Galinskyauthor=E.+Esteyauthor=S.+D.+Nimerauthor=W.+Grandinauthor=D.+Lebwohlauthor=Y.+Wangauthor=P.+Cohenauthor=E.+A.+Foxauthor=D.+Neubergauthor=J.+Clarkauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Patients+with+acute+myeloid+leukemia+and+an+activating+mutation+in+FLT3+respond+to+a+small-molecule+FLT3+tyrosine+kinase+inhibitor%2C+PKC412&doi=10.1182%2Fblood-2004-03-0891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412</span></div><div class="casAuthors">Stone, Richard M.; DeAngelo, Daniel J.; Klimek, Virginia; Galinsky, Ilene; Estey, Eli; Nimer, Stephen D.; Grandin, Wilson; Lebwohl, David; Wang, Yanfeng; Cohen, Pamela; Fox, Edward A.; Neuberg, Donna; Clark, Jennifer; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-60</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug therapy.  We treated 20 patients, each with mutant FLT3 relapsed/refractory AML or high-grade myelodysplastic syndrome and not believed to be candidates for chemotherapy, with an FLT3 tyrosine kinase inhibitor, PKC412 (N-benzoylstaurosporine), at a dose of 75 mg 3 times daily by mouth.  The drug was generally well tolerated, although 2 patients developed fatal pulmonary events of unclear etiol.  The peripheral blast count decreased by 50% in 14 patients (70%).  Seven patients (35%) experienced a greater than 2-log redn. in peripheral blast count for at least 4 wk (median response duration, 13 wk; range, 9-47 wk); PKC412 reduced bone marrow blast counts by 50% in 6 patients (2 of these to < 5%).  FLT3 autophosphorylation was inhibited in most of the responding patients, indicating in vivo target inhibition at the dose schedule used in this study.  PKC412 is an oral tyrosine kinase inhibitor with clin. activity in patients with AML whose blasts have an activating mutation of FLT3, suggesting potential use in combination with active agents, such as chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu297bLj2zDLVg90H21EOLACvtfcHk0lhpU7Bkhufy7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXis1GksA%253D%253D&md5=8683325acf03f9cb523b7b8564c531b8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-03-0891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-03-0891%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DKlimek%26aufirst%3DV.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DGrandin%26aufirst%3DW.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DFox%26aufirst%3DE.%2BA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DPatients%2520with%2520acute%2520myeloid%2520leukemia%2520and%2520an%2520activating%2520mutation%2520in%2520FLT3%2520respond%2520to%2520a%2520small-molecule%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%252C%2520PKC412%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D54%26epage%3D60%26doi%3D10.1182%2Fblood-2004-03-0891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1016/s1535-6108(02)00069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1016%2Fs1535-6108%2802%2900069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=12124173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVKjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=433-443&author=E.+Weisbergauthor=C.+Boultonauthor=L.+M.+Kellyauthor=P.+Manleyauthor=D.+Fabbroauthor=T.+Meyerauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Inhibition+of+mutant+FLT3+receptors+in+leukemia+cells+by+the+small+molecule+tyrosine+kinase+inhibitor+PKC412&doi=10.1016%2Fs1535-6108%2802%2900069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412</span></div><div class="casAuthors">Weisberg, Ellen; Boulton, Christina; Kelly, Louise M.; Manley, Paul; Fabbro, Doriano; Meyer, Thomas; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Constitutively activating FLT3 receptor mutations have been found in 35% of patients with acute myeloblastic leukemia (AML).  Here we report the identification of a small mol. FLT3 tyrosine kinase inhibitor PKC412, which selectively induced G1 arrest and apoptosis of Ba/F3 cell lines expressing mutant FLT3 (IC50 < 10 nM) by directly inhibiting the tyrosine kinase.  Ba/F3-FLT3 cell lines made resistant to PKC412 demonstrated overexpression of mutant FLT3, confirming that FLT3 is the target of this drug.  Finally, progressive leukemia was prevented in PKC412-treated Balb/c mice transplanted with marrow transduced with a FLT3-ITD-expressing retrovirus.  PKC412 is a potent inhibitor of mutant FLT3 and is a candidate for testing as an antileukemia agent in AML patients with mutant FLT3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq5mVxGyiCu7Vg90H21EOLACvtfcHk0lhpU7Bkhufy7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVKjsb4%253D&md5=612331d927bd2ca41319b77aaea6cfd1</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fs1535-6108%2802%2900069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1535-6108%252802%252900069-7%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DBoulton%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DInhibition%2520of%2520mutant%2520FLT3%2520receptors%2520in%2520leukemia%2520cells%2520by%2520the%2520small%2520molecule%2520tyrosine%2520kinase%2520inhibitor%2520PKC412%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D1%26spage%3D433%26epage%3D443%26doi%3D10.1016%2Fs1535-6108%2802%2900069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprankle, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. S.</span></span> <span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">2984</span>– <span class="NLM_lpage">2992</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-05-222034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2009-05-222034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=19654408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=H.+K.+Patelauthor=M.+Levisauthor=R.+C.+Armstrongauthor=J.+Jamesauthor=S.+S.+Bhagwat&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29&doi=10.1182%2Fblood-2009-05-222034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span></div><div class="casAuthors">Zarrinkar, Patrick P.; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; Brigham, Daniel; Belli, Barbara; Karaman, Mazen W.; Pratz, Keith W.; Pallares, Gabriel; Chao, Qi; Sprankle, Kelly G.; Patel, Hitesh K.; Levis, Mark; Armstrong, Robert C.; James, Joyce; Bhagwat, Shripad S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2984-2992</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approx. 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy.  We report the characterization of AC220, a second-generation FLT3 inhibitor, and a comparison of AC220 with the first-generation FLT3 inhibitors CEP-701, MLN-518, PKC-412, sorafenib, and sunitinib.  AC220 exhibits low nanomolar potency in biochem. and cellular assays and exceptional kinase selectivity, and in animal models is efficacious at doses as low as 1 mg/kg given orally once daily.  The data reveal that the combination of excellent potency, selectivity, and pharmacokinetic properties is unique to AC220, which therefore is the first drug candidate with a profile that matches the characteristics desirable for a clin. FLT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_RzDr7kzxsLVg90H21EOLACvtfcHk0lgvEM3xY0yX-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN&md5=4f8368a7b2eab9d1234ef36e01f5f260</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-222034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-222034%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2984%26epage%3D2992%26doi%3D10.1182%2Fblood-2009-05-222034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thom, C.</span></span> <span> </span><span class="NLM_article-title">Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2499</span>– <span class="NLM_lpage">2501</span>, <span class="refDoi"> DOI: 10.2217/fon.15.188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.2217%2Ffon.15.188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=26279055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKktrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=2499-2501&author=C.+Thom&title=Preliminary+data+on+ASP2215%3A+tolerability+and+efficacy+in+acute+myeloid+leukemia+patients&doi=10.2217%2Ffon.15.188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients</span></div><div class="casAuthors">Thom, Claire</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2499-2501</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Claire Thom speaks to Gemma Westcott, Commissioning Editor: Claire Thom joined Astellas in 2013 as the Therapeutic Area Head for Oncol. in Global Development.  In that role, she also serves as the STAR leader for Oncol. for Astellas.  Prior to Astellas, she spent 12 years with Takeda.  Her last position was Senior Vice President, Portfolio Management, Drug Development Management and Medical Informatics and Strategic Operations within the Medical Division (the Division within Millennium responsible for oncol. clin. drug development within Takeda).  During her 4 years at Millennium, at various times, she had responsibility within the Medical Division for leading portfolio management, business operations (medical finance, annual and mid-range financial planning, space planning and operations, headcount resourcing, development goals process), clin. development operations (clin. operations, programming, data management, statistics, medical writing, clin. outsourcing), drug development management (project management), medical informatics (technol. support for the division) and the strategic project management office for the division.  Prior to joining Millennium, Claire Thom spent 18 mo working in Osaka, Japan, during which she was responsible for developing the oncol. strategy for Takeda that culminated in the acquisition of Millennium.  Before going to Japan, she held positions of varying responsibility within the Takeda US development organization including the management of regulatory affairs, safety, biometrics and data management, clin. research and quality assurance.  Claire Thom has particular expertise in organizational design and efficiency; she has successfully worked through integrations across multiple functions and redesigned business processes.  She has a PharmD from University of Illinois (IL, USA) and over 20 years of pharmaceutical experience including positions in medical affairs and new product planning (over 11 years at Searle) and drug development (over 12 years at Takeda/Millennium).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAQfw_oqEZorVg90H21EOLACvtfcHk0lgvEM3xY0yX-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKktrvE&md5=d15842247b3170602a436a19cb5a63d6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2217%2Ffon.15.188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.15.188%26sid%3Dliteratum%253Aachs%26aulast%3DThom%26aufirst%3DC.%26atitle%3DPreliminary%2520data%2520on%2520ASP2215%253A%2520tolerability%2520and%2520efficacy%2520in%2520acute%2520myeloid%2520leukemia%2520patients%26jtitle%3DFuture%2520Oncol.%26date%3D2015%26volume%3D11%26spage%3D2499%26epage%3D2501%26doi%3D10.2217%2Ffon.15.188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mentens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marynen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">6385</span>– <span class="NLM_lpage">6389</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-04-2148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1158%2F0008-5472.can-04-2148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=15374944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6385-6389&author=J.+Coolsauthor=N.+Mentensauthor=P.+Furetauthor=D.+Fabbroauthor=J.+J.+Clarkauthor=J.+D.+Griffinauthor=P.+Marynenauthor=D.+G.+Gilliland&title=Prediction+of+resistance+to+small+molecule+FLT3+inhibitors%3A+implications+for+molecularly+targeted+therapy+of+acute+leukemia&doi=10.1158%2F0008-5472.can-04-2148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Resistance to Small Molecule FLT3 Inhibitors: Implications for Molecularly Targeted Therapy of Acute Leukemia</span></div><div class="casAuthors">Cools, Jan; Mentens, Nicole; Furet, Pascal; Fabbro, Doriano; Clark, Jennifer J.; Griffin, James D.; Marynen, Peter; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6385-6389</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutations in the receptor tyrosine kinase FLT3 occur frequently in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).  Small mols. that selectively inhibit FLT3 kinase activity induce apoptosis in blasts from AML patients with FLT3 mutations and prolong survival in animal models of FLT3-induced myeloproliferative disease.  A spectrum of structurally different small mols. with activity against FLT3 have been described, and their efficacy for treatment of AML and ALL is now being investigated in clin. trials.  Here, the authors describe the results of an in vitro screen designed to identify mutations in the ATP-binding pocket of FLT3 that confer resistance to tyrosine kinase inhibitors.  Mutations at four different positions (Ala-627, Asn-676, Phe-691, and Gly-697) were identified that confer varying degrees of resistance to PKC412, SU5614, or K-252a.  FLT3 proteins mutated at Ala-627, Asn-676, or Phe-691 remained sensitive to higher concns. of the inhibitors, but the G697R mutation conferred high-level resistance to each of these inhibitors as well as to six addnl. exptl. inhibitors.  These data provide insights into potential mechanisms of acquired resistance of FLT3 to small mol. inhibitors and indicate that the G697R mutation may be a clin. problematic resistance mutation that warrants proactive screening for addnl. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEFVcyQVB8A7Vg90H21EOLACvtfcHk0lgvEM3xY0yX-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlt7c%253D&md5=84771d97a435fe109d28539f6c560459</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-04-2148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-04-2148%26sid%3Dliteratum%253Aachs%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DPrediction%2520of%2520resistance%2520to%2520small%2520molecule%2520FLT3%2520inhibitors%253A%2520implications%2520for%2520molecularly%2520targeted%2520therapy%2520of%2520acute%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6385%26epage%3D6389%26doi%3D10.1158%2F0008-5472.can-04-2148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janakakumara, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, K.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palaniyandi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-S.</span></span> <span> </span><span class="NLM_article-title">Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">4052</span>– <span class="NLM_lpage">4062</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-05-156422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2008-05-156422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=19144991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4052-4062&author=J.+Zhouauthor=C.+Biauthor=J.+V.+Janakakumaraauthor=S.-C.+Liuauthor=W.-J.+Chngauthor=K.-G.+Tayauthor=L.-F.+Poonauthor=Z.+Xieauthor=S.+Palaniyandiauthor=H.+Yuauthor=K.+B.+Glaserauthor=D.+H.+Albertauthor=S.+K.+Davidsenauthor=C.-S.+Chen&title=Enhanced+activation+of+STAT+pathways+and+overexpression+of+survivin+confer+resistance+to+FLT3+inhibitors+and+could+be+therapeutic+targets+in+AML&doi=10.1182%2Fblood-2008-05-156422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML</span></div><div class="casAuthors">Zhou, Jianbiao; Bi, Chonglei; Janakakumara, Jasinghe V.; Liu, Shaw-Cheng; Chng, Wee-Joo; Tay, Kian-Ghee; Poon, Lai-Fong; Xie, Zhigang; Palaniyandi, Senthilnathan; Yu, Hanry; Glaser, Keith B.; Albert, Daniel H.; Davidsen, Steven K.; Chen, Chien-Shing</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4052-4062</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">To further investigate potential mechanisms of resistance to FLT3 inhibitors, we developed a resistant cell line by long-term culture of MV4-11 cells with ABT-869, designated as MV4-11-R.  Gene profiling reveals up-regulation of FLT3LG (FLT3 ligand) and BIRC5 (survivin), but down-regulation of SOCS1, SOCS2, and SOCS3 in MV4-11-R cells.  Hypermethylation of these SOCS genes leads to their transcriptional silencing.  Survivin is directly regulated by STAT3.  Stimulation of the parental MV4-11 cells with FLT3 ligand increases the expression of survivin and phosphorylated protein STAT1, STAT3, STAT5.  Targeting survivin by short-hairpin RNA (shRNA) in MV4-11-R cells induces apoptosis and augments ABT-869-mediated cytotoxicity.  Overexpression of survivin protects MV4-11 from apoptosis.  Subtoxic dose of indirubin deriv. (IDR) E804 resensitizes MV4-11-R to ABT-869 treatment by inhibiting STAT signaling activity and abolishing survivin expression.  Combining IDR E804 with ABT-869 shows potent in vivo efficacy in the MV4-11-R xenograft model.  Taken together, these results demonstrate that enhanced activation of STAT pathways and overexpression of survivin are important mechanisms of resistance to ABT-869, suggesting that the STAT pathways and survivin could be potential targets for reducing resistance developed in patients receiving FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8UwB_aZ-B0LVg90H21EOLACvtfcHk0lgvEM3xY0yX-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWrtr4%253D&md5=2410f1d8a508ec87ba146c3a90a74b85</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-05-156422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-05-156422%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DBi%26aufirst%3DC.%26aulast%3DJanakakumara%26aufirst%3DJ.%2BV.%26aulast%3DLiu%26aufirst%3DS.-C.%26aulast%3DChng%26aufirst%3DW.-J.%26aulast%3DTay%26aufirst%3DK.-G.%26aulast%3DPoon%26aufirst%3DL.-F.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DPalaniyandi%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DC.-S.%26atitle%3DEnhanced%2520activation%2520of%2520STAT%2520pathways%2520and%2520overexpression%2520of%2520survivin%2520confer%2520resistance%2520to%2520FLT3%2520inhibitors%2520and%2520could%2520be%2520therapeutic%2520targets%2520in%2520AML%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D4052%26epage%3D4062%26doi%3D10.1182%2Fblood-2008-05-156422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikezoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furihata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeffler, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span> <span> </span><span class="NLM_article-title">Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">2512</span>– <span class="NLM_lpage">2521</span>, <span class="refDoi"> DOI: 10.1002/ijc.25910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1002%2Fijc.25910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=21207414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2jt77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=2512-2521&author=T.+Ikezoeauthor=S.+Kojimaauthor=M.+Furihataauthor=J.+Yangauthor=C.+Nishiokaauthor=A.+Takeuchiauthor=M.+Isakaauthor=H.+P.+Koefflerauthor=A.+Yokoyama&title=Expression+of+p-JAK2+predicts+clinical+outcome+and+is+a+potential+molecular+target+of+acute+myelogenous+leukemia&doi=10.1002%2Fijc.25910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia</span></div><div class="casAuthors">Ikezoe, Takayuki; Kojima, Shinsuke; Furihata, Mutsuo; Yang, Jing; Nishioka, Chie; Takeuchi, Asako; Isaka, Mayuka; Koeffler, H. Phillip; Yokoyama, Akihito</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2512-2521</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Our study detd. if Janus kinase 2 (JAK2) was activated in acute myelogenous leukemia (AML; n = 77, excluding acute promyelocytic leukemia) by immunohistochem. (IHC) using a phosphor-specific antibody against JAK2. p-JAK2 was detectable in all cases, although its levels varied between patient samples (high levels, n = 31; low levels, n = 46).  The quantification of levels of p-JAK2 by IHC was well correlated with that assessed by Western blot analyses and fluorescence-activated cell sorting (FACS).  Levels of p-JAK2 were directly correlated with high white blood cell count (52.3 × 103/L in patients with high p-JAK2 vs. 28.3 × 103/L in patients with low p-JAK2, p < 0.01) and were inversely correlated with complete remission rates (45% in patients with high p-JAK2 vs. 78% in patients with low p-JAK2, p < 0.003).  In addn., multivariate anal. confirmed that high levels of p-JAK2 remained a significant factor for overall survival (hazard ratio = 2.213; 95% confidence interval, 1.212-4.041, p = 0.023).  Moreover, we found that AZ960, a novel and specific inhibitor of the JAK2 kinase, potently inhibited the clonogenic growth and induced apoptosis of freshly isolated AML cells from patients in assocn. with cleavage of caspase 3 and downregulation of anti-apoptotic Bcl-xL proteins.  Taken together, JAK2 may be a promising mol. target for treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9L8HwJhfH-rVg90H21EOLACvtfcHk0li1OqUsut4sYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2jt77N&md5=5821c50baeb0d36708c1c30ee8a38e15</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fijc.25910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25910%26sid%3Dliteratum%253Aachs%26aulast%3DIkezoe%26aufirst%3DT.%26aulast%3DKojima%26aufirst%3DS.%26aulast%3DFurihata%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNishioka%26aufirst%3DC.%26aulast%3DTakeuchi%26aufirst%3DA.%26aulast%3DIsaka%26aufirst%3DM.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26aulast%3DYokoyama%26aufirst%3DA.%26atitle%3DExpression%2520of%2520p-JAK2%2520predicts%2520clinical%2520outcome%2520and%2520is%2520a%2520potential%2520molecular%2520target%2520of%2520acute%2520myelogenous%2520leukemia%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D2512%26epage%3D2521%26doi%3D10.1002%2Fijc.25910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. W.</span></span> <span> </span><span class="NLM_article-title">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fleu.2011.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=21691275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGqu7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1751-1759&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=C.+Y.+Huauthor=H.+Hentzeauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=Y.+K.+Lohauthor=L.+C.+Ongauthor=A.+D.+Williamauthor=A.+Leeauthor=A.+Poulsenauthor=R.+Jayaramanauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+W.+Wood&title=SB1518%2C+a+novel+macrocyclic+pyrimidine-based+JAK2+inhibitor+for+the+treatment+of+myeloid+and+lymphoid+malignancies&doi=10.1038%2Fleu.2011.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span></div><div class="casAuthors">Hart, S.; Goh, K. C.; Novotny-Diermayr, V.; Hu, C. Y.; Hentze, H.; Tan, Y. C.; Madan, B.; Amalini, C.; Loh, Y. K.; Ong, L. C.; William, A. D.; Lee, A.; Poulsen, A.; Jayaraman, R.; Ong, K. H.; Ethirajulu, K.; Dymock, B. W.; Wood, J. W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1751-1759</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SB1518 is an innovative pyrimidine-based macrocycle that shows a unique kinase profile with selective inhibition of Janus Kinase-2 (JAK2; IC50=23 and 19 n for JAK2WT and JAK2V617F, resp.) within the JAK family (IC50=1280, 520 and 50 n for JAK1, JK3 and TYK2, resp.) and fms-like tyrosine kinase-3 (FLT3; IC50=22 n).  SB1518 shows potent effects on cellular JAK/STAT pathways, inhibiting tyrosine phosphorylation on JAK2 (Y221) and downstream STATs.  As a consequence SB1518 has potent anti-proliferative effects on myeloid and lymphoid cell lines driven by mutant or wild-type JAK2 or FLT3, resulting from cell cycle arrest and induction of apoptosis.  SB1518 has favorable pharmacokinetic properties after oral dosing in mice, is well tolerated and significantly reduces splenomegaly and hepatomegaly in a JAK2V617F-driven disease model.  SB1518 dose-dependently inhibits intra-tumor JAK2/STAT5 signaling, leading to tumor growth inhibition in a s.c. model generated with SET-2 cells derived from a JAK2V617F patient with megakaryoblastic leukemia.  Moreover, SB1518 is active against primary erythroid progenitor cells sampled from patients with myeloproliferative disease.  In summary, SB1518 has a unique profile and is efficacious and well tolerated in JAK2-dependent models.  These favorable properties are now being confirmed in clin. studies in patients with myelofibrosis and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOG8Fk52CR87Vg90H21EOLACvtfcHk0li1OqUsut4sYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGqu7bL&md5=ae5a5ae0efaaa8f51909e8c82c84610d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.148%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHu%26aufirst%3DC.%2BY.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BW.%26atitle%3DSB1518%252C%2520a%2520novel%2520macrocyclic%2520pyrimidine-based%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloid%2520and%2520lymphoid%2520malignancies%26jtitle%3DLeukemia%26date%3D2011%26volume%3D25%26spage%3D1751%26epage%3D1759%26doi%3D10.1038%2Fleu.2011.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia</span>. <i>Blood Canc. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>, <span class="NLM_elocation-id">e44</span> <span class="refDoi"> DOI: 10.1038/bcj.2011.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fbcj.2011.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=22829080" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=L.+C.+Ongauthor=B.+Khengauthor=A.+Cheongauthor=J.+Zhouauthor=W.+J.+Chngauthor=J.+M.+Wood&title=Pacritinib+%28SB1518%29%2C+a+JAK2%2FFLT3+inhibitor+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1038%2Fbcj.2011.43"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2011.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2011.43%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DKheng%26aufirst%3DB.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DPacritinib%2520%2528SB1518%2529%252C%2520a%2520JAK2%252FFLT3%2520inhibitor%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%2520Canc.%2520J.%26date%3D2011%26volume%3D1%26doi%3D10.1038%2Fbcj.2011.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odenike, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granston, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Fayoumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeg, H. J.</span></span> <span> </span><span class="NLM_article-title">Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">137</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0367-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1186%2Fs13045-016-0367-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=27931243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=137&author=S.+Verstovsekauthor=O.+Odenikeauthor=J.+W.+Singerauthor=T.+Granstonauthor=S.+Al-Fayoumiauthor=H.+J.+Deeg&title=Phase+1%2F2+study+of+pacritinib%2C+a+next+generation+JAK2%2FFLT3+inhibitor%2C+in+myelofibrosis+or+other+myeloid+malignancies&doi=10.1186%2Fs13045-016-0367-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies</span></div><div class="casAuthors">Verstovsek, Srdan; Odenike, Olatoyosi; Singer, Jack W.; Granston, Tanya; Al-Fayoumi, Suliman; Deeg, H. Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">137/1-137/12</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R.  This multicenter phase 1/2 study evaluated the max. tolerated dose (MTD), safety, and clin. activity of pacritinib in patients with myelofibrosis (MF) and other advanced myeloid malignancies.  Methods: In the phase 1 dose-escalation part of the study, 43 adults with advanced myeloid malignancies received pacritinib 100 to 600 mg once daily (QD).  In the phase 2 part of the study, 31 adults with refractory or intermediate- or high-risk newly diagnosed MF and any degree of cytopenia received pacritinib 400 mg QD.  The primary endpoint is a ≥35% redn. in spleen vol. at week 24 as detd. by magnetic resonance imaging.  Results: Five patients (11.6%) experienced a dose-limiting toxicity during cycle 1 of phase 1.  The clin. benefit rate was 86.0% (13 patients achieving clin. improvement and 24 patients having stable disease).  The MTD was established at 500 mg QD, and the recommended phase 2 dose was 400 mg QD.  In phase 2, the primary endpoint was achieved by 23.5% of evaluable patients (4/17), with 47.4% (9/19) achieving a ≥50% spleen length redn. at week 24 as measured by phys. examn.  At week 24, 38.9% of evaluable patients (7/18) achieved a ≥50% decrease in MF Quality of Life and Symptom Assessment total score.  Gastrointestinal toxicities were the most common adverse events and were predominantly grade 1/2 in severity.  Grade 3/4 anemia was reported in 5/31 patients and grade 3/4 thrombocytopenia was reported in 3/31 patients.  The most frequent AEs considered to be treatment related were diarrhea (28/31), nausea (15/31), vomiting (9/31), and fatigue (4/31).  Grade 3 treatment-related AEs were reported in seven patients (22.6%), four of whom had diarrhea.  No grade 4/5 treatment-related AEs were reported.  No leukopenia, neutropenia, or lymphopenia were reported.  Conclusions: Pacritinib was well tolerated and demonstrated clin. activity in MF.  The study suggests that pacritinib has unique characteristics, namely a lack of substantial myelosuppression and manageable side effects, making it an attractive target for further evaluation in MF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogL-MeJzFd-rVg90H21EOLACvtfcHk0lgIyTslU4I5ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVylsLY%253D&md5=98d67cff6441e0219ba7d333ef049016</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0367-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0367-x%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DOdenike%26aufirst%3DO.%26aulast%3DSinger%26aufirst%3DJ.%2BW.%26aulast%3DGranston%26aufirst%3DT.%26aulast%3DAl-Fayoumi%26aufirst%3DS.%26aulast%3DDeeg%26aufirst%3DH.%2BJ.%26atitle%3DPhase%25201%252F2%2520study%2520of%2520pacritinib%252C%2520a%2520next%2520generation%2520JAK2%252FFLT3%2520inhibitor%252C%2520in%2520myelofibrosis%2520or%2520other%2520myeloid%2520malignancies%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D137%26doi%3D10.1186%2Fs13045-016-0367-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4638</span>– <span class="NLM_lpage">4658</span>, <span class="refDoi"> DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.-H.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+Macrocycle+11-%282-Pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+Potent+Janus+Kinase+2%2FFms-Like+Tyrosine+Kinase-3+%28JAK2%2FFLT3%29+Inhibitor+for+the+Treatment+of+Myelofibrosis+and+Lymphoma&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0lgIyTslU4I5ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.-H.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520Macrocycle%252011-%25282-Pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520Potent%2520Janus%2520Kinase%25202%252FFms-Like%2520Tyrosine%2520Kinase-3%2520%2528JAK2%252FFLT3%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Myelofibrosis%2520and%2520Lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchemin, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusewitt, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briesewitz, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">2075</span>– <span class="NLM_lpage">2083</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-02-071266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2007-02-071266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=17537993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2075-2083&author=L.+Wangauthor=J.+Wangauthor=B.+W.+Blaserauthor=A.-M.+Ducheminauthor=D.+F.+Kusewittauthor=T.+Liuauthor=M.+A.+Caligiuriauthor=R.+Briesewitz&title=Pharmacologic+inhibition+of+CDK4%2F6%3A+mechanistic+evidence+for+selective+activity+or+acquired+resistance+in+acute+myeloid+leukemia&doi=10.1182%2Fblood-2007-02-071266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span></div><div class="casAuthors">Wang, Lisheng; Wang, Jie; Blaser, Bradley W.; Duchemin, Anne-Marie; Kusewitt, Donna F.; Liu, Tom; Caligiuri, Michael A.; Briesewitz, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2075-2083</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Entry into the cell cycle is mediated by cyclin-dependent kinase 4/6 (CDK4/6) activation, followed by CDK2 activation.  We found that pharmacol. inhibition of the Flt3 internal tandem duplication (ITD), a mutated receptor tyrosine kinase commonly found in patients with acute myelogenous leukemia (AML), led to the down-regulation of cyclin D2 and D3 followed by retinoblastoma protein (pRb) dephosphorylation and G1 cell-cycle arrest.  This implicated the D-cyclin-CDK4/6 complex as a downstream effector of Flt3 ITD signaling.  Indeed, single-agent PD0332991, a selective CDK4/6 inhibitor, caused sustained cell-cycle arrest in Flt3 ITD AML cell lines and prolonged survival in an in vivo model of Flt3 ITD AML.  PD0332991 caused an initial cell-cycle arrest in well-established Flt3 wild-type (wt) AML cell lines, but this was overcome by down-regulation of p27Kip and reactivation of CDK2.  This acquired resistance was not obsd. in a Flt3 ITD and a Flt3 wt sample from a patient with primary AML.  In summary, the mechanism of cell-cycle arrest after treatment of Flt3 ITD AML with a Flt3 inhibitor involves down-regulation of cyclin D2 and D3.  As such, CDK4/6 can be a therapeutic target in Flt3 ITD AML but also in primary Flt3 wt AML.  Finally, acquired resistance to CDK4/6 inhibition can arise through activation CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiH_wOIP8jJLVg90H21EOLACvtfcHk0lgIyTslU4I5ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK&md5=5f68ef6deacf3789e428731722f8c5ff</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-02-071266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-02-071266%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBlaser%26aufirst%3DB.%2BW.%26aulast%3DDuchemin%26aufirst%3DA.-M.%26aulast%3DKusewitt%26aufirst%3DD.%2BF.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DBriesewitz%26aufirst%3DR.%26atitle%3DPharmacologic%2520inhibition%2520of%2520CDK4%252F6%253A%2520mechanistic%2520evidence%2520for%2520selective%2520activity%2520or%2520acquired%2520resistance%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2075%26epage%3D2083%26doi%3D10.1182%2Fblood-2007-02-071266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, M. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGraffenreid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deignan, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaizerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lively, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihalic, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchomel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3430</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Choauthor=R.+V.+Connorsauthor=M.+DeGraffenreidauthor=J.+T.+Deignanauthor=J.+Duquetteauthor=P.+Fanauthor=B.+Fisherauthor=J.+Fuauthor=J.+N.+Huardauthor=J.+Kaizermanauthor=K.+S.+Keeganauthor=C.+Liauthor=K.+Liauthor=Y.+Liauthor=L.+Liangauthor=W.+Liuauthor=S.+E.+Livelyauthor=M.-C.+Loauthor=J.+Maauthor=D.+L.+McMinnauthor=J.+T.+Mihalicauthor=K.+Modiauthor=R.+Ngoauthor=K.+Pattabiramanauthor=D.+E.+Piperauthor=C.+Quevaauthor=M.+L.+Ragainsauthor=J.+Suchomelauthor=S.+Thibaultauthor=N.+Walkerauthor=X.+Wangauthor=Z.+Wangauthor=M.+Wanskaauthor=P.+M.+Wehnauthor=M.+F.+Weidnerauthor=A.+J.+Zhangauthor=X.+Zhaoauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Daiauthor=L.+R.+McGeeauthor=J.+C.+Medina&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+dual+kinase+inhibitor+with+preferential+affinity+for+the+activated+state+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0ljg3gBLtHAy7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DConnors%26aufirst%3DR.%2BV.%26aulast%3DDeGraffenreid%26aufirst%3DM.%26aulast%3DDeignan%26aufirst%3DJ.%2BT.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DHuard%26aufirst%3DJ.%2BN.%26aulast%3DKaizerman%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLively%26aufirst%3DS.%2BE.%26aulast%3DLo%26aufirst%3DM.-C.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DMihalic%26aufirst%3DJ.%2BT.%26aulast%3DModi%26aufirst%3DK.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPattabiraman%26aufirst%3DK.%26aulast%3DPiper%26aufirst%3DD.%2BE.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DRagains%26aufirst%3DM.%2BL.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWanska%26aufirst%3DM.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520dual%2520kinase%2520inhibitor%2520with%2520preferential%2520affinity%2520for%2520the%2520activated%2520state%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uras, I. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheicher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellutti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prchal-Murphy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tigan, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubicek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexl, V.</span></span> <span> </span><span class="NLM_article-title">Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">2890</span>– <span class="NLM_lpage">2902</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-11-683581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2015-11-683581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=27099147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ars7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=2890-2902&author=I.+Z.+Urasauthor=G.+J.+Walterauthor=R.+Scheicherauthor=F.+Belluttiauthor=M.+Prchal-Murphyauthor=A.+S.+Tiganauthor=P.+Valentauthor=F.+H.+Heidelauthor=S.+Kubicekauthor=C.+Schollauthor=S.+Fr%C3%B6hlingauthor=V.+Sexl&title=Palbociclib+treatment+of+FLT3-ITD%2B+AML+cells+uncovers+a+kinase-dependent+transcriptional+regulation+of+FLT3+and+PIM1+by+CDK6&doi=10.1182%2Fblood-2015-11-683581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6</span></div><div class="casAuthors">Uras, Iris Z.; Walter, Gina J.; Scheicher, Ruth; Bellutti, Florian; Prchal-Murphy, Michaela; Tigan, Anca S.; Valent, Peter; Heidel, Florian H.; Kubicek, Stefan; Scholl, Claudia; Froehling, Stefan; Sexl, Veronika</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2890-2902</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Up to 30% of patients with acute myeloid leukemia have constitutively activating internal tandem duplications (ITDs) of the FLT3 receptor tyrosine kinase.  Such mutations are assocd. with a poor prognosis and a high propensity to relapse after remission.  FLT3 inhibitors are being developed as targeted therapy for FLT3-ITD+ acute myeloid leukemia; however, their use is complicated by rapid development of resistance, which illustrates the need for addnl. therapeutic targets.  We show that the US Food and Drug Administration-approved CDK4/6 kinase inhibitor palbociclib induces apoptosis of FLT3-ITD leukemic cells.  The effect is specific for FLT3-mutant cells and is ascribed to the transcriptional activity of CDK6: CDK6 but not its functional homolog CDK4 is found at the promoters of the FLT3 and PIM1 genes, another important leukemogenic driver.  There CDK6 regulates transcription in a kinase-dependent manner.  Of potential clin. relevance, combined treatment with palbociclib and FLT3 inhibitors results in synergistic cytotoxicity.  Simultaneously targeting two crit. signaling nodes in leukemogenesis could represent a therapeutic breakthrough, leading to complete remission and overcoming resistance to FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsmyPMjz8SYLVg90H21EOLACvtfcHk0ljg3gBLtHAy7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ars7zP&md5=63ac18917c968342abf1600403eed3e9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-11-683581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-11-683581%26sid%3Dliteratum%253Aachs%26aulast%3DUras%26aufirst%3DI.%2BZ.%26aulast%3DWalter%26aufirst%3DG.%2BJ.%26aulast%3DScheicher%26aufirst%3DR.%26aulast%3DBellutti%26aufirst%3DF.%26aulast%3DPrchal-Murphy%26aufirst%3DM.%26aulast%3DTigan%26aufirst%3DA.%2BS.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26aulast%3DKubicek%26aufirst%3DS.%26aulast%3DScholl%26aufirst%3DC.%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DSexl%26aufirst%3DV.%26atitle%3DPalbociclib%2520treatment%2520of%2520FLT3-ITD%252B%2520AML%2520cells%2520uncovers%2520a%2520kinase-dependent%2520transcriptional%2520regulation%2520of%2520FLT3%2520and%2520PIM1%2520by%2520CDK6%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D2890%26epage%3D2902%26doi%3D10.1182%2Fblood-2015-11-683581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuzzo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minuzzo, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinazza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bresolin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Indraccolo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Accordi, B.</span></span> <span> </span><span class="NLM_article-title">Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">2750</span>– <span class="NLM_lpage">2761</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-05-784603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2017-05-784603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=29101238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Cjur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=2750-2761&author=V.+Serafinauthor=G.+Capuzzoauthor=G.+Milaniauthor=S.+A.+Minuzzoauthor=M.+Pinazzaauthor=R.+Bortolozziauthor=S.+Bresolinauthor=E.+Porc%C3%B9author=C.+Frassonauthor=S.+Indraccoloauthor=G.+Bassoauthor=B.+Accordi&title=Glucocorticoid+resistance+is+reverted+by+LCK+inhibition+in+pediatric+T-cell+acute+lymphoblastic+leukemia&doi=10.1182%2Fblood-2017-05-784603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia</span></div><div class="casAuthors">Serafin, Valentina; Capuzzo, Giorgia; Milani, Gloria; Minuzzo, Sonia Anna; Pinazza, Marica; Bortolozzi, Roberta; Bresolin, Silvia; Porcu, Elena; Frasson, Chiara; Indraccolo, Stefano; Basso, Giuseppe; Accordi, Benedetta</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2750-2761</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Pediatric T-acute lymphoblastic leukemia (T-ALL) patients often display resistance to glucocorticoid (GC) treatment.  These patients, classified as prednisone poor responders (PPR), have poorer outcome than do the other pediatric T-ALL patients receiving a high-risk adapted therapy.  Because glucocorticoids are administered to ALL patients during all the different phases of therapy, GC resistance represents an important challenge to improving the outcome for these patients.  Mechanisms underlying resistance are not yet fully unraveled; thus our research focused on the identification of deregulated signaling pathways to point out new targeted approaches.  We first identified, by reverse-phase protein arrays, the lymphocyte cell-specific protein-tyrosine kinase (LCK) as aberrantly activated in PPR patients.  We showed that LCK inhibitors, such as dasatinib, bosutinib, nintedanib, and WH-4-023, are able to induce cell death in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC resistance, even at therapeutic drug concns.  This was confirmed by specific LCK gene silencing and ex vivo combined treatment of cells from PPR patient-derived xenografts.  Moreover, we obsd. that LCK hyperactivation in PPR patients upregulates the calcineurin/nuclear factor of activated T cells signaling triggering to interleukin-4 (IL-4) overexpression.  GC-sensitive cells cultured with IL-4 display an increased resistance to dexamethasone, whereas the inhibition of IL-4 signaling could increase GC-induced apoptosis in resistant cells.  Treatment with dexamethasone and dasatinib also impaired engraftment of leukemia cells in vivo.  Our results suggest a quickly actionable approach to supporting conventional therapies and overcoming GC resistance in pediatric T-ALL patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQm_rduInbzLVg90H21EOLACvtfcHk0lgY9xa_5K-Img"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Cjur%252FL&md5=9103800c495bccdd2bac3a7f4496babb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-784603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-784603%26sid%3Dliteratum%253Aachs%26aulast%3DSerafin%26aufirst%3DV.%26aulast%3DCapuzzo%26aufirst%3DG.%26aulast%3DMilani%26aufirst%3DG.%26aulast%3DMinuzzo%26aufirst%3DS.%2BA.%26aulast%3DPinazza%26aufirst%3DM.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DBresolin%26aufirst%3DS.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DFrasson%26aufirst%3DC.%26aulast%3DIndraccolo%26aufirst%3DS.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DAccordi%26aufirst%3DB.%26atitle%3DGlucocorticoid%2520resistance%2520is%2520reverted%2520by%2520LCK%2520inhibition%2520in%2520pediatric%2520T-cell%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D2750%26epage%3D2761%26doi%3D10.1182%2Fblood-2017-05-784603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iriyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takei, M.</span></span> <span> </span><span class="NLM_article-title">Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation</span>. <i>Cancer Cell Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">37</span>, <span class="refDoi"> DOI: 10.1186/s12935-016-0314-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1186%2Fs12935-016-0314-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=27182202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVertbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=37&author=N.+Iriyamaauthor=B.+Yuanauthor=Y.+Hattaauthor=N.+Takagiauthor=M.+Takei&title=Lyn%2C+a+tyrosine+kinase+closely+linked+to+the+differentiation+status+of+primary+acute+myeloid+leukemia+blasts%2C+associates+with+negative+regulation+of+all-trans+retinoic+acid+%28ATRA%29+and+dihydroxyvitamin+D3+%28VD3%29-induced+HL-60+cells+differentiation&doi=10.1186%2Fs12935-016-0314-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation</span></div><div class="casAuthors">Iriyama, Noriyoshi; Yuan, Bo; Hatta, Yoshihiro; Takagi, Norio; Takei, Masami</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell International</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37/1-37/11</span>CODEN:
                <span class="NLM_cas:coden">CCIACC</span>;
        ISSN:<span class="NLM_cas:issn">1475-2867</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Lyn, an import member of Src family kinases (SFKs), is supposed to be implicated in acute myeloid leukemia (AML) pathogenesis and development by participation in AML differentiation, yet the details still remain incompletely understood.  The expression status of Lyn and its correlation with multiple clin. parameters including cell differentiation degree, different cytogenetic risk classification, and the activity of myeloperoxidase (MPO) were thus investigated.  To address the mechanisms underlying the involvement of Lyn in differentiation induction, the effects of dasatinib, an inhibitor for SFKs including Lyn, on the alterations of all-trans retinoic acid (ATRA)- or dihydroxyvitamin D3 (VD3)-induced differentiation, and c-Myc protein expression were investigated.  Methods: Primary AML blasts were obtained from 31 newly diagnosed AML patients with different French-American- British (FAB) subtypes.  The expression of phosphorylated and total Lyn, c-Myc, and CD11b, CD11c and CD15 was analyzed by flow cytometry.  The activation of Akt and Erk known to be involved in the regulation of c-Myc expression was investigated using western blotting.  Results: Significant higher expression levels of total Lyn were obsd. in AML patients with favorable cytogenetics, higher MPO activity and FAB M2 subtype.  A clear pos. correlation between the expression levels of Lyn and differentiation status of primary AML blasts was obsd.  Dasatinib inhibited the expression of phosphorylated Lyn, and further enhanced the differentiation-inducing activity of ATRA and VD3 in HL-60 cells.  Augmented downregulation of c-Myc protein expression was obsd. in the combination treatment with ATRA, VD3 and dasatinib compared to treatment with each reagent alone in HL-60 cells.  The suppression of the activation of Akt and Erk was also obsd. concomitantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4p0geTA5adbVg90H21EOLACvtfcHk0lgY9xa_5K-Img"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVertbk%253D&md5=309998fa1ecd5d80bc459d0323a1bfeb</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1186%2Fs12935-016-0314-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12935-016-0314-5%26sid%3Dliteratum%253Aachs%26aulast%3DIriyama%26aufirst%3DN.%26aulast%3DYuan%26aufirst%3DB.%26aulast%3DHatta%26aufirst%3DY.%26aulast%3DTakagi%26aufirst%3DN.%26aulast%3DTakei%26aufirst%3DM.%26atitle%3DLyn%252C%2520a%2520tyrosine%2520kinase%2520closely%2520linked%2520to%2520the%2520differentiation%2520status%2520of%2520primary%2520acute%2520myeloid%2520leukemia%2520blasts%252C%2520associates%2520with%2520negative%2520regulation%2520of%2520all-trans%2520retinoic%2520acid%2520%2528ATRA%2529%2520and%2520dihydroxyvitamin%2520D3%2520%2528VD3%2529-induced%2520HL-60%2520cells%2520differentiation%26jtitle%3DCancer%2520Cell%2520Int.%26date%3D2016%26volume%3D16%26spage%3D37%26doi%3D10.1186%2Fs12935-016-0314-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawahara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oishi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witthuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">et, a.</span></span> <span> </span><span class="NLM_article-title">Functional activation of JAK1 and JAK3 by selective association with IL-2 receptor subunits</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>266</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1126/science.7973659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1126%2Fscience.7973659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=7973659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFyqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1994&pages=1045-1047&author=T.+Miyazakiauthor=A.+Kawaharaauthor=H.+Fujiiauthor=Y.+Nakagawaauthor=Y.+Minamiauthor=Z.+Liuauthor=I.+Oishiauthor=O.+Silvennoinenauthor=B.+Witthuhnauthor=J.+Ihleauthor=a.+et&title=Functional+activation+of+JAK1+and+JAK3+by+selective+association+with+IL-2+receptor+subunits&doi=10.1126%2Fscience.7973659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits</span></div><div class="casAuthors">Miyazaki, Takaaki; Kawahara, Atsuo; Fujii, Hodaka; Nakagawa, Yoko; Minami, Yasuhiro; Liu, Zhao-Jun; Oishi, Isao; Silvennoinen, Olli; Witthuhn, Bruce A.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue">5187</span>),
    <span class="NLM_cas:pages">1045-7</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The interleukin-2 receptor (IL-2R) consists of three subunits: the IL-2Rα, IL-2Rβ, and IL-2Rγ chains, the last of which is also used in the receptors for IL-4, IL-7, and IL-9.  Stimulation with IL-2 induces the tyrosine phosphorylation and activation of the Janus kinases Jak1 and Jak3.  Jak1 and Jak3 were selectively assocd. with "serine-rich" region of IL-2Rβ and the C-terminal region of IL-2Rγ, resp.  Both regions were necessary for IL-2 signaling.  Furthermore, Jak3-neg. fibroblasts expressing reconstituted IL-2R became responsive to IL-2 after the addnl. expression of Jak3 complementary DNA.  Thus, activation of Jak1 and Jak3 may be a key event in IL-2 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEJB1ra0tS_rVg90H21EOLACvtfcHk0lgY9xa_5K-Img"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFyqs7s%253D&md5=3494ec6a9ee34fd16904fc5ef4bc3c56</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1126%2Fscience.7973659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.7973659%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DKawahara%26aufirst%3DA.%26aulast%3DFujii%26aufirst%3DH.%26aulast%3DNakagawa%26aufirst%3DY.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DOishi%26aufirst%3DI.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DWitthuhn%26aufirst%3DB.%26aulast%3DIhle%26aufirst%3DJ.%26aulast%3Det%26aufirst%3Da.%26atitle%3DFunctional%2520activation%2520of%2520JAK1%2520and%2520JAK3%2520by%2520selective%2520association%2520with%2520IL-2%2520receptor%2520subunits%26jtitle%3DScience%26date%3D1994%26volume%3D266%26spage%3D1045%26epage%3D1047%26doi%3D10.1126%2Fscience.7973659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Newen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaper, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeve, L.</span></span> <span> </span><span class="NLM_article-title">Interleukin-6-type cytokine signalling through the gp130/JAK/STAT pathway</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1042/bj3340297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1042%2Fbj3340297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=9716487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFOls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=1998&pages=297-314&author=P.+C.+Heinrichauthor=I.+Behrmannauthor=G.+Muller-Newenauthor=F.+Schaperauthor=L.+Graeve&title=Interleukin-6-type+cytokine+signalling+through+the+gp130%2FJAK%2FSTAT+pathway&doi=10.1042%2Fbj3340297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-6-type cytokine signaling through the gp 130/Jak/STAT pathway</span></div><div class="casAuthors">Heinrich, Peter C.; Behrmann, Iris; Muller-Newen, Gerhard; Schaper, Fred; Graeve, Lutz</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">297-314</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review with 225 refs.  The family of cytokines signaling through the common receptor subunit gp130 comprises interleukin (IL)-6, IL-11, leukemia inhibitory factor, oncostatin M, ciliary neurotrophic factor, and cardiotrophin-1.  These so-called IL-6-type cytokines are important in the regulation of complex cellular processes (gene activation, proliferation, and differentiation).  The authors focus here on the assembly of receptor complexes after ligand binding, the activation of receptor-assocd. kinases of the Janus family, and the recruitment and phosphorylation of transcription factors of the STAT family, which dimerize, translocate to the nucleus, and bind to enhancer elements of resp. target genes leading to transcriptional activation.  The important players in the signaling pathway, namely the cytokines and the receptor components, the Janus kinases Jak1, Jak2 and Tyk2, the signal transducers and activators of transcription STAT1 and STAT3 and the tyrosine phosphatase SHP2 are introduced and their structural/functional properties are discussed.  Furthermore, the authors discuss various mechanisms involved in the termination of the IL-6-type cytokine signaling, namely the action of tyrosine phosphatases, proteasome, Jak kinase inhibitors SOCS (suppressor of cytokine signaling), protein inhibitors of activated STATs (PIAS), and internalization of the cytokine receptors via gp130.  Although all IL-6-type cytokines signal through the gp130/Jak/STAT pathway, the comparison of their physiol. properties shows that they elicit not only similar, but also distinct, biol. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqmo0Vn2hFsbVg90H21EOLACvtfcHk0ljBAWYJ9QQmOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFOls7c%253D&md5=46365a3d4092c7f3bdeb742795daaf94</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1042%2Fbj3340297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3340297%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DP.%2BC.%26aulast%3DBehrmann%26aufirst%3DI.%26aulast%3DMuller-Newen%26aufirst%3DG.%26aulast%3DSchaper%26aufirst%3DF.%26aulast%3DGraeve%26aufirst%3DL.%26atitle%3DInterleukin-6-type%2520cytokine%2520signalling%2520through%2520the%2520gp130%252FJAK%252FSTAT%2520pathway%26jtitle%3DBiochem.%2520J.%26date%3D1998%26volume%3D334%26spage%3D297%26epage%3D314%26doi%3D10.1042%2Fbj3340297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Groot, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenderman, L.</span></span> <span> </span><span class="NLM_article-title">Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">619</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1016/s0898-6568(98)00023-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1016%2Fs0898-6568%2898%2900023-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=9794243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFKqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=619-628&author=R.+P.+de%0AGrootauthor=P.+J.+Cofferauthor=L.+Koenderman&title=Regulation+of+proliferation%2C+differentiation+and+survival+by+the+IL-3%2FIL-5%2FGM-CSF+receptor+family&doi=10.1016%2Fs0898-6568%2898%2900023-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family</span></div><div class="casAuthors">De Groot, Rolf P.; Coffer, Paul J.; Koenderman, Leo</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">619-628</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 176 refs.  The receptors for the IL-3/IL-5/GM-CSF cytokine family are composed of a heterodimeric complex of a cytokine-specific α chain and a common β chain (βc).  Binding of IL-3/IL-5/GM-CSF to their resp. receptors rapidly induces activation of multiple intracellular signaling pathways, including the Ras-Raf-ERK, the JAK/STAT, the phosphatidylinositol 3-kinase PKB, and the JNK/SAPK and p38 signaling pathways.  This review focuses on recent advancements in understanding how these different signaling pathways are activated by IL-3/IL-5/GM-CSF receptors, and how the individual pathways contribute to the pleiotropic effects of IL-3/IL-5/GM-CSF on their target cells, including proliferation, differentiation, survival, and effector functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWTBwWW7K8iLVg90H21EOLACvtfcHk0ljBAWYJ9QQmOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFKqt7Y%253D&md5=8efa49440eb6a80561ec7e1fa473eb74</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fs0898-6568%2898%2900023-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0898-6568%252898%252900023-0%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BGroot%26aufirst%3DR.%2BP.%26aulast%3DCoffer%26aufirst%3DP.%2BJ.%26aulast%3DKoenderman%26aufirst%3DL.%26atitle%3DRegulation%2520of%2520proliferation%252C%2520differentiation%2520and%2520survival%2520by%2520the%2520IL-3%252FIL-5%252FGM-CSF%2520receptor%2520family%26jtitle%3DCell.%2520Signalling%26date%3D1998%26volume%3D10%26spage%3D619%26epage%3D628%26doi%3D10.1016%2Fs0898-6568%2898%2900023-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plimack, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorusso, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, S. G.</span></span> <span> </span><span class="NLM_article-title">AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2013-0198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1634%2Ftheoncologist.2013-0198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=23847256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A280%3ADC%252BC3sfgtFelsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=819-820&author=E.+R.+Plimackauthor=P.+M.+Lorussoauthor=P.+McCoonauthor=W.+Tangauthor=A.+D.+Krebsauthor=G.+Curtauthor=S.+G.+Eckhardt&title=AZD1480%3A+a+phase+I+study+of+a+novel+JAK2+inhibitor+in+solid+tumors&doi=10.1634%2Ftheoncologist.2013-0198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors</span></div><div class="casAuthors">Plimack Elizabeth R; Lorusso Patricia M; McCoon Patricia; Tang Weifeng; Krebs Annetta D; Curt Gregory; Eckhardt S Gail</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">819-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD1480 is a novel agent that inhibits Janus-associated kinases 1 and 2 (JAK1 and JAK2).  The primary objective of this phase I study was to investigate the safety and tolerability of AZD1480 when administered as monotherapy to patients with solid tumors.  METHODS:  Thirty-eight patients with advanced malignancies were treated at doses of 10-70 mg once daily (QD) and 20-45 mg b.i.d.  RESULTS:  Pharmacokinetic (PK) analysis revealed rapid absorption and elimination with minimal accumulation after repeated QD or b.i.d. dosing.  Exposure increased in a dose-dependent manner from 10-50 mg.  Maximum plasma concentration (Cmax) was attained ∼1 hour after dose, and t1/2 was ∼5 hours.  Pharmacodynamic analysis of circulating granulocytes demonstrated maximum phosphorylated STAT3 (pSTAT3) inhibition 1-2 hours after dose, coincident with Cmax, and greater pSTAT3 inhibition at higher doses.  The average pSTAT3 inhibition in granulocytes at the highest dose tested, 70 mg QD, was 56% (standard deviation: ±21%) at steady-state drug levels.  Dose-limiting toxicities (DLTs) consisted of pleiotropic neurologic adverse events (AEs), including dizziness, anxiety, ataxia, memory loss, hallucinations, and behavior changes.  These AEs were generally reversible with dose reduction or treatment cessation.  CONCLUSIONS:  Whether the DLTs were due to inhibition of JAK-1/2 or to off-target effects is unknown.  The unusual DLTs and the lack of clinical activity led to discontinuation of development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0C-aojk4K4brIbt-tGZmxfW6udTcc2eYp7HI7yIPImbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfgtFelsA%253D%253D&md5=1fd650bdef456d9912cb84d7ae9970f1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2013-0198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2013-0198%26sid%3Dliteratum%253Aachs%26aulast%3DPlimack%26aufirst%3DE.%2BR.%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26aulast%3DMcCoon%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DKrebs%26aufirst%3DA.%2BD.%26aulast%3DCurt%26aufirst%3DG.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26atitle%3DAZD1480%253A%2520a%2520phase%2520I%2520study%2520of%2520a%2520novel%2520JAK2%2520inhibitor%2520in%2520solid%2520tumors%26jtitle%3DOncologist%26date%3D2013%26volume%3D18%26spage%3D819%26epage%3D820%26doi%3D10.1634%2Ftheoncologist.2013-0198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=21860433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=236-243&author=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=S.+Hartauthor=L.+C.+Ongauthor=Y.+K.+Lohauthor=A.+Cheongauthor=Y.+C.+Tanauthor=C.+Huauthor=R.+Jayaramanauthor=A.+D.+Williamauthor=E.+T.+Sunauthor=B.+W.+Dymockauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=F.+Burrowsauthor=J.+M.+Wood&title=TG02%2C+a+novel+oral+multi-kinase+inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+potent+anti-leukemic+properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span></div><div class="casAuthors">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A. D.; Sun, E. T.; Dymock, B. W.; Ong, K. H.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3.  It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs.  TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis.  Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02.  Comparison with ref. inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells.  In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling.  TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60).  These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clin. evaluation of TG02 in patients with advanced leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMelEE91r_BrVg90H21EOLACvtfcHk0ljDAr0VhLbbFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D&md5=30af7dc302f9c421924b5b0062e82655</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DTG02%252C%2520a%2520novel%2520oral%2520multi-kinase%2520inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520potent%2520anti-leukemic%2520properties%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D236%26epage%3D243%26doi%3D10.1038%2Fleu.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekonnen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomusange, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahaman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, S. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Highly potent, selective, and orally bioavailable 4-thiazol-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1892</span>– <span class="NLM_lpage">1915</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01670</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01670" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVers74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1892-1915&author=S.+Tadesseauthor=M.+Yuauthor=L.+B.+Mekonnenauthor=F.+Lamauthor=S.+Islamauthor=K.+Tomusangeauthor=M.+H.+Rahamanauthor=B.+Nollauthor=S.+K.+C.+Basnetauthor=T.+Teoauthor=H.+Albrechtauthor=R.+Milneauthor=S.+Wang&title=Highly+potent%2C+selective%2C+and+orally+bioavailable+4-thiazol-N-%28pyridin-2-yl%29pyrimidin-2-amine+cyclin-dependent+kinases+4+and+6+inhibitors+as+anticancer+drug+candidates%3A+design%2C+synthesis%2C+and+evaluation&doi=10.1021%2Facs.jmedchem.6b01670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation</span></div><div class="casAuthors">Tadesse, Solomon; Yu, Mingfeng; Mekonnen, Laychiluh B.; Lam, Frankie; Islam, Saiful; Tomusange, Khamis; Rahaman, Muhammed H.; Noll, Benjamin; Basnet, Sunita K. C.; Teo, Theodosia; Albrecht, Hugo; Milne, Robert; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1892-1915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin D dependent kinases (CDK4 and CDK6) regulate entry into S phase of the cell cycle and are validated targets for anticancer drug discovery.  Herein the authors detail the discovery of a novel series of 4-thiazolyl-N-(pyridin-2-yl)pyrimidin-2-amine derivs. as highly potent and selective inhibitors of CDK4 and CDK6.  Medicinal chem. optimization resulted in I, an orally bioavailable inhibitor mol. with remarkable selectivity.  Repeated oral administration of I caused marked inhibition of tumor growth in MV4-11 acute myeloid leukemia mouse xenografts without having a neg. effect on body wt. and showing any sign of clin. toxicity.  The data merit I as a clin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTYZFfCuD687Vg90H21EOLACvtfcHk0ljDAr0VhLbbFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVers74%253D&md5=9ce8385ba9c977b9dc8d6d5d03b077aa</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01670%26sid%3Dliteratum%253Aachs%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DMekonnen%26aufirst%3DL.%2BB.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DIslam%26aufirst%3DS.%26aulast%3DTomusange%26aufirst%3DK.%26aulast%3DRahaman%26aufirst%3DM.%2BH.%26aulast%3DNoll%26aufirst%3DB.%26aulast%3DBasnet%26aufirst%3DS.%2BK.%2BC.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DHighly%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%25204-thiazol-N-%2528pyridin-2-yl%2529pyrimidin-2-amine%2520cyclin-dependent%2520kinases%25204%2520and%25206%2520inhibitors%2520as%2520anticancer%2520drug%2520candidates%253A%2520design%252C%2520synthesis%252C%2520and%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1892%26epage%3D1915%26doi%3D10.1021%2Facs.jmedchem.6b01670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gucký, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Řezníčková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radošová
Muchová, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klejová, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malínková, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazgier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepšík, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divoký, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryštof, V.</span></span> <span> </span><span class="NLM_article-title">Discovery of <i>N</i><sup>2</sup>-(4-amino-cyclohexyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-(4-morpholin-4-ylmethyl-phenyl)-9<i>H</i>-purine-2,6-diamine as a potent FLT3 kinase inhibitor for acute myeloid leukemia with FLT3 mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3855</span>– <span class="NLM_lpage">3869</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01529</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01529" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVahsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3855-3869&author=T.+Guck%C3%BDauthor=E.+%C5%98ezn%C3%AD%C4%8Dkov%C3%A1author=T.+Rado%C5%A1ov%C3%A1%0AMuchov%C3%A1author=R.+Jordaauthor=Z.+Klejov%C3%A1author=V.+Mal%C3%ADnkov%C3%A1author=K.+Berkaauthor=V.+Bazgierauthor=H.+Ajaniauthor=M.+Lep%C5%A1%C3%ADkauthor=V.+Divok%C3%BDauthor=V.+Kry%C5%A1tof&title=Discovery+of+N2-%284-amino-cyclohexyl%29-9-cyclopentyl-N6-%284-morpholin-4-ylmethyl-phenyl%29-9H-purine-2%2C6-diamine+as+a+potent+FLT3+kinase+inhibitor+for+acute+myeloid+leukemia+with+FLT3+mutations&doi=10.1021%2Facs.jmedchem.7b01529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations</span></div><div class="casAuthors">Gucky, Tomas; Reznickova, Eva; Radosova Muchova, Tereza; Jorda, Radek; Klejova, Zuzana; Malinkova, Veronika; Berka, Karel; Bazgier, Vaclav; Ajani, Haresh; Lepsik, Martin; Divoky, Vladimir; Krystof, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3855-3869</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to std. cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3.  We present novel 2,6,9-trisubstituted purine derivs. with potent FLT3 inhibitory activity.  The lead compd. 7d displays nanomolar activity in biochem. assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive.  The MV4-11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis.  Addnl., a single dose of 7d in mice with s.c. MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect obsd. after administration of the ref. FLT3 inhibitor quizartinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ88Wx0YxwWLVg90H21EOLACvtfcHk0ljDAr0VhLbbFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVahsr0%253D&md5=cbc982a08f1905840e273e23c825a134</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01529%26sid%3Dliteratum%253Aachs%26aulast%3DGuck%25C3%25BD%26aufirst%3DT.%26aulast%3D%25C5%2598ezn%25C3%25AD%25C4%258Dkov%25C3%25A1%26aufirst%3DE.%26aulast%3DRado%25C5%25A1ov%25C3%25A1%2BMuchov%25C3%25A1%26aufirst%3DT.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DKlejov%25C3%25A1%26aufirst%3DZ.%26aulast%3DMal%25C3%25ADnkov%25C3%25A1%26aufirst%3DV.%26aulast%3DBerka%26aufirst%3DK.%26aulast%3DBazgier%26aufirst%3DV.%26aulast%3DAjani%26aufirst%3DH.%26aulast%3DLep%25C5%25A1%25C3%25ADk%26aufirst%3DM.%26aulast%3DDivok%25C3%25BD%26aufirst%3DV.%26aulast%3DKry%25C5%25A1tof%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520N2-%25284-amino-cyclohexyl%2529-9-cyclopentyl-N6-%25284-morpholin-4-ylmethyl-phenyl%2529-9H-purine-2%252C6-diamine%2520as%2520a%2520potent%2520FLT3%2520kinase%2520inhibitor%2520for%2520acute%2520myeloid%2520leukemia%2520with%2520FLT3%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3855%26epage%3D3869%26doi%3D10.1021%2Facs.jmedchem.7b01529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard
Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-methyl-1<i>H</i>-imidazole derivatives as potent JAK2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1021/jm401546n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401546n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=144-158&author=Q.+Suauthor=S.+Ioannidisauthor=C.+Chuaquiauthor=L.+Almeidaauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Blockauthor=T.+Howardauthor=S.+Huangauthor=D.+Huszarauthor=J.+A.+Readauthor=C.+Rivard%0ACostaauthor=J.+Shiauthor=M.+Suauthor=M.+Yeauthor=M.+Zinda&title=Discovery+of+1-methyl-1H-imidazole+derivatives+as+potent+JAK2+inhibitors&doi=10.1021%2Fjm401546n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors</span></div><div class="casAuthors">Su, Qibin; Ioannidis, Stephanos; Chuaqui, Claudio; Almeida, Lynsie; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Block, Michael; Howard, Tina; Huang, Shan; Huszar, Dennis; Read, Jon A.; Rivard Costa, Caroline; Shi, Jie; Su, Mei; Ye, Minwei; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-158</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure based design, synthesis, and biol. evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described.  Using the C-ring fragment from our first clin. candidate AZD1480 (I), optimization of the series led to the discovery of compd. II, a potent, orally bioavailable Jak2 inhibitor.  Compd. II displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells.  Compd. II demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczgU5RpFv1bVg90H21EOLACvtfcHk0liUy2NcGB297A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL&md5=88c57119ec77d084a91a1123fd9dea86</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm401546n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401546n%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DBlock%26aufirst%3DM.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DRivard%2BCosta%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25201-methyl-1H-imidazole%2520derivatives%2520as%2520potent%2520JAK2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D144%26epage%3D158%26doi%3D10.1021%2Fjm401546n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-chloro-<i>N</i><sup>2</sup>-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-<i>N</i><sup>4</sup>-(5-methyl-1<i>H</i>-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the JAK/STAT pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1021/jm1011319</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1011319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFarsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=262-276&author=S.+Ioannidisauthor=M.+L.+Lambauthor=T.+Wangauthor=L.+Almeidaauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=B.+Pengauthor=M.+Suauthor=H.-J.+Zhangauthor=E.+Hoffmannauthor=C.+Rivardauthor=I.+Greenauthor=T.+Howardauthor=H.+Pollardauthor=J.+Readauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Yeauthor=D.+Huszarauthor=M.+Zinda&title=Discovery+of+5-chloro-N2-%5B%281S%29-1-%285-fluoropyrimidin-2-yl%29ethyl%5D-N4-%285-methyl-1H-pyrazol-3-yl%29pyrimidine-2%2C4-diamine+%28AZD1480%29+as+a+novel+inhibitor+of+the+JAK%2FSTAT+pathway&doi=10.1021%2Fjm1011319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway</span></div><div class="casAuthors">Ioannidis, Stephanos; Lamb, Michelle L.; Wang, Tao; Almeida, Lynsie; Block, Michael H.; Davies, Audrey M.; Peng, Bo; Su, Mei; Zhang, Hai-Jun; Hoffmann, Ethan; Rivard, Caroline; Green, Isabelle; Howard, Tina; Pollard, Hannah; Read, Jon; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Ye, Min-Wei; Huszar, Dennis; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">262-276</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematol. malignancies characterized by clonal expansion of one or more myeloid lineages.  The discovery of the Jak2 V617F gain of function mutation highlighted Jak2 as a potential therapeutic target in the MPNs.  Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor.  9E inhibits signaling and proliferation of Jak2 V617F cell lines in vitro, demonstrates in vivo efficacy in a TEL-Jak2 model, has excellent phys. properties and preclin. pharmacokinetics, and is currently being evaluated in Phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMG6RQUv4HqbVg90H21EOLACvtfcHk0liUy2NcGB297A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFarsr%252FN&md5=c8141c5b0e25a007e68b6e2567a576fe</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm1011319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1011319%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.-J.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DGreen%26aufirst%3DI.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DPollard%26aufirst%3DH.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25205-chloro-N2-%255B%25281S%2529-1-%25285-fluoropyrimidin-2-yl%2529ethyl%255D-N4-%25285-methyl-1H-pyrazol-3-yl%2529pyrimidine-2%252C4-diamine%2520%2528AZD1480%2529%2520as%2520a%2520novel%2520inhibitor%2520of%2520the%2520JAK%252FSTAT%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D262%26epage%3D276%26doi%3D10.1021%2Fjm1011319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasarskis, A.</span></span> <span> </span><span class="NLM_article-title">Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 ″Gatekeeper″ F691L mutation with PLX3397</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-15-0060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1158%2F2159-8290.cd-15-0060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=25847190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=668-679&author=C.+C.+Smithauthor=C.+Zhangauthor=K.+C.+Linauthor=E.+A.+Lasaterauthor=Y.+Zhangauthor=E.+Massiauthor=L.+E.+Damonauthor=M.+Pendletonauthor=A.+Bashirauthor=R.+Sebraauthor=A.+Perlauthor=A.+Kasarskis&title=Characterizing+and+overriding+the+structural+mechanism+of+the+quizartinib-resistant+FLT3+%E2%80%B3Gatekeeper%E2%80%B3+F691L+mutation+with+PLX3397&doi=10.1158%2F2159-8290.cd-15-0060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397</span></div><div class="casAuthors">Smith, Catherine C.; Zhang, Chao; Lin, Kimberly C.; Lasater, Elisabeth A.; Zhang, Ying; Massi, Evan; Damon, Lauren E.; Pendleton, Matthew; Bashir, Ali; Sebra, Robert; Perl, Alexander; Kasarskis, Andrew; Shellooe, Rafe; Tsang, Garson; Carias, Heidi; Powell, Ben; Burton, Elizabeth A.; Matusow, Bernice; Zhang, Jiazhong; Spevak, Wayne; Ibrahim, Prabha N.; Le, Mai H.; Hsu, Henry H.; Habets, Gaston; West, Brian L.; Bollag, Gideon; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">668-679</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PLX3397 inhibits the growth of quizartinib-resistant FLT3-ITD+ AML cells expressing the gatekeeper F691L mutation in vitro and in vivo, but not cells expressing kinase domain mutations in the FLT3 activation loop.  Tyrosine kinase domain mutations are a common cause of acquired clin. resistance to tyrosine kinase inhibitors (TKI) used to treat cancer, including the FLT3 inhibitor quizartinib.  Mutation of kinase "gatekeeper" residues, which control access to an allosteric pocket adjacent to the ATP-binding site, has been frequently implicated in TKI resistance.  The mol. underpinnings of gatekeeper mutation-mediated resistance are incompletely understood.  We report the first cocrystal structure of FLT3 with the TKI quizartinib, which demonstrates that quizartinib binding relies on essential edge-to-face arom. interactions with the gatekeeper F691 residue, and F830 within the highly conserved Asp-Phe-Gly motif in the activation loop.  This reliance makes quizartinib critically vulnerable to gatekeeper and activation loop substitutions while minimizing the impact of mutations elsewhere.  Moreover, we identify PLX3397, a novel FLT3 inhibitor that retains activity against the F691L mutant due to a binding mode that depends less vitally on specific interactions with the gatekeeper position.  Significance: We report the first cocrystal structure of FLT3 with a kinase inhibitor, elucidating the structural mechanism of resistance due to the gatekeeper F691L mutation.  PLX3397 is a novel FLT3 inhibitor with in vitro activity against this mutation but is vulnerable to kinase domain mutations in the FLT3 activation loop.  Cancer Discov; 5(6); 668-79. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9oYwTJ6cznrVg90H21EOLACvtfcHk0liUy2NcGB297A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D&md5=7e76b2892a49a6e4701f534fce212ca4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.cd-15-0060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.cd-15-0060%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMassi%26aufirst%3DE.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DBashir%26aufirst%3DA.%26aulast%3DSebra%26aufirst%3DR.%26aulast%3DPerl%26aufirst%3DA.%26aulast%3DKasarskis%26aufirst%3DA.%26atitle%3DCharacterizing%2520and%2520overriding%2520the%2520structural%2520mechanism%2520of%2520the%2520quizartinib-resistant%2520FLT3%2520%25E2%2580%25B3Gatekeeper%25E2%2580%25B3%2520F691L%2520mutation%2520with%2520PLX3397%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D668%26epage%3D679%26doi%3D10.1158%2F2159-8290.cd-15-0060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chufeng Zhang, Wenyan Qi, Yong Li, Minghai Tang, Tao Yang, Kongjun Liu, Yong Chen, Dexin Deng, Mingli Xiang, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (4)
                                     , 1966-1988. <a href="https://doi.org/10.1021/acs.jmedchem.0c01468" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01468</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01468%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B3-%2525284-%2525282-%252528%2525281H-Indol-5-yl%252529amino%252529-5-fluoropyrimidin-4-yl%252529-1H-pyrazol-1-yl%252529propanenitrile%252BDerivatives%252Bas%252BSelective%252BTYK2%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BInflammatory%252BBowel%252BDisease%26aulast%3DZhang%26aufirst%3DChufeng%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D28082020%26date%3D16022021%26volume%3D64%26issue%3D4%26spage%3D1966%26epage%3D1988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Yang, Mengshi Hu, Yong Chen, Mingli Xiang, Minghai Tang, Wenyan Qi, Mingsong Shi, Jun He, Xue Yuan, Chufeng Zhang, Kongjun Liu, Jiewen Li, Zhuang Yang, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14921-14936. <a href="https://doi.org/10.1021/acs.jmedchem.0c01488" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01488%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DN-%252528Pyrimidin-2-yl%252529-1%25252C2%25252C3%25252C4-tetrahydroisoquinolin-6-amine%252BDerivatives%252Bas%252BSelective%252BJanus%252BKinase%252B2%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BMyeloproliferative%252BNeoplasms%26aulast%3DYang%26aufirst%3DTao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26082020%26date%3D30112020%26volume%3D63%26issue%3D23%26spage%3D14921%26epage%3D14936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yue Zhong, Run-Ze Qiu, Shan-Liang Sun, Chao Zhao, Tian-Yuan Fan, Min Chen, Nian-Guang Li, <span class="NLM_string-name hlFld-ContribAuthor">Zhi-Hao Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12403-12428. <a href="https://doi.org/10.1021/acs.jmedchem.0c00696" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00696%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BFms-like%252BTyrosine%252BKinase%252B3%252BInhibitors%25253A%252BAn%252BAttractive%252Band%252BEfficient%252BMethod%252Bfor%252Bthe%252BTreatment%252Bof%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DZhong%26aufirst%3DYue%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26042020%26date%3D21072020%26date%3D13072020%26volume%3D63%26issue%3D21%26spage%3D12403%26epage%3D12428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiali  Zhu</span>, <span class="hlFld-ContribAuthor ">Tao  Yang</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Zhuang  Yang</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Haoyu  Ye</span>, <span class="hlFld-ContribAuthor ">Yu  Tang</span>, <span class="hlFld-ContribAuthor ">Zhixuan  Cheng</span>, <span class="hlFld-ContribAuthor ">Ping  Lin</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Studies on the anti-psoriasis effects and its mechanism of a dual JAK2/FLT3 inhibitor flonoltinib maleate. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2021,</strong> <em>137 </em>, 111373. <a href="https://doi.org/10.1016/j.biopha.2021.111373" title="DOI URL">https://doi.org/10.1016/j.biopha.2021.111373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2021.111373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2021.111373%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DStudies%252Bon%252Bthe%252Banti-psoriasis%252Beffects%252Band%252Bits%252Bmechanism%252Bof%252Ba%252Bdual%252BJAK2%25252FFLT3%252Binhibitor%252Bflonoltinib%252Bmaleate%26aulast%3DZhu%26aufirst%3DJiali%26date%3D2021%26volume%3D137%26spage%3D111373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoying  Lyu</span>, <span class="hlFld-ContribAuthor ">Chungen  Li</span>, <span class="hlFld-ContribAuthor ">Jin  Zhang</span>, <span class="hlFld-ContribAuthor ">Liang  Wang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Jiang</span>, <span class="hlFld-ContribAuthor ">Yusen  Shui</span>, <span class="hlFld-ContribAuthor ">Lan  Chen</span>, <span class="hlFld-ContribAuthor ">Youfu  Luo</span>, <span class="hlFld-ContribAuthor ">Xin  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">A Novel Small Molecule, LCG-N25, Inhibits Oral Streptococcal Biofilm. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Microbiology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fmicb.2021.654692" title="DOI URL">https://doi.org/10.3389/fmicb.2021.654692</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmicb.2021.654692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmicb.2021.654692%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Microbiology%26atitle%3DA%252BNovel%252BSmall%252BMolecule%25252C%252BLCG-N25%25252C%252BInhibits%252BOral%252BStreptococcal%252BBiofilm%26aulast%3DLyu%26aufirst%3DXiaoying%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Guo</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 600-620. <a href="https://doi.org/10.1002/cmdc.202000658" title="DOI URL">https://doi.org/10.1002/cmdc.202000658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000658%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BMultitargeted%252BTyrosine%252BKinase%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DGuo%26aufirst%3DTing%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D600%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuping  Zhao</span>, <span class="hlFld-ContribAuthor ">Muhammad  Bilal</span>, <span class="hlFld-ContribAuthor ">Ali  Raza</span>, <span class="hlFld-ContribAuthor ">Muhammad Imran  Khan</span>, <span class="hlFld-ContribAuthor ">Shahid  Mehmood</span>, <span class="hlFld-ContribAuthor ">Uzma  Hayat</span>, <span class="hlFld-ContribAuthor ">Sherif T.S.  Hassan</span>, <span class="hlFld-ContribAuthor ">Hafiz M.N.  Iqbal</span>. </span><span class="cited-content_cbyCitation_article-title">Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>168 </em>, 22-37. <a href="https://doi.org/10.1016/j.ijbiomac.2020.12.009" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2020.12.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2020.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2020.12.009%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DTyrosine%252Bkinase%252Binhibitors%252Band%252Btheir%252Bunique%252Btherapeutic%252Bpotentialities%252Bto%252Bcombat%252Bcancer%26aulast%3DZhao%26aufirst%3DYuping%26date%3D2021%26volume%3D168%26spage%3D22%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lexian  Tong</span>, <span class="hlFld-ContribAuthor ">Xuemei  Li</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in FLT3 inhibitors for acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 961-981. <a href="https://doi.org/10.4155/fmc-2019-0365" title="DOI URL">https://doi.org/10.4155/fmc-2019-0365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0365%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252BFLT3%252Binhibitors%252Bfor%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DTong%26aufirst%3DLexian%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D961%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A). Schematic showing plans for splitting the loop of pacritinib; (B) docking result of the designed compound (molecule A) in the JAK2 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>); (C) docking result of the designed compound (molecule A) in the FLT3 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Docking result of the designed compound (molecule B) in the JAK2 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>); (B) docking result of the designed compound (molecule B) in the FLT3 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinome-wide selectivity profiling of compound <b>18e</b> with the Kinase Profile assay by Eurofins Discovery. Measurements were performed at a concentration of 0.1 μM of the inhibitor in duplicate. The % control means remaining active kinase percentage. The affinity was defined with respect to a dimethyl sulfoxide (DMSO) control. TREEspot image was mapped with the TREEspot software tool provided by DiscoverX Corporation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Molecular docking of <b>18e</b> in the cavity of the JAK2 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>); (B) molecular docking of <b>18e</b> in the cavity of the FLT3 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A,B) MV4-11 and SET-2 cells were treated with <b>18e</b> for 2 h at 0.008, 0.04, 0.2, 1 μM, respectively. The cells were harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis with the indicated antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Cell cycle effects of <b>18e</b> on MV4-11 cells. Cells were treated with increasing concentrations of <b>18e</b> for 24 h, harvested, fixed, and stained with propidium iodide prior to flow cytometric analysis. (B) Effects of <b>18e</b> on the induction of apoptosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Tumor volume changes following the treatment of <b>18e</b> at doses of 30 mg/kg (po) and 60 mg/kg; (B) tumor weight of each mouse on day 14; (C) average body weights for <b>18e</b>-treated mice groups; (D) tumor volume changes following the treatment of <b>18e</b> at doses of 30 mg/kg (po) and 60 mg/kg (po) in the SET-2 xenograft model; (E) tumor weight of each mouse on day 18; (F) average body weights for <b>18e</b>-treated mice groups; (H) inhibition of the spleen growth in the Ba/F-JAK2<sup>V617F</sup> allograft model; (I) spleen weight of each mouse on day 25; (G) inhibition of the liver growth in the Ba/F-JAK2<sup>V617F</sup> allograft model; *, <i>P</i> < 0.05 **, <i>P</i> < 0.01 ***, <i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Intermediates <b>3a–g</b> and <b>5a–b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate halide, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux; (b) 2,4-dichloropyrimidine derivatives, dioxane/EtOH/water (v/v/v, 7/3/4), 80 °C, 2 h; (c) TFA, DCM; (d) appropriate halide, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, rt.</p></p></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of Compounds <b>12a–q</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate N-heterocycles, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux; (b) 80% hydrazine hydrate, Pd/C 10%, methanol, rt; (c) 2-chloropyrimidine derivatives, dioxane, reflux, 4 h, N<sub>2</sub> atmosphere; (d) TFA, DCM; (e) appropriate halide, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, rt.</p></p></figure><figure data-id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/medium/jm9b01348_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Syntheses of Compounds <b>18a–s</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01348/20191122/images/large/jm9b01348_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01348&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate N-heterocycles, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux; (b–d) appropriate halide, NaH, anhydrous DMF, rt; (e) 80% hydrazine hydrate, Pd/C 10%, methanol, rt; (f) 2-chloropyrimidine derivatives, dioxane, reflux, 4 h, N<sub>2</sub> atmosphere; (g) TFA, DCM; (h) appropriate halide, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, rt.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i79">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28042" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28042" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 45 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, I. M.</span></span> <span> </span><span class="NLM_article-title">Jaks and stats in signaling by the cytokine receptor superfamily</span>. <i>Trends Genet.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/s0168-9525(00)89000-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1016%2Fs0168-9525%2800%2989000-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=7716810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADyaK2MXjvFeit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1995&pages=69-74&author=J.+N.+Ihleauthor=I.+M.+Kerr&title=Jaks+and+stats+in+signaling+by+the+cytokine+receptor+superfamily&doi=10.1016%2Fs0168-9525%2800%2989000-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Jaks and Stats in signaling by the cytokine receptor superfamily</span></div><div class="casAuthors">Ihle, James N.; Kerr, Ian M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Genetics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-74</span>CODEN:
                <span class="NLM_cas:coden">TRGEE2</span>;
        ISSN:<span class="NLM_cas:issn">0168-9525</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 67 refs.  Many cytokines mediate their biol. effects through interaction with a distinct family of receptors termed the cytokine receptor superfamily.  Although members of this family lack catalytic domains, they couple ligand binding to tyrosine phosphorylation.  Recent studies have shown that a novel family of cytoplasmic protein tyrosine kinases, termed the Janus kinases (Jaks), assoc. with the cytokine receptors and are catalytically activated after ligand binding.  The activated Jaks phosphorylate and activate members of a novel family of transcription factors termed signal transducers and activators of transcription (Stats).  In addn., many cytokines induce the phosphorylation of SHC, Vav and the p85 subunit of PI-3 kinase.  The region of the receptors proximal to the cytoplasmic membrane is required for Jak assocn., mitogenesis, Stat activation and Vav phosphorylation.  The membrane-distal region, which contains the major sites of tyrosine phosphorylation, is required for phosphorylation of SHC and p85, not for mitogenesis, thus allowing functional dissection of the signaling pathways activated by cytokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohCPhhcjNDsrVg90H21EOLACvtfcHk0ljLEm8px0BUBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjvFeit7s%253D&md5=005308d2c15a703a93e01a711d7da802</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fs0168-9525%2800%2989000-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0168-9525%252800%252989000-9%26sid%3Dliteratum%253Aachs%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26aulast%3DKerr%26aufirst%3DI.%2BM.%26atitle%3DJaks%2520and%2520stats%2520in%2520signaling%2520by%2520the%2520cytokine%2520receptor%2520superfamily%26jtitle%3DTrends%2520Genet.%26date%3D1995%26volume%3D11%26spage%3D69%26epage%3D74%26doi%3D10.1016%2Fs0168-9525%2800%2989000-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, J.</span></span> <span> </span><span class="NLM_article-title">TheJanusprotein tyrosine kinases in hematopoietic cytokine signaling</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1006/smim.1995.0029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1006%2Fsmim.1995.0029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=8520029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADyaK2MXotFegsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1995&pages=247-254&author=J.+Ihle&title=TheJanusprotein+tyrosine+kinases+in+hematopoietic+cytokine+signaling&doi=10.1006%2Fsmim.1995.0029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus protein tyrosine kinases in hematopoietic cytokine signaling</span></div><div class="casAuthors">Ihle, James N.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">247-54</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A review, with 57 refs.  Cytokines regulate cellular functions through their interaction with members of the cytokine receptor superfamily.  These receptors couple ligand binding to induction of tyrosine phosphorylation through their assocn. with the Janus protein tyrosine kinases (Jaks).  Receptor dimerization induces Jak homo- or hetero-assocns., autophosphorylation and activation of Jak catalytic activity.  The activated Jaks are hypothesized to phosphorylate the receptors as well as a no. of proteins involved in cellular signaling including SHC, the p85 subunit of PI 3-kinase, Vav and members of the Signal Transducers and Activators of Transcription (Stats) family of transcription factors.  Receptor phosphorylation also allows assocn. of hematopoietic cell phosphatase with the receptor complex, resulting in its down-regulation.  Receptor mutants have allowed the identification of specific domains that are required for each function and their correlation with biol. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0h0L8HCyoGrVg90H21EOLACvtfcHk0ljLEm8px0BUBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotFegsbk%253D&md5=a8c59be585bea4be3217663cc618f815</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1006%2Fsmim.1995.0029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsmim.1995.0029%26sid%3Dliteratum%253Aachs%26aulast%3DIhle%26aufirst%3DJ.%26atitle%3DTheJanusprotein%2520tyrosine%2520kinases%2520in%2520hematopoietic%2520cytokine%2520signaling%26jtitle%3DSemin.%2520Immunol.%26date%3D1995%26volume%3D7%26spage%3D247%26epage%3D254%26doi%3D10.1006%2Fsmim.1995.0029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Regulation of JAK-STAT signalling in the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+signalling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lh828WyMwMqfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signalling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">STATs in cancer inflammation and immunity: a leading role for STAT3</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1038/nrc2734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fnrc2734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=19851315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=798-809&author=H.+Yuauthor=D.+Pardollauthor=R.+Jove&title=STATs+in+cancer+inflammation+and+immunity%3A+a+leading+role+for+STAT3&doi=10.1038%2Fnrc2734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">STATs in cancer inflammation and immunity: a leading role for STAT3</span></div><div class="casAuthors">Yu, Hua; Pardoll, Drew; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">798-809</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Commensurate with their roles in regulating cytokine-dependent inflammation and immunity, signal transducer and activator of transcription (STAT) proteins are central in detg. whether immune responses in the tumor microenvironment promote or inhibit cancer.  Persistently activated STAT3 and, to some extent, STAT5 increase tumor cell proliferation, survival and invasion while suppressing anti-tumor immunity.  The persistent activation of STAT3 also mediates tumor-promoting inflammation.  STAT3 has this dual role in tumor inflammation and immunity by promoting pro-oncogenic inflammatory pathways, including nuclear factor-κB (NF-κB) and interleukin-6 (IL-6)-GP130-Janus kinase (JAK) pathways, and by opposing STAT1- and NF-κB-mediated T helper 1 anti-tumor immune responses.  Consequently, STAT3 is a promising target to redirect inflammation for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYvEMN5YrxbbVg90H21EOLACvtfcHk0lh828WyMwMqfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP&md5=e431d0bd9eabd8f1ef703211be3d5cc9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc2734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2734%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DPardoll%26aufirst%3DD.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DSTATs%2520in%2520cancer%2520inflammation%2520and%2520immunity%253A%2520a%2520leading%2520role%2520for%2520STAT3%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D798%26epage%3D809%26doi%3D10.1038%2Fnrc2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taoka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinsmore, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenstein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczak, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugay-Murphy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-amino-5<i>H</i>-pyrido[4,3-b]indol-4-carboxamide inhibitors of janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7334</span>– <span class="NLM_lpage">7349</span>, <span class="refDoi"> DOI: 10.1021/jm200909u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200909u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WksL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7334-7349&author=J.+Limauthor=B.+Taokaauthor=R.+D.+Otteauthor=K.+Spencerauthor=C.+J.+Dinsmoreauthor=M.+D.+Altmanauthor=G.+Chanauthor=C.+Rosensteinauthor=S.+Sharmaauthor=H.-P.+Suauthor=A.+A.+Szewczakauthor=L.+Xuauthor=H.+Yinauthor=J.+Zugay-Murphyauthor=C.+G.+Marshallauthor=J.+R.+Young&title=Discovery+of+1-amino-5H-pyrido%5B4%2C3-b%5Dindol-4-carboxamide+inhibitors+of+janus+kinase+2+%28JAK2%29+for+the+treatment+of+myeloproliferative+disorders&doi=10.1021%2Fjm200909u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-Amino-5H-pyrido[4,3-b]indol-4-carboxamide Inhibitors of Janus Kinase 2 (JAK2) for the Treatment of Myeloproliferative Disorders</span></div><div class="casAuthors">Lim, Jongwon; Taoka, Brandon; Otte, Ryan D.; Spencer, Kerrie; Dinsmore, Christopher J.; Altman, Michael D.; Chan, Grace; Rosenstein, Craig; Sharma, Sujata; Su, Hua-Poo; Szewczak, Alexander A.; Xu, Lin; Yin, Hong; Zugay-Murphy, Joan; Marshall, C. Gary; Young, Jonathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7334-7349</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The JAK-STAT pathway mediates signaling by cytokines, which control survival, proliferation, and differentiation of a variety of cells.  In recent years, a single point mutation (V617F) in the tyrosine kinase JAK2 was found to be present with a high incidence in myeloproliferative disorders (MPDs).  This mutation led to hyperactivation of JAK2, cytokine-independent signaling, and subsequent activation of downstream signaling networks.  The genetic, biol., and physiol. evidence suggests that JAK2 inhibitors could be effective in treating MPDs.  De novo design efforts of new scaffolds identified 1-amino-5H-pyrido[4,3-b]indol-4-carboxamides as a new viable lead series.  Subsequent optimization of cell potency, metabolic stability, and off-target activities of the leads led to the discovery of 7-(2-aminopyrimidin-5-yl)-1-{[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b]indole-4-carboxamide (65).  Compd. 65 is a potent, orally active inhibitor of JAK2 with excellent selectivity, PK profile, and in vivo efficacy in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3NgzLh6I6LLVg90H21EOLACvtfcHk0lgQOZyB__6S_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WksL3E&md5=e80e29f1d8794a31602925559c6ebe09</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm200909u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200909u%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DTaoka%26aufirst%3DB.%26aulast%3DOtte%26aufirst%3DR.%2BD.%26aulast%3DSpencer%26aufirst%3DK.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DH.-P.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DZugay-Murphy%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26atitle%3DDiscovery%2520of%25201-amino-5H-pyrido%255B4%252C3-b%255Dindol-4-carboxamide%2520inhibitors%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7334%26epage%3D7349%26doi%3D10.1021%2Fjm200909u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F. H.</span></span> <span> </span><span class="NLM_article-title">Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">854</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.3390/cells8080854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.3390%2Fcells8080854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslWntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=854-872&author=F.+Pernerauthor=C.+Pernerauthor=T.+Ernstauthor=F.+H.+Heidel&title=Roles+of+JAK2+in+aging%2C+inflammation%2C+hematopoiesis+and+malignant+transformation&doi=10.3390%2Fcells8080854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation</span></div><div class="casAuthors">Perner, Florian; Perner, Caroline; Ernst, Thomas; Heidel, Florian H.</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">854</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Clonal alterations in hematopoietic cells occur during aging and are often assocd. with the establishment of a subclin. inflammatory environment.  Several age-related conditions and diseases may be initiated or promoted by these alterations.  JAK2 mutations are among the most frequently mutated genes in blood cells during aging.  The most common mutation within the JAK2 gene is JAK2-V617F that leads to constitutive activation of the kinase and thereby aberrant engagement of downstream signaling pathways.  JAK2 mutations can act as central drivers of myeloproliferative neoplasia, a pre-leukemic and age-related malignancy.  Likewise, hyperactive JAK-signaling is a hallmark of immune diseases and critically influences inflammation, coagulation and thrombosis.  In this review we aim to summarize the current knowledge on JAK2 in clonal hematopoiesis during aging, the role of JAK-signaling in inflammation and lymphocyte biol. and JAK2 function in age-related diseases and malignant transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfbCzDy7BOo7Vg90H21EOLACvtfcHk0lgQOZyB__6S_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslWntbw%253D&md5=8433e74cbd00a65cd218101e5ca62d79</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fcells8080854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8080854%26sid%3Dliteratum%253Aachs%26aulast%3DPerner%26aufirst%3DF.%26aulast%3DPerner%26aufirst%3DC.%26aulast%3DErnst%26aufirst%3DT.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26atitle%3DRoles%2520of%2520JAK2%2520in%2520aging%252C%2520inflammation%252C%2520hematopoiesis%2520and%2520malignant%2520transformation%26jtitle%3DCells%26date%3D2019%26volume%3D8%26spage%3D854%26epage%3D872%26doi%3D10.3390%2Fcells8080854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valent, P.</span></span> <span> </span><span class="NLM_article-title">Targeting the JAK2-STAT5 pathway in CML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1386</span>– <span class="NLM_lpage">1388</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-07-585943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2014-07-585943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=25170113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOksbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=1386-1388&author=P.+Valent&title=Targeting+the+JAK2-STAT5+pathway+in+CML&doi=10.1182%2Fblood-2014-07-585943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the JAK2-STAT5 pathway in CML</span></div><div class="casAuthors">Valent, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1386-1388</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">In this issue of Blood, Gallipoli et al show that combined targeting of BCR/ABL1 and Janus kinase 2 (JAK2) by 2 established kinase inhibitors, nilotinib (NI) and the JAK1/2 kinase inhibitor ruxolitinib (RUX), results in synergistic growth inhibition in immature CD34+ stem and progenitor cells obtained from patients with chronic myeloid leukemia (CML).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI_uUIq_U9uLVg90H21EOLACvtfcHk0lgAVrfjyTDWpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOksbrF&md5=f8ca828c5ee6fff8870a69784baf60e9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-07-585943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-07-585943%26sid%3Dliteratum%253Aachs%26aulast%3DValent%26aufirst%3DP.%26atitle%3DTargeting%2520the%2520JAK2-STAT5%2520pathway%2520in%2520CML%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D1386%26epage%3D1388%26doi%3D10.1182%2Fblood-2014-07-585943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallipoli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopcroft, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheadon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whetton, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jørgensen, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holyoake, T. L.</span></span> <span> </span><span class="NLM_article-title">JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1492</span>– <span class="NLM_lpage">1501</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-12-545640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2013-12-545640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=24957147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOksbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=1492-1501&author=P.+Gallipoliauthor=A.+Cookauthor=S.+Rhodesauthor=L.+Hopcroftauthor=H.+Wheadonauthor=A.+D.+Whettonauthor=H.+G.+J%C3%B8rgensenauthor=R.+Bhatiaauthor=T.+L.+Holyoake&title=JAK2%2FSTAT5+inhibition+by+nilotinib+with+ruxolitinib+contributes+to+the+elimination+of+CML+CD34%2B+cells+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2013-12-545640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo</span></div><div class="casAuthors">Gallipoli, Paolo; Cook, Amy; Rhodes, Susan; Hopcroft, Lisa; Wheadon, Helen; Whetton, Anthony D.; Jorgensen, Heather G.; Bhatia, Ravi; Holyoake, Tessa L.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1492-1501</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Chronic myeloid leukemia (CML) stem cell survival is not dependent on BCR-ABL protein kinase and treatment with ABL tyrosine kinase inhibitors cures only a minority of CML patients, thus highlighting the need for novel therapeutic targets.  The Janus kinase (JAK)2/signal transducer and activator of transcription (STAT)5 pathway has recently been explored for providing putative survival signals to CML stem/progenitor cells (SPCs) with contradictory results.  We investigated the role of this pathway using the JAK2 inhibitor, ruxolitinib (RUX).  We demonstrated that the combination of RUX, at clin. achievable concns., with the specific and potent tyrosine kinase inhibitor nilotinib, reduced the activity of the JAK2/STAT5 pathway in vitro relative to either single agent alone.  These effects correlated with increased apoptosis of CML SPCs in vitro and a redn. in primitive quiescent CML stem cells, including NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ mice repopulating cells, induced by combination treatment.  A degree of toxicity toward normal SPCs was obsd. with the combination treatment, although this related to mature B-cell engraftment in NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ mice with minimal effects on primitive CD34+ cells.  These results support the JAK2/STAT5 pathway as a relevant therapeutic target in CML SPCs and endorse the current use of nilotinib in combination with RUX in clin. trials to eradicate persistent disease in CML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSb66kAP82FrVg90H21EOLACvtfcHk0lgAVrfjyTDWpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOksbjI&md5=e641197ed6514b5a8ef62321ef65a69d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-12-545640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-12-545640%26sid%3Dliteratum%253Aachs%26aulast%3DGallipoli%26aufirst%3DP.%26aulast%3DCook%26aufirst%3DA.%26aulast%3DRhodes%26aufirst%3DS.%26aulast%3DHopcroft%26aufirst%3DL.%26aulast%3DWheadon%26aufirst%3DH.%26aulast%3DWhetton%26aufirst%3DA.%2BD.%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DH.%2BG.%26aulast%3DBhatia%26aufirst%3DR.%26aulast%3DHolyoake%26aufirst%3DT.%2BL.%26atitle%3DJAK2%252FSTAT5%2520inhibition%2520by%2520nilotinib%2520with%2520ruxolitinib%2520contributes%2520to%2520the%2520elimination%2520of%2520CML%2520CD34%252B%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D1492%26epage%3D1501%26doi%3D10.1182%2Fblood-2013-12-545640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span> <span> </span><span class="NLM_article-title">JAK/STAT signaling in hematological malignancies</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2601</span>– <span class="NLM_lpage">2613</span>, <span class="refDoi"> DOI: 10.1038/onc.2012.347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fonc.2012.347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=22869151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=2601-2613&author=W.+Vainchenkerauthor=S.+N.+Constantinescu&title=JAK%2FSTAT+signaling+in+hematological+malignancies&doi=10.1038%2Fonc.2012.347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">JAK/STAT signaling in hematological malignancies</span></div><div class="casAuthors">Vainchenker, W.; Constantinescu, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2601-2613</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is crit. in blood formation and immune response.  Many of those receptors transmit anti-apoptotic, proliferative and differentiation signals, and their expression and functions are crit. for the formation of blood lineages.  Several cancers, including blood malignancies, have been assocd. with constitutive activation of members of the STAT family, which normally require JAK-mediated tyrosine phosphorylation for transcriptional activation.  More recently, human myeloproliferative neoplasms were discovered to be assocd. with a unique acquired somatic mutation in JAK2 (JAK2 V617F), rare exon 12 JAK2 mutations, or thrombopoietin receptor mutations that constitutively activate wild-type JAK2.  Prompted by these observations, many studies have explored the possibility that JAKs, cytokine receptors, or other components of the JAK/STAT pathway are mutated or upregulated in several hematol. malignancies.  This has been obsd. in certain pediatric acute lymphoblastic leukemias and adult T-cell lymphoblastic leukemias, and overexpression of JAK2 seems to be important in Hodgkin lymphoma.  Here we discuss the nature and resp. contribution of mutations dysregulating the JAK/STAT pathway in hematol. malignancies and present examples in which such mutations drive the disease, contribute to the phenotype, or provide a survival and proliferative advantage.  JAK inhibitors are making their way into the therapeutic arsenal (for example, in myelofibrosis), and we discuss the possibility that other hematol. diseases might benefit from treatment with these inhibitors in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwfhpAymyJbVg90H21EOLACvtfcHk0lgdXXy8srrWfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN&md5=f491a126765e10fbfbb73f6e04fd64e6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.347%26sid%3Dliteratum%253Aachs%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DJAK%252FSTAT%2520signaling%2520in%2520hematological%2520malignancies%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D2601%26epage%3D2613%26doi%3D10.1038%2Fonc.2012.347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopp, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christodoulou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Bodegom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Zwet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layer, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tivey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadleigh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andraos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dölemeyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zender, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallan, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baffert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangrevelinghe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radimerski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, D. M.</span></span> <span> </span><span class="NLM_article-title">Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1016%2Fj.ccell.2015.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=26175414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1GrtL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=29-41&author=S.-C.+Wuauthor=L.+S.+Liauthor=N.+Koppauthor=J.+Monteroauthor=B.+Chapuyauthor=A.+Yodaauthor=A.+L.+Christieauthor=H.+Liuauthor=A.+Christodoulouauthor=D.+van+Bodegomauthor=J.+van+der+Zwetauthor=J.+V.+Layerauthor=T.+Tiveyauthor=A.+A.+Laneauthor=J.+A.+Ryanauthor=S.+Y.+Ngauthor=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=D.+Steensmaauthor=M.+Wadleighauthor=M.+Harrisauthor=E.+Mandonauthor=N.+Ebelauthor=R.+Andraosauthor=V.+Romanetauthor=A.+D%C3%B6lemeyerauthor=D.+Sterkerauthor=M.+Zenderauthor=S.+J.+Rodigauthor=M.+Murakamiauthor=F.+Hofmannauthor=F.+Kuoauthor=M.+J.+Eckauthor=L.+B.+Silvermanauthor=S.+E.+Sallanauthor=A.+Letaiauthor=F.+Baffertauthor=E.+Vangrevelingheauthor=T.+Radimerskiauthor=C.+Gaulauthor=D.+M.+Weinstock&title=Activity+of+the+type+II+JAK2+inhibitor+CHZ868+in+B+cell+acute+lymphoblastic+leukemia&doi=10.1016%2Fj.ccell.2015.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia</span></div><div class="casAuthors">Wu, Shuo-Chieh; Li, Loretta S.; Kopp, Nadja; Montero, Joan; Chapuy, Bjoern; Yoda, Akinori; Christie, Amanda L.; Liu, Huiyun; Christodoulou, Alexandra; van Bodegom, Diederik; van der Zwet, Jordy; Layer, Jacob V.; Tivey, Trevor; Lane, Andrew A.; Ryan, Jeremy A.; Ng, Samuel Y.; DeAngelo, Daniel J.; Stone, Richard M.; Steensma, David; Wadleigh, Martha; Harris, Marian; Mandon, Emeline; Ebel, Nicolas; Andraos, Rita; Romanet, Vincent; Dolemeyer, Arno; Sterker, Dario; Zender, Michael; Rodig, Scott J.; Murakami, Masato; Hofmann, Francesco; Kuo, Frank; Eck, Michael J.; Silverman, Lewis B.; Sallan, Stephen E.; Letai, Anthony; Baffert, Fabienne; Vangrevelinghe, Eric; Radimerski, Thomas; Gaul, Christoph; Weinstock, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-41</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A variety of cancers depend on JAK2 signaling, including the high-risk subset of B cell acute lymphoblastic leukemias (B-ALLs) with CRLF2 rearrangements.  Type I JAK2 inhibitors induce paradoxical JAK2 hyperphosphorylation in these leukemias and have limited activity.  To improve the efficacy of JAK2 inhibition in B-ALL, we developed the type II inhibitor CHZ868, which stabilizes JAK2 in an inactive conformation.  CHZ868 potently suppressed the growth of CRLF2-rearranged human B-ALL cells, abrogated JAK2 signaling, and improved survival in mice with human or murine B-ALL.  CHZ868 and dexamethasone synergistically induced apoptosis in JAK2-dependent B-ALLs and further improved in vivo survival compared to CHZ868 alone.  These data support the testing of type II JAK2 inhibition in patients with JAK2-dependent leukemias and other disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSNPgN7ef4crVg90H21EOLACvtfcHk0lgdXXy8srrWfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1GrtL7O&md5=18fd3585f9615ab0cf4cf41e2493b71a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DS.-C.%26aulast%3DLi%26aufirst%3DL.%2BS.%26aulast%3DKopp%26aufirst%3DN.%26aulast%3DMontero%26aufirst%3DJ.%26aulast%3DChapuy%26aufirst%3DB.%26aulast%3DYoda%26aufirst%3DA.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DChristodoulou%26aufirst%3DA.%26aulast%3Dvan%2BBodegom%26aufirst%3DD.%26aulast%3Dvan%2Bder%2BZwet%26aufirst%3DJ.%26aulast%3DLayer%26aufirst%3DJ.%2BV.%26aulast%3DTivey%26aufirst%3DT.%26aulast%3DLane%26aufirst%3DA.%2BA.%26aulast%3DRyan%26aufirst%3DJ.%2BA.%26aulast%3DNg%26aufirst%3DS.%2BY.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DSteensma%26aufirst%3DD.%26aulast%3DWadleigh%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DM.%26aulast%3DMandon%26aufirst%3DE.%26aulast%3DEbel%26aufirst%3DN.%26aulast%3DAndraos%26aufirst%3DR.%26aulast%3DRomanet%26aufirst%3DV.%26aulast%3DD%25C3%25B6lemeyer%26aufirst%3DA.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DZender%26aufirst%3DM.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DKuo%26aufirst%3DF.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSilverman%26aufirst%3DL.%2BB.%26aulast%3DSallan%26aufirst%3DS.%2BE.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DBaffert%26aufirst%3DF.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DRadimerski%26aufirst%3DT.%26aulast%3DGaul%26aufirst%3DC.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26atitle%3DActivity%2520of%2520the%2520type%2520II%2520JAK2%2520inhibitor%2520CHZ868%2520in%2520B%2520cell%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D29%26epage%3D41%26doi%3D10.1016%2Fj.ccell.2015.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plosker, G. L.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib: a review of its use in patients with myelofibrosis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0351-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1007%2Fs40265-015-0351-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=25601187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=297-308&author=G.+L.+Plosker&title=Ruxolitinib%3A+a+review+of+its+use+in+patients+with+myelofibrosis&doi=10.1007%2Fs40265-015-0351-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis</span></div><div class="casAuthors">Plosker, Greg L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-308</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib (Jakavi, Jakafi) is an orally administered inhibitor of Janus kinases (JAK) 1 and 2 used in the management of patients with myelofibrosis.  Clin. trials with ruxolitinib, notably the phase III COMFORT-I and -II studies and their extensions, have demonstrated marked and durable clin. benefits in terms of redns. in splenomegaly and disease-related symptoms in patients with intermediate-2 or high-risk myelofibrosis.  Ruxolitinib was also assocd. with improvements in health-related quality of life and functioning.  Despite the crossover of patients in control groups to ruxolitinib, results of the COMFORT studies and their extensions indicate a survival advantage for patients randomized to ruxolitinib.  The beneficial effects of ruxolitinib were obsd. across subgroups of myelofibrosis patients, including those not harbouring the JAK2V617F mutation.  Improvements in splenomegaly and disease-related symptoms were also obsd. in a trial in Japanese/Asian patients with myelofibrosis and in myelofibrosis patients with a low baseline platelet count.  Dose-related anemia and thrombocytopenia were common in clin. trials with ruxolitinib, but rarely led to discontinuation of therapy and were managed with dosage modifications and/or transfusions of packed red blood cells.  In addn. to the USA and EU, ruxolitinib is now approved in a no. of other countries, including Japan, and remains the only approved drug for the treatment of myelofibrosis, although various other agents are undergoing investigation.  Appropriate monitoring and dosage titrn. are important to achieve optimal clin. benefits of ruxolitinib.  Further research, including studies evaluating ruxolitinib-based combination therapy, may also help to optimize treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjqinnNMi_PLVg90H21EOLACvtfcHk0lgdXXy8srrWfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeisrg%253D&md5=58970b22ffdaab2e4a3d8ee7dffdb72f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0351-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0351-8%26sid%3Dliteratum%253Aachs%26aulast%3DPlosker%26aufirst%3DG.%2BL.%26atitle%3DRuxolitinib%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520patients%2520with%2520myelofibrosis%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D297%26epage%3D308%26doi%3D10.1007%2Fs40265-015-0351-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingua::EN::Titlecase, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ali, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gisslinger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoops, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuitty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalbovskaya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalakrishna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbui, T.</span></span> <span> </span><span class="NLM_article-title">Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1707</span>, <span class="refDoi"> DOI: 10.1038/leu.2016.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fleu.2016.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=27211272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWlsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1701-1707&author=C.+N.+Harrisonauthor=A.+M.+Lingua%3A%3AEN%3A%3ATitlecaseauthor=A.+M.+Vannucchiauthor=J.-J.+Kiladjianauthor=H.+K.+Al-Aliauthor=H.+Gisslingerauthor=L.+Knoopsauthor=F.+Cervantesauthor=M.+M.+Jonesauthor=K.+Sunauthor=M.+McQuittyauthor=V.+Stalbovskayaauthor=P.+Gopalakrishnaauthor=T.+Barbui&title=Long-term+findings+from+COMFORT-II%2C+a+phase+3+study+of+ruxolitinib+vs+best+available+therapy+for+myelofibrosis&doi=10.1038%2Fleu.2016.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis</span></div><div class="casAuthors">Harrison, C. N.; Vannucchi, A. M.; Kiladjian, J.-J.; Al-Ali, H. K.; Gisslinger, H.; Knoops, L.; Cervantes, F.; Jones, M. M.; Sun, K.; McQuitty, M.; Stalbovskaya, V.; Gopalakrishna, P.; Barbui, T.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1701-1707</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies.  COMFORT-II was a randomized (2:1), open-label phase 3 study in patients with myelofibrosis; patients randomized to BAT could crossover to ruxolitinib upon protocol-defined disease progression or after the primary end point, confounding long-term comparisons.  At week 48, 28% (41/146) of patients randomized to ruxolitinib achieved ≥35% decrease in spleen vol. (primary end point) compared with no patients on BAT (P<0.001).  Among the 78 patients (53.4%) in the ruxolitinib arm who achieved ≥35% redns. in spleen vol. at any time, the probability of maintaining response was 0.48 (95% confidence interval (CI), 0.35-0.60) at 5 years (median, 3.2 years).  Median overall survival was not reached in the ruxolitinib arm and was 4.1 years in the BAT arm.  There was a 33% redn. in risk of death with ruxolitinib compared with BAT by intent-to-treat anal. (hazard ratio (HR)=0.67; 95% CI, 0.44-1.02; P=0.06); the crossover-cor. HR was 0.44 (95% CI, 0.18-1.04; P=0.06).  There was no unexpected increased incidence of adverse events with longer exposure.  This final anal. showed that spleen vol. redns. with ruxolitinib were maintained with continued therapy and may be assocd. with survival benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwVXL4Oxo3bVg90H21EOLACvtfcHk0lhUpHISkeWS1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWlsbvE&md5=d3265028a6e4617b1ee1c214f09b34ab</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.148%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26aulast%3DLingua%253A%253AEN%253A%253ATitlecase%26aufirst%3DA.%2BM.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26aulast%3DAl-Ali%26aufirst%3DH.%2BK.%26aulast%3DGisslinger%26aufirst%3DH.%26aulast%3DKnoops%26aufirst%3DL.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DJones%26aufirst%3DM.%2BM.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DMcQuitty%26aufirst%3DM.%26aulast%3DStalbovskaya%26aufirst%3DV.%26aulast%3DGopalakrishna%26aufirst%3DP.%26aulast%3DBarbui%26aufirst%3DT.%26atitle%3DLong-term%2520findings%2520from%2520COMFORT-II%252C%2520a%2520phase%25203%2520study%2520of%2520ruxolitinib%2520vs%2520best%2520available%2520therapy%2520for%2520myelofibrosis%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D1701%26epage%3D1707%26doi%3D10.1038%2Fleu.2016.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariette, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winthrop, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charles-Schoeman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thirunavukkarasu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenhaupt, J.</span></span> <span> </span><span class="NLM_article-title">Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1253</span>– <span class="NLM_lpage">1262</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2016-210457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1136%2Fannrheumdis-2016-210457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=28143815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOitr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=1253-1262&author=S.+B.+Cohenauthor=Y.+Tanakaauthor=X.+Marietteauthor=J.+R.+Curtisauthor=E.+B.+Leeauthor=P.+Nashauthor=K.+L.+Winthropauthor=C.+Charles-Schoemanauthor=K.+Thirunavukkarasuauthor=R.+DeMasiauthor=J.+Geierauthor=K.+Kwokauthor=L.+Wangauthor=R.+Rieseauthor=J.+Wollenhaupt&title=Long-term+safety+of+tofacitinib+for+the+treatment+of+rheumatoid+arthritis+up+to+8.5+years%3A+integrated+analysis+of+data+from+the+global+clinical+trials&doi=10.1136%2Fannrheumdis-2016-210457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials</span></div><div class="casAuthors">Cohen, Stanley B.; Tanaka, Yoshiya; Mariette, Xavier; Curtis, Jeffrey R.; Lee, Eun Bong; Nash, Peter; Winthrop, Kevin L.; Charles-Schoeman, Christina; Thirunavukkarasu, Krishan; DeMasi, Ryan; Geier, Jamie; Kwok, Kenneth; Wang, Lisy; Riese, Richard; Wollenhaupt, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1253-1262</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).  We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA.  Methods: Data were pooled for all tofacitinib-treated patients (data cut-off: 31 March 2015).  Incidence rates (IRs; patients with event/100 patient-years) and 95% CIs are reported for adverse events (AEs) of interest.  Results: 6194 patients received tofacitinib for a total 19 406 patient-years' exposure; median exposure was 3.4 patient-years.  IR (95% CI) for serious AEs was 9.4 (9.0 to 9.9); IR for serious infections was 2.7 (2.5 to 3.0).  IR for (all) herpes zoster was 3.9 (3.6 to 4.2); IR for disseminated or multidermatomal herpes zoster was 0.3 (0.2 to 0.4).  IR for opportunistic infections (excluding tuberculosis) was 0.3 (0.2 to 0.4) and was 0.2 (0.1 to 0.3) for tuberculosis.  IR for malignancies (excluding nonmelanoma skin cancer (NMSC)) was 0.9 (0.8 to 1.0); NMSC IR was 0.6 (0.5 to 0.7).  IR for gastrointestinal perforations was 0.1 (0.1 to 0.2).  Anal. of IR for serious infections, herpes zoster and malignancies by 6-mo intervals did not reveal any notable increase in IR with longer-duration tofacitinib exposure.  Conclusion: This anal. of tofacitinib exposure up to 8.5 years allowed estn. of safety events with improved precision vs. previous tofacitinib reports.  AEs were generally stable over time; no new safety signals were obsd. compared with previous tofacitinib reports.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI4-zQlojJALVg90H21EOLACvtfcHk0lhUpHISkeWS1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOitr%252FK&md5=4bd429b9deebee6bf0151e89dbf76f49</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2016-210457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2016-210457%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DMariette%26aufirst%3DX.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DNash%26aufirst%3DP.%26aulast%3DWinthrop%26aufirst%3DK.%2BL.%26aulast%3DCharles-Schoeman%26aufirst%3DC.%26aulast%3DThirunavukkarasu%26aufirst%3DK.%26aulast%3DDeMasi%26aufirst%3DR.%26aulast%3DGeier%26aufirst%3DJ.%26aulast%3DKwok%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRiese%26aufirst%3DR.%26aulast%3DWollenhaupt%26aufirst%3DJ.%26atitle%3DLong-term%2520safety%2520of%2520tofacitinib%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520up%2520to%25208.5%2520years%253A%2520integrated%2520analysis%2520of%2520data%2520from%2520the%2520global%2520clinical%2520trials%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2017%26volume%3D76%26spage%3D1253%26epage%3D1262%26doi%3D10.1136%2Fannrheumdis-2016-210457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Fedratinib: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1725</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01205-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1007%2Fs40265-019-01205-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=31571162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOlu7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1719-1725&author=H.+A.+Blair&title=Fedratinib%3A+First+Approval&doi=10.1007%2Fs40265-019-01205-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Fedratinib: First approval for treating myelofibrosis</span></div><div class="casAuthors">Blair, Hannah A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1719-1725</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Fedratinib (INREBIC) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis.  In August 2019, fedratinib received its first global approval in the USA for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.  Phase III clin. development for myelofibrosis is ongoing worldwide.  This article summarizes the milestones in the development of fedratinib leading to this first approval for myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0phtMTwbye7Vg90H21EOLACvtfcHk0lgTubx4K1WLJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOlu7rP&md5=36fa843febf45050d5dd2d1044b715c8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01205-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01205-x%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DFedratinib%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1719%26epage%3D1725%26doi%3D10.1007%2Fs40265-019-01205-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirewalt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span> <span> </span><span class="NLM_article-title">The role of FLT3 in haematopoietic malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1038/nrc1169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fnrc1169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=12951584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=650-665&author=D.+L.+Stirewaltauthor=J.+P.+Radich&title=The+role+of+FLT3+in+haematopoietic+malignancies&doi=10.1038%2Fnrc1169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The role of FLT3 in hematopoietic malignancies</span></div><div class="casAuthors">Stirewalt, Derek L.; Radich, Jerald P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">650-665</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Normal haematopoietic cells use complex systems to control proliferation, differentiation and cell death.  The control of proliferation is, in part, accomplished through the ligand-induced stimulation of receptor tyrosine kinases, which signal to downstream effectors through the RAS pathway.  Recently, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, which encodes a receptor tyrosine kinase, have been found to be the most common genetic lesion in acute myeloid leukemia (AML), occurring in ∼25% of cases.  Exploring the mechanism by which these FLT3 mutations cause uncontrolled proliferation might lead to a better understanding of how cells become cancerous and provide insights for the development of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRONPQkpemorVg90H21EOLACvtfcHk0lgTubx4K1WLJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D&md5=97183b7a6087fafe20bfc695f403825b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrc1169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1169%26sid%3Dliteratum%253Aachs%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520role%2520of%2520FLT3%2520in%2520haematopoietic%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D650%26epage%3D665%26doi%3D10.1038%2Fnrc1169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermaat, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, W.</span></span> <span> </span><span class="NLM_article-title">Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi"> DOI: 10.1186/1756-8722-2-23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1186%2F1756-8722-2-23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=19490647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A280%3ADC%252BD1MvjsFWqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=23&author=T.+K.+Gregoryauthor=D.+Waldauthor=Y.+Chenauthor=J.+M.+Vermaatauthor=Y.+Xiongauthor=W.+Tse&title=Molecular+prognostic+markers+for+adult+acute+myeloid+leukemia+with+normal+cytogenetics&doi=10.1186%2F1756-8722-2-23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics</span></div><div class="casAuthors">Gregory Tara K; Wald David; Chen Yichu; Vermaat Johanna M; Xiong Yin; Tse William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the differentiation of hematopoietic progenitor cells along with uncontrolled proliferation.  In approximately 60% of cases, specific recurrent chromosomal aberrations can be identified by modern cytogenetic techniques.  This cytogenetic information is the single most important tool to classify patients at their initial diagnosis into three prognostic categories: favorable, intermediate, and poor risk.  Currently, favorable risk AML patients are usually treated with contemporary chemotherapy while poor risk AML patients receive allogeneic stem cell transplantation if suitable stem cell donors exist.  The largest subgroup of AML patients (aproximately 40%) have no identifiable cytogenetic abnormalities and are classified as intermediate risk.  The optimal therapeutic strategies for these patients are still largely unclear.  Recently, it is becoming increasingly evident that it is possible to identify a subgroup of poorer risk patients among those with normal cytogenic AML (NC-AML).  Molecular risk stratification for NC-AML patients may be possible due to mutations of NPM1, FLT3, MLL, and CEBPalpha as well as alterations in expression levels of BAALC, MN1, ERG, and AF1q.  Further prospective studies are needed to confirm if poorer risk NC-AML patients have improved clinical outcomes after more aggressive therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTfW9d1-8T8SM8MEzWGjS9fW6udTcc2eb6k7e6pVZmVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvjsFWqsg%253D%253D&md5=64980fe9c46b79baedc8eca3635c818a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-2-23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-2-23%26sid%3Dliteratum%253Aachs%26aulast%3DGregory%26aufirst%3DT.%2BK.%26aulast%3DWald%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DVermaat%26aufirst%3DJ.%2BM.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DTse%26aufirst%3DW.%26atitle%3DMolecular%2520prognostic%2520markers%2520for%2520adult%2520acute%2520myeloid%2520leukemia%2520with%2520normal%2520cytogenetics%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2009%26volume%3D2%26spage%3D23%26doi%3D10.1186%2F1756-8722-2-23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span> <span> </span><span class="NLM_article-title">Current findings for recurring mutations in acute myeloid leukemia</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">36</span>, <span class="refDoi"> DOI: 10.1186/1756-8722-4-36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1186%2F1756-8722-4-36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=21917154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yqsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=36&author=S.+Takahashi&title=Current+findings+for+recurring+mutations+in+acute+myeloid+leukemia&doi=10.1186%2F1756-8722-4-36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Current findings for recurring mutations in acute myeloid leukemia</span></div><div class="casAuthors">Takahashi, Shinichiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of acute myeloid leukemia (AML) is a multistep process that requires at least two genetic abnormalities for the development of the disease.  The identification of genetic mutations in AML has greatly advanced our understanding of leukemogenesis.  Recently, the use of novel technologies, such as massively parallel DNA sequencing or high-resoln. single-nucleotide polymorphism arrays, has allowed the identification of several novel recurrent gene mutations in AML.  The aim of this review is to summarize the current findings for the identification of these gene mutations (Dnmt, TET2, IDH1/2, NPM1, ASXL1, etc.), most of which are frequently found in cytogenetically normal AML.  The cooperative interactions of these mol. aberrations and their interactions with class I/II mutations are presented.  The prognostic and predictive significances of these aberrations are also reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB0uxjzh73P7Vg90H21EOLACvtfcHk0lh_OuvfQJLLoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yqsLnN&md5=7152c049fe2c2cf80934c232a3070676</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-4-36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-4-36%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DS.%26atitle%3DCurrent%2520findings%2520for%2520recurring%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2011%26volume%3D4%26spage%3D36%26doi%3D10.1186%2F1756-8722-4-36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringhoffer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salih, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachbaur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamparter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidzik, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleanu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Späth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">German-Austrian, A. M. L. S. G.</span></span> <span> </span><span class="NLM_article-title">Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3441</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-05-578070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2014-05-578070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=25270908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2nsbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3441-3449&author=R.+F.+Schlenkauthor=S.+Kayserauthor=L.+Bullingerauthor=G.+Kobbeauthor=J.+Casperauthor=M.+Ringhofferauthor=G.+Heldauthor=P.+Brossartauthor=M.+L%C3%BCbbertauthor=H.+R.+Salihauthor=T.+Kindlerauthor=H.+A.+Horstauthor=G.+Wulfauthor=D.+Nachbaurauthor=K.+G%C3%B6tzeauthor=A.+Lamparterauthor=P.+Paschkaauthor=V.+I.+Gaidzikauthor=V.+Teleanuauthor=D.+Sp%C3%A4thauthor=A.+Bennerauthor=J.+Krauterauthor=A.+Ganserauthor=H.+D%C3%B6hnerauthor=K.+D%C3%B6hnerauthor=A.+M.+L.+S.+G.+German-Austrian&title=Differential+impact+of+allelic+ratio+and+insertion+site+in+FLT3-ITD-positive+AML+with+respect+to+allogeneic+transplantation&doi=10.1182%2Fblood-2014-05-578070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation</span></div><div class="casAuthors">Schlenk, Richard F.; Kayser, Sabine; Bullinger, Lars; Kobbe, Guido; Casper, Jochen; Ringhoffer, Mark; Held, Gerhard; Brossart, Peter; Luebbert, Michael; Salih, Helmut R.; Kindler, Thomas; Horst, Heinz A.; Wulf, Gerald; Nachbaur, David; Goetze, Katharina; Lamparter, Alexander; Paschka, Peter; Gaidzik, Verena I.; Teleanu, Veronica; Spaeth, Daniela; Benner, Axel; Krauter, Juergen; Ganser, Arnold; Doehner, Hartmut; Doehner, Konstanze</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3441-3449</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The objective was to evaluate the prognostic and predictive impact of allelic ratio and insertion site (IS) of internal tandem duplications (ITDs), as well as concurrent gene mutations, with regard to postremission therapy in 323 patients with FLT3-ITD-pos. acute myeloid leukemia (AML).  Increasing FLT3-ITD allelic ratio (P = .004) and IS in the tyrosine kinase domain 1 (TKD1, P = .06) were assocd. with low complete remission (CR) rates.  After postremission therapy including intensive chemotherapy (n = 121) or autologous hematopoietic stem cell transplantation (HSCT, n = 17), an allelic ratio ≥ 0.51 was assocd. with an unfavorable relapse-free (RFS, P = .0008) and overall survival (OS, P = .004); after allogeneic HSCT (n = 93), outcome was significantly improved in patients with a high allelic ratio (RFS, P = .02; OS, P = .03), whereas no benefit was seen in patients with a low allelic ratio (RFS, P = .38; OS, P = .64).  Multivariable analyses revealed a high allelic ratio as a predictive factor for the beneficial effect of allogeneic HSCT; ITD IS in TKD1 remained an unfavorable factor, whereas no prognostic impact of concurrent gene mutations was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-3OpzDAfbwLVg90H21EOLACvtfcHk0lh_OuvfQJLLoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2nsbbN&md5=d505ffab0eb1820edec6d5657d17db41</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-05-578070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-05-578070%26sid%3Dliteratum%253Aachs%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DKayser%26aufirst%3DS.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DKobbe%26aufirst%3DG.%26aulast%3DCasper%26aufirst%3DJ.%26aulast%3DRinghoffer%26aufirst%3DM.%26aulast%3DHeld%26aufirst%3DG.%26aulast%3DBrossart%26aufirst%3DP.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26aulast%3DSalih%26aufirst%3DH.%2BR.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DHorst%26aufirst%3DH.%2BA.%26aulast%3DWulf%26aufirst%3DG.%26aulast%3DNachbaur%26aufirst%3DD.%26aulast%3DG%25C3%25B6tze%26aufirst%3DK.%26aulast%3DLamparter%26aufirst%3DA.%26aulast%3DPaschka%26aufirst%3DP.%26aulast%3DGaidzik%26aufirst%3DV.%2BI.%26aulast%3DTeleanu%26aufirst%3DV.%26aulast%3DSp%25C3%25A4th%26aufirst%3DD.%26aulast%3DBenner%26aufirst%3DA.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DGerman-Austrian%26aufirst%3DA.%2BM.%2BL.%2BS.%2BG.%26atitle%3DDifferential%2520impact%2520of%2520allelic%2520ratio%2520and%2520insertion%2520site%2520in%2520FLT3-ITD-positive%2520AML%2520with%2520respect%2520to%2520allogeneic%2520transplantation%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D3441%26epage%3D3449%26doi%3D10.1182%2Fblood-2014-05-578070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01594</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01594" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKitbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=875-892&author=X.+Liangauthor=B.+Wangauthor=C.+Chenauthor=A.+Wangauthor=C.+Huauthor=F.+Zouauthor=K.+Yuauthor=Q.+Liuauthor=F.+Liauthor=Z.+Huauthor=T.+Luauthor=J.+Wangauthor=L.+Wangauthor=E.+L.+Weisbergauthor=L.+Liauthor=R.+Xiaauthor=W.+Wangauthor=T.+Renauthor=J.+Geauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+N-%284-%286-Acetamidopyrimidin-4-yloxy%29phenyl%29-2-%282-%28trifluoromethyl%29phenyl%29acetamide+%28CHMFL-FLT3-335%29+as+a+Potent+FMS-like+Tyrosine+Kinase+3+Internal+Tandem+Duplication+%28FLT3-ITD%29+Mutant+Selective+Inhibitor+for+Acute+Myeloid+Leukemia&doi=10.1021%2Facs.jmedchem.8b01594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a potent FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutant selective inhibitor for acute myeloid leukemia</span></div><div class="casAuthors">Liang, Xiaofei; Wang, Beilei; Chen, Cheng; Wang, Aoli; Hu, Chen; Zou, Fengming; Yu, Kailin; Liu, Qingwang; Li, Feng; Hu, Zhenquan; Lu, Tingting; Wang, Junjie; Wang, Li; Weisberg, Ellen L.; Li, Lili; Xia, Ruixiang; Wang, Wenchao; Ren, Tao; Ge, Jian; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">875-892</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most of the current FMS-like tyrosine kinase 3 (FLT3) inhibitors lack selectivity between FLT3 kinase and cKIT kinase as well as the FLT3 wt and internal tandem duplication (ITD) mutants.  We report a new compd. I, which displays GI50 values of 30-80 nM against different ITD mutants and achieves selectivity over both FLT3 wt (8-fold) and cKIT kinase in the transformed BaF3 cells (>300-fold). I potently inhibits the proliferation of the FLT3-ITD-pos. acute myeloid leukemia cancer lines through suppression of the phosphorylation of FLT3 kinase and downstream signaling pathways, induction of apoptosis, and arresting the cell cycle into the G0/G1 phase. I also displays potent antiproliferative effect against FLT3-ITD-pos. patient primary cells, whereas it does not apparently affect FLT3 wt primary cells.  In addn., it also exhibits a good therapeutic window to PBMC compared to PKC412.  In the in vivo studies, I demonstrates favorable PK profiles and suppresses the tumor growth in the MV4-11 cell inoculated mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdi_MAkOsXkLVg90H21EOLACvtfcHk0liRH7lZSuAtsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKitbnE&md5=b802859e517d8156353481f41128f7a1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01594%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520N-%25284-%25286-Acetamidopyrimidin-4-yloxy%2529phenyl%2529-2-%25282-%2528trifluoromethyl%2529phenyl%2529acetamide%2520%2528CHMFL-FLT3-335%2529%2520as%2520a%2520Potent%2520FMS-like%2520Tyrosine%2520Kinase%25203%2520Internal%2520Tandem%2520Duplication%2520%2528FLT3-ITD%2529%2520Mutant%2520Selective%2520Inhibitor%2520for%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D875%26epage%3D892%26doi%3D10.1021%2Facs.jmedchem.8b01594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimek, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-03-0891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2004-03-0891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=15345597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD2MXis1GksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=54-60&author=R.+M.+Stoneauthor=D.+J.+DeAngeloauthor=V.+Klimekauthor=I.+Galinskyauthor=E.+Esteyauthor=S.+D.+Nimerauthor=W.+Grandinauthor=D.+Lebwohlauthor=Y.+Wangauthor=P.+Cohenauthor=E.+A.+Foxauthor=D.+Neubergauthor=J.+Clarkauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Patients+with+acute+myeloid+leukemia+and+an+activating+mutation+in+FLT3+respond+to+a+small-molecule+FLT3+tyrosine+kinase+inhibitor%2C+PKC412&doi=10.1182%2Fblood-2004-03-0891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412</span></div><div class="casAuthors">Stone, Richard M.; DeAngelo, Daniel J.; Klimek, Virginia; Galinsky, Ilene; Estey, Eli; Nimer, Stephen D.; Grandin, Wilson; Lebwohl, David; Wang, Yanfeng; Cohen, Pamela; Fox, Edward A.; Neuberg, Donna; Clark, Jennifer; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-60</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug therapy.  We treated 20 patients, each with mutant FLT3 relapsed/refractory AML or high-grade myelodysplastic syndrome and not believed to be candidates for chemotherapy, with an FLT3 tyrosine kinase inhibitor, PKC412 (N-benzoylstaurosporine), at a dose of 75 mg 3 times daily by mouth.  The drug was generally well tolerated, although 2 patients developed fatal pulmonary events of unclear etiol.  The peripheral blast count decreased by 50% in 14 patients (70%).  Seven patients (35%) experienced a greater than 2-log redn. in peripheral blast count for at least 4 wk (median response duration, 13 wk; range, 9-47 wk); PKC412 reduced bone marrow blast counts by 50% in 6 patients (2 of these to < 5%).  FLT3 autophosphorylation was inhibited in most of the responding patients, indicating in vivo target inhibition at the dose schedule used in this study.  PKC412 is an oral tyrosine kinase inhibitor with clin. activity in patients with AML whose blasts have an activating mutation of FLT3, suggesting potential use in combination with active agents, such as chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu297bLj2zDLVg90H21EOLACvtfcHk0liRH7lZSuAtsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXis1GksA%253D%253D&md5=8683325acf03f9cb523b7b8564c531b8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-03-0891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-03-0891%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DKlimek%26aufirst%3DV.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DGrandin%26aufirst%3DW.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DFox%26aufirst%3DE.%2BA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DPatients%2520with%2520acute%2520myeloid%2520leukemia%2520and%2520an%2520activating%2520mutation%2520in%2520FLT3%2520respond%2520to%2520a%2520small-molecule%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%252C%2520PKC412%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D54%26epage%3D60%26doi%3D10.1182%2Fblood-2004-03-0891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1016/s1535-6108(02)00069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1016%2Fs1535-6108%2802%2900069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=12124173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVKjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=433-443&author=E.+Weisbergauthor=C.+Boultonauthor=L.+M.+Kellyauthor=P.+Manleyauthor=D.+Fabbroauthor=T.+Meyerauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Inhibition+of+mutant+FLT3+receptors+in+leukemia+cells+by+the+small+molecule+tyrosine+kinase+inhibitor+PKC412&doi=10.1016%2Fs1535-6108%2802%2900069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412</span></div><div class="casAuthors">Weisberg, Ellen; Boulton, Christina; Kelly, Louise M.; Manley, Paul; Fabbro, Doriano; Meyer, Thomas; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Constitutively activating FLT3 receptor mutations have been found in 35% of patients with acute myeloblastic leukemia (AML).  Here we report the identification of a small mol. FLT3 tyrosine kinase inhibitor PKC412, which selectively induced G1 arrest and apoptosis of Ba/F3 cell lines expressing mutant FLT3 (IC50 < 10 nM) by directly inhibiting the tyrosine kinase.  Ba/F3-FLT3 cell lines made resistant to PKC412 demonstrated overexpression of mutant FLT3, confirming that FLT3 is the target of this drug.  Finally, progressive leukemia was prevented in PKC412-treated Balb/c mice transplanted with marrow transduced with a FLT3-ITD-expressing retrovirus.  PKC412 is a potent inhibitor of mutant FLT3 and is a candidate for testing as an antileukemia agent in AML patients with mutant FLT3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq5mVxGyiCu7Vg90H21EOLACvtfcHk0liRH7lZSuAtsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVKjsb4%253D&md5=612331d927bd2ca41319b77aaea6cfd1</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fs1535-6108%2802%2900069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1535-6108%252802%252900069-7%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DBoulton%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DInhibition%2520of%2520mutant%2520FLT3%2520receptors%2520in%2520leukemia%2520cells%2520by%2520the%2520small%2520molecule%2520tyrosine%2520kinase%2520inhibitor%2520PKC412%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D1%26spage%3D433%26epage%3D443%26doi%3D10.1016%2Fs1535-6108%2802%2900069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprankle, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. S.</span></span> <span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">2984</span>– <span class="NLM_lpage">2992</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-05-222034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2009-05-222034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=19654408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=H.+K.+Patelauthor=M.+Levisauthor=R.+C.+Armstrongauthor=J.+Jamesauthor=S.+S.+Bhagwat&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29&doi=10.1182%2Fblood-2009-05-222034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span></div><div class="casAuthors">Zarrinkar, Patrick P.; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; Brigham, Daniel; Belli, Barbara; Karaman, Mazen W.; Pratz, Keith W.; Pallares, Gabriel; Chao, Qi; Sprankle, Kelly G.; Patel, Hitesh K.; Levis, Mark; Armstrong, Robert C.; James, Joyce; Bhagwat, Shripad S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2984-2992</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approx. 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy.  We report the characterization of AC220, a second-generation FLT3 inhibitor, and a comparison of AC220 with the first-generation FLT3 inhibitors CEP-701, MLN-518, PKC-412, sorafenib, and sunitinib.  AC220 exhibits low nanomolar potency in biochem. and cellular assays and exceptional kinase selectivity, and in animal models is efficacious at doses as low as 1 mg/kg given orally once daily.  The data reveal that the combination of excellent potency, selectivity, and pharmacokinetic properties is unique to AC220, which therefore is the first drug candidate with a profile that matches the characteristics desirable for a clin. FLT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_RzDr7kzxsLVg90H21EOLACvtfcHk0liPFTSNrHeUUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN&md5=4f8368a7b2eab9d1234ef36e01f5f260</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-222034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-222034%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2984%26epage%3D2992%26doi%3D10.1182%2Fblood-2009-05-222034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thom, C.</span></span> <span> </span><span class="NLM_article-title">Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2499</span>– <span class="NLM_lpage">2501</span>, <span class="refDoi"> DOI: 10.2217/fon.15.188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.2217%2Ffon.15.188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=26279055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKktrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=2499-2501&author=C.+Thom&title=Preliminary+data+on+ASP2215%3A+tolerability+and+efficacy+in+acute+myeloid+leukemia+patients&doi=10.2217%2Ffon.15.188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients</span></div><div class="casAuthors">Thom, Claire</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2499-2501</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Claire Thom speaks to Gemma Westcott, Commissioning Editor: Claire Thom joined Astellas in 2013 as the Therapeutic Area Head for Oncol. in Global Development.  In that role, she also serves as the STAR leader for Oncol. for Astellas.  Prior to Astellas, she spent 12 years with Takeda.  Her last position was Senior Vice President, Portfolio Management, Drug Development Management and Medical Informatics and Strategic Operations within the Medical Division (the Division within Millennium responsible for oncol. clin. drug development within Takeda).  During her 4 years at Millennium, at various times, she had responsibility within the Medical Division for leading portfolio management, business operations (medical finance, annual and mid-range financial planning, space planning and operations, headcount resourcing, development goals process), clin. development operations (clin. operations, programming, data management, statistics, medical writing, clin. outsourcing), drug development management (project management), medical informatics (technol. support for the division) and the strategic project management office for the division.  Prior to joining Millennium, Claire Thom spent 18 mo working in Osaka, Japan, during which she was responsible for developing the oncol. strategy for Takeda that culminated in the acquisition of Millennium.  Before going to Japan, she held positions of varying responsibility within the Takeda US development organization including the management of regulatory affairs, safety, biometrics and data management, clin. research and quality assurance.  Claire Thom has particular expertise in organizational design and efficiency; she has successfully worked through integrations across multiple functions and redesigned business processes.  She has a PharmD from University of Illinois (IL, USA) and over 20 years of pharmaceutical experience including positions in medical affairs and new product planning (over 11 years at Searle) and drug development (over 12 years at Takeda/Millennium).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAQfw_oqEZorVg90H21EOLACvtfcHk0liPFTSNrHeUUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKktrvE&md5=d15842247b3170602a436a19cb5a63d6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2217%2Ffon.15.188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.15.188%26sid%3Dliteratum%253Aachs%26aulast%3DThom%26aufirst%3DC.%26atitle%3DPreliminary%2520data%2520on%2520ASP2215%253A%2520tolerability%2520and%2520efficacy%2520in%2520acute%2520myeloid%2520leukemia%2520patients%26jtitle%3DFuture%2520Oncol.%26date%3D2015%26volume%3D11%26spage%3D2499%26epage%3D2501%26doi%3D10.2217%2Ffon.15.188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mentens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marynen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">6385</span>– <span class="NLM_lpage">6389</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-04-2148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1158%2F0008-5472.can-04-2148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=15374944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6385-6389&author=J.+Coolsauthor=N.+Mentensauthor=P.+Furetauthor=D.+Fabbroauthor=J.+J.+Clarkauthor=J.+D.+Griffinauthor=P.+Marynenauthor=D.+G.+Gilliland&title=Prediction+of+resistance+to+small+molecule+FLT3+inhibitors%3A+implications+for+molecularly+targeted+therapy+of+acute+leukemia&doi=10.1158%2F0008-5472.can-04-2148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Resistance to Small Molecule FLT3 Inhibitors: Implications for Molecularly Targeted Therapy of Acute Leukemia</span></div><div class="casAuthors">Cools, Jan; Mentens, Nicole; Furet, Pascal; Fabbro, Doriano; Clark, Jennifer J.; Griffin, James D.; Marynen, Peter; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6385-6389</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutations in the receptor tyrosine kinase FLT3 occur frequently in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).  Small mols. that selectively inhibit FLT3 kinase activity induce apoptosis in blasts from AML patients with FLT3 mutations and prolong survival in animal models of FLT3-induced myeloproliferative disease.  A spectrum of structurally different small mols. with activity against FLT3 have been described, and their efficacy for treatment of AML and ALL is now being investigated in clin. trials.  Here, the authors describe the results of an in vitro screen designed to identify mutations in the ATP-binding pocket of FLT3 that confer resistance to tyrosine kinase inhibitors.  Mutations at four different positions (Ala-627, Asn-676, Phe-691, and Gly-697) were identified that confer varying degrees of resistance to PKC412, SU5614, or K-252a.  FLT3 proteins mutated at Ala-627, Asn-676, or Phe-691 remained sensitive to higher concns. of the inhibitors, but the G697R mutation conferred high-level resistance to each of these inhibitors as well as to six addnl. exptl. inhibitors.  These data provide insights into potential mechanisms of acquired resistance of FLT3 to small mol. inhibitors and indicate that the G697R mutation may be a clin. problematic resistance mutation that warrants proactive screening for addnl. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEFVcyQVB8A7Vg90H21EOLACvtfcHk0liPFTSNrHeUUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlt7c%253D&md5=84771d97a435fe109d28539f6c560459</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-04-2148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-04-2148%26sid%3Dliteratum%253Aachs%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DPrediction%2520of%2520resistance%2520to%2520small%2520molecule%2520FLT3%2520inhibitors%253A%2520implications%2520for%2520molecularly%2520targeted%2520therapy%2520of%2520acute%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6385%26epage%3D6389%26doi%3D10.1158%2F0008-5472.can-04-2148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janakakumara, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, K.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palaniyandi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-S.</span></span> <span> </span><span class="NLM_article-title">Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">4052</span>– <span class="NLM_lpage">4062</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-05-156422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2008-05-156422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=19144991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4052-4062&author=J.+Zhouauthor=C.+Biauthor=J.+V.+Janakakumaraauthor=S.-C.+Liuauthor=W.-J.+Chngauthor=K.-G.+Tayauthor=L.-F.+Poonauthor=Z.+Xieauthor=S.+Palaniyandiauthor=H.+Yuauthor=K.+B.+Glaserauthor=D.+H.+Albertauthor=S.+K.+Davidsenauthor=C.-S.+Chen&title=Enhanced+activation+of+STAT+pathways+and+overexpression+of+survivin+confer+resistance+to+FLT3+inhibitors+and+could+be+therapeutic+targets+in+AML&doi=10.1182%2Fblood-2008-05-156422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML</span></div><div class="casAuthors">Zhou, Jianbiao; Bi, Chonglei; Janakakumara, Jasinghe V.; Liu, Shaw-Cheng; Chng, Wee-Joo; Tay, Kian-Ghee; Poon, Lai-Fong; Xie, Zhigang; Palaniyandi, Senthilnathan; Yu, Hanry; Glaser, Keith B.; Albert, Daniel H.; Davidsen, Steven K.; Chen, Chien-Shing</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4052-4062</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">To further investigate potential mechanisms of resistance to FLT3 inhibitors, we developed a resistant cell line by long-term culture of MV4-11 cells with ABT-869, designated as MV4-11-R.  Gene profiling reveals up-regulation of FLT3LG (FLT3 ligand) and BIRC5 (survivin), but down-regulation of SOCS1, SOCS2, and SOCS3 in MV4-11-R cells.  Hypermethylation of these SOCS genes leads to their transcriptional silencing.  Survivin is directly regulated by STAT3.  Stimulation of the parental MV4-11 cells with FLT3 ligand increases the expression of survivin and phosphorylated protein STAT1, STAT3, STAT5.  Targeting survivin by short-hairpin RNA (shRNA) in MV4-11-R cells induces apoptosis and augments ABT-869-mediated cytotoxicity.  Overexpression of survivin protects MV4-11 from apoptosis.  Subtoxic dose of indirubin deriv. (IDR) E804 resensitizes MV4-11-R to ABT-869 treatment by inhibiting STAT signaling activity and abolishing survivin expression.  Combining IDR E804 with ABT-869 shows potent in vivo efficacy in the MV4-11-R xenograft model.  Taken together, these results demonstrate that enhanced activation of STAT pathways and overexpression of survivin are important mechanisms of resistance to ABT-869, suggesting that the STAT pathways and survivin could be potential targets for reducing resistance developed in patients receiving FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8UwB_aZ-B0LVg90H21EOLACvtfcHk0lhg6RD24jNYig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWrtr4%253D&md5=2410f1d8a508ec87ba146c3a90a74b85</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-05-156422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-05-156422%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DBi%26aufirst%3DC.%26aulast%3DJanakakumara%26aufirst%3DJ.%2BV.%26aulast%3DLiu%26aufirst%3DS.-C.%26aulast%3DChng%26aufirst%3DW.-J.%26aulast%3DTay%26aufirst%3DK.-G.%26aulast%3DPoon%26aufirst%3DL.-F.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DPalaniyandi%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DC.-S.%26atitle%3DEnhanced%2520activation%2520of%2520STAT%2520pathways%2520and%2520overexpression%2520of%2520survivin%2520confer%2520resistance%2520to%2520FLT3%2520inhibitors%2520and%2520could%2520be%2520therapeutic%2520targets%2520in%2520AML%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D4052%26epage%3D4062%26doi%3D10.1182%2Fblood-2008-05-156422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikezoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furihata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeffler, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span> <span> </span><span class="NLM_article-title">Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">2512</span>– <span class="NLM_lpage">2521</span>, <span class="refDoi"> DOI: 10.1002/ijc.25910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1002%2Fijc.25910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=21207414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2jt77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=2512-2521&author=T.+Ikezoeauthor=S.+Kojimaauthor=M.+Furihataauthor=J.+Yangauthor=C.+Nishiokaauthor=A.+Takeuchiauthor=M.+Isakaauthor=H.+P.+Koefflerauthor=A.+Yokoyama&title=Expression+of+p-JAK2+predicts+clinical+outcome+and+is+a+potential+molecular+target+of+acute+myelogenous+leukemia&doi=10.1002%2Fijc.25910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia</span></div><div class="casAuthors">Ikezoe, Takayuki; Kojima, Shinsuke; Furihata, Mutsuo; Yang, Jing; Nishioka, Chie; Takeuchi, Asako; Isaka, Mayuka; Koeffler, H. Phillip; Yokoyama, Akihito</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2512-2521</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Our study detd. if Janus kinase 2 (JAK2) was activated in acute myelogenous leukemia (AML; n = 77, excluding acute promyelocytic leukemia) by immunohistochem. (IHC) using a phosphor-specific antibody against JAK2. p-JAK2 was detectable in all cases, although its levels varied between patient samples (high levels, n = 31; low levels, n = 46).  The quantification of levels of p-JAK2 by IHC was well correlated with that assessed by Western blot analyses and fluorescence-activated cell sorting (FACS).  Levels of p-JAK2 were directly correlated with high white blood cell count (52.3 × 103/L in patients with high p-JAK2 vs. 28.3 × 103/L in patients with low p-JAK2, p < 0.01) and were inversely correlated with complete remission rates (45% in patients with high p-JAK2 vs. 78% in patients with low p-JAK2, p < 0.003).  In addn., multivariate anal. confirmed that high levels of p-JAK2 remained a significant factor for overall survival (hazard ratio = 2.213; 95% confidence interval, 1.212-4.041, p = 0.023).  Moreover, we found that AZ960, a novel and specific inhibitor of the JAK2 kinase, potently inhibited the clonogenic growth and induced apoptosis of freshly isolated AML cells from patients in assocn. with cleavage of caspase 3 and downregulation of anti-apoptotic Bcl-xL proteins.  Taken together, JAK2 may be a promising mol. target for treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9L8HwJhfH-rVg90H21EOLACvtfcHk0lhg6RD24jNYig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2jt77N&md5=5821c50baeb0d36708c1c30ee8a38e15</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fijc.25910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25910%26sid%3Dliteratum%253Aachs%26aulast%3DIkezoe%26aufirst%3DT.%26aulast%3DKojima%26aufirst%3DS.%26aulast%3DFurihata%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNishioka%26aufirst%3DC.%26aulast%3DTakeuchi%26aufirst%3DA.%26aulast%3DIsaka%26aufirst%3DM.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26aulast%3DYokoyama%26aufirst%3DA.%26atitle%3DExpression%2520of%2520p-JAK2%2520predicts%2520clinical%2520outcome%2520and%2520is%2520a%2520potential%2520molecular%2520target%2520of%2520acute%2520myelogenous%2520leukemia%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D2512%26epage%3D2521%26doi%3D10.1002%2Fijc.25910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. W.</span></span> <span> </span><span class="NLM_article-title">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fleu.2011.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=21691275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGqu7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1751-1759&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=C.+Y.+Huauthor=H.+Hentzeauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=Y.+K.+Lohauthor=L.+C.+Ongauthor=A.+D.+Williamauthor=A.+Leeauthor=A.+Poulsenauthor=R.+Jayaramanauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+W.+Wood&title=SB1518%2C+a+novel+macrocyclic+pyrimidine-based+JAK2+inhibitor+for+the+treatment+of+myeloid+and+lymphoid+malignancies&doi=10.1038%2Fleu.2011.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span></div><div class="casAuthors">Hart, S.; Goh, K. C.; Novotny-Diermayr, V.; Hu, C. Y.; Hentze, H.; Tan, Y. C.; Madan, B.; Amalini, C.; Loh, Y. K.; Ong, L. C.; William, A. D.; Lee, A.; Poulsen, A.; Jayaraman, R.; Ong, K. H.; Ethirajulu, K.; Dymock, B. W.; Wood, J. W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1751-1759</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SB1518 is an innovative pyrimidine-based macrocycle that shows a unique kinase profile with selective inhibition of Janus Kinase-2 (JAK2; IC50=23 and 19 n for JAK2WT and JAK2V617F, resp.) within the JAK family (IC50=1280, 520 and 50 n for JAK1, JK3 and TYK2, resp.) and fms-like tyrosine kinase-3 (FLT3; IC50=22 n).  SB1518 shows potent effects on cellular JAK/STAT pathways, inhibiting tyrosine phosphorylation on JAK2 (Y221) and downstream STATs.  As a consequence SB1518 has potent anti-proliferative effects on myeloid and lymphoid cell lines driven by mutant or wild-type JAK2 or FLT3, resulting from cell cycle arrest and induction of apoptosis.  SB1518 has favorable pharmacokinetic properties after oral dosing in mice, is well tolerated and significantly reduces splenomegaly and hepatomegaly in a JAK2V617F-driven disease model.  SB1518 dose-dependently inhibits intra-tumor JAK2/STAT5 signaling, leading to tumor growth inhibition in a s.c. model generated with SET-2 cells derived from a JAK2V617F patient with megakaryoblastic leukemia.  Moreover, SB1518 is active against primary erythroid progenitor cells sampled from patients with myeloproliferative disease.  In summary, SB1518 has a unique profile and is efficacious and well tolerated in JAK2-dependent models.  These favorable properties are now being confirmed in clin. studies in patients with myelofibrosis and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOG8Fk52CR87Vg90H21EOLACvtfcHk0lhsfIwB35VAKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGqu7bL&md5=ae5a5ae0efaaa8f51909e8c82c84610d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.148%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHu%26aufirst%3DC.%2BY.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BW.%26atitle%3DSB1518%252C%2520a%2520novel%2520macrocyclic%2520pyrimidine-based%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloid%2520and%2520lymphoid%2520malignancies%26jtitle%3DLeukemia%26date%3D2011%26volume%3D25%26spage%3D1751%26epage%3D1759%26doi%3D10.1038%2Fleu.2011.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia</span>. <i>Blood Canc. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>, <span class="NLM_elocation-id">e44</span> <span class="refDoi"> DOI: 10.1038/bcj.2011.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fbcj.2011.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=22829080" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=L.+C.+Ongauthor=B.+Khengauthor=A.+Cheongauthor=J.+Zhouauthor=W.+J.+Chngauthor=J.+M.+Wood&title=Pacritinib+%28SB1518%29%2C+a+JAK2%2FFLT3+inhibitor+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1038%2Fbcj.2011.43"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2011.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2011.43%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DKheng%26aufirst%3DB.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DPacritinib%2520%2528SB1518%2529%252C%2520a%2520JAK2%252FFLT3%2520inhibitor%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%2520Canc.%2520J.%26date%3D2011%26volume%3D1%26doi%3D10.1038%2Fbcj.2011.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odenike, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granston, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Fayoumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeg, H. J.</span></span> <span> </span><span class="NLM_article-title">Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">137</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0367-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1186%2Fs13045-016-0367-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=27931243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=137&author=S.+Verstovsekauthor=O.+Odenikeauthor=J.+W.+Singerauthor=T.+Granstonauthor=S.+Al-Fayoumiauthor=H.+J.+Deeg&title=Phase+1%2F2+study+of+pacritinib%2C+a+next+generation+JAK2%2FFLT3+inhibitor%2C+in+myelofibrosis+or+other+myeloid+malignancies&doi=10.1186%2Fs13045-016-0367-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies</span></div><div class="casAuthors">Verstovsek, Srdan; Odenike, Olatoyosi; Singer, Jack W.; Granston, Tanya; Al-Fayoumi, Suliman; Deeg, H. Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">137/1-137/12</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R.  This multicenter phase 1/2 study evaluated the max. tolerated dose (MTD), safety, and clin. activity of pacritinib in patients with myelofibrosis (MF) and other advanced myeloid malignancies.  Methods: In the phase 1 dose-escalation part of the study, 43 adults with advanced myeloid malignancies received pacritinib 100 to 600 mg once daily (QD).  In the phase 2 part of the study, 31 adults with refractory or intermediate- or high-risk newly diagnosed MF and any degree of cytopenia received pacritinib 400 mg QD.  The primary endpoint is a ≥35% redn. in spleen vol. at week 24 as detd. by magnetic resonance imaging.  Results: Five patients (11.6%) experienced a dose-limiting toxicity during cycle 1 of phase 1.  The clin. benefit rate was 86.0% (13 patients achieving clin. improvement and 24 patients having stable disease).  The MTD was established at 500 mg QD, and the recommended phase 2 dose was 400 mg QD.  In phase 2, the primary endpoint was achieved by 23.5% of evaluable patients (4/17), with 47.4% (9/19) achieving a ≥50% spleen length redn. at week 24 as measured by phys. examn.  At week 24, 38.9% of evaluable patients (7/18) achieved a ≥50% decrease in MF Quality of Life and Symptom Assessment total score.  Gastrointestinal toxicities were the most common adverse events and were predominantly grade 1/2 in severity.  Grade 3/4 anemia was reported in 5/31 patients and grade 3/4 thrombocytopenia was reported in 3/31 patients.  The most frequent AEs considered to be treatment related were diarrhea (28/31), nausea (15/31), vomiting (9/31), and fatigue (4/31).  Grade 3 treatment-related AEs were reported in seven patients (22.6%), four of whom had diarrhea.  No grade 4/5 treatment-related AEs were reported.  No leukopenia, neutropenia, or lymphopenia were reported.  Conclusions: Pacritinib was well tolerated and demonstrated clin. activity in MF.  The study suggests that pacritinib has unique characteristics, namely a lack of substantial myelosuppression and manageable side effects, making it an attractive target for further evaluation in MF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogL-MeJzFd-rVg90H21EOLACvtfcHk0lhsfIwB35VAKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVylsLY%253D&md5=98d67cff6441e0219ba7d333ef049016</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0367-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0367-x%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DOdenike%26aufirst%3DO.%26aulast%3DSinger%26aufirst%3DJ.%2BW.%26aulast%3DGranston%26aufirst%3DT.%26aulast%3DAl-Fayoumi%26aufirst%3DS.%26aulast%3DDeeg%26aufirst%3DH.%2BJ.%26atitle%3DPhase%25201%252F2%2520study%2520of%2520pacritinib%252C%2520a%2520next%2520generation%2520JAK2%252FFLT3%2520inhibitor%252C%2520in%2520myelofibrosis%2520or%2520other%2520myeloid%2520malignancies%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D137%26doi%3D10.1186%2Fs13045-016-0367-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4638</span>– <span class="NLM_lpage">4658</span>, <span class="refDoi"> DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.-H.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+Macrocycle+11-%282-Pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+Potent+Janus+Kinase+2%2FFms-Like+Tyrosine+Kinase-3+%28JAK2%2FFLT3%29+Inhibitor+for+the+Treatment+of+Myelofibrosis+and+Lymphoma&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0lgJ2IMtsES51A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.-H.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520Macrocycle%252011-%25282-Pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520Potent%2520Janus%2520Kinase%25202%252FFms-Like%2520Tyrosine%2520Kinase-3%2520%2528JAK2%252FFLT3%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Myelofibrosis%2520and%2520Lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchemin, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusewitt, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briesewitz, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">2075</span>– <span class="NLM_lpage">2083</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-02-071266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2007-02-071266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=17537993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2075-2083&author=L.+Wangauthor=J.+Wangauthor=B.+W.+Blaserauthor=A.-M.+Ducheminauthor=D.+F.+Kusewittauthor=T.+Liuauthor=M.+A.+Caligiuriauthor=R.+Briesewitz&title=Pharmacologic+inhibition+of+CDK4%2F6%3A+mechanistic+evidence+for+selective+activity+or+acquired+resistance+in+acute+myeloid+leukemia&doi=10.1182%2Fblood-2007-02-071266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span></div><div class="casAuthors">Wang, Lisheng; Wang, Jie; Blaser, Bradley W.; Duchemin, Anne-Marie; Kusewitt, Donna F.; Liu, Tom; Caligiuri, Michael A.; Briesewitz, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2075-2083</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Entry into the cell cycle is mediated by cyclin-dependent kinase 4/6 (CDK4/6) activation, followed by CDK2 activation.  We found that pharmacol. inhibition of the Flt3 internal tandem duplication (ITD), a mutated receptor tyrosine kinase commonly found in patients with acute myelogenous leukemia (AML), led to the down-regulation of cyclin D2 and D3 followed by retinoblastoma protein (pRb) dephosphorylation and G1 cell-cycle arrest.  This implicated the D-cyclin-CDK4/6 complex as a downstream effector of Flt3 ITD signaling.  Indeed, single-agent PD0332991, a selective CDK4/6 inhibitor, caused sustained cell-cycle arrest in Flt3 ITD AML cell lines and prolonged survival in an in vivo model of Flt3 ITD AML.  PD0332991 caused an initial cell-cycle arrest in well-established Flt3 wild-type (wt) AML cell lines, but this was overcome by down-regulation of p27Kip and reactivation of CDK2.  This acquired resistance was not obsd. in a Flt3 ITD and a Flt3 wt sample from a patient with primary AML.  In summary, the mechanism of cell-cycle arrest after treatment of Flt3 ITD AML with a Flt3 inhibitor involves down-regulation of cyclin D2 and D3.  As such, CDK4/6 can be a therapeutic target in Flt3 ITD AML but also in primary Flt3 wt AML.  Finally, acquired resistance to CDK4/6 inhibition can arise through activation CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiH_wOIP8jJLVg90H21EOLACvtfcHk0lgJ2IMtsES51A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK&md5=5f68ef6deacf3789e428731722f8c5ff</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-02-071266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-02-071266%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBlaser%26aufirst%3DB.%2BW.%26aulast%3DDuchemin%26aufirst%3DA.-M.%26aulast%3DKusewitt%26aufirst%3DD.%2BF.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DBriesewitz%26aufirst%3DR.%26atitle%3DPharmacologic%2520inhibition%2520of%2520CDK4%252F6%253A%2520mechanistic%2520evidence%2520for%2520selective%2520activity%2520or%2520acquired%2520resistance%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2075%26epage%3D2083%26doi%3D10.1182%2Fblood-2007-02-071266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, M. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGraffenreid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deignan, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaizerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lively, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihalic, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchomel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3430</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Choauthor=R.+V.+Connorsauthor=M.+DeGraffenreidauthor=J.+T.+Deignanauthor=J.+Duquetteauthor=P.+Fanauthor=B.+Fisherauthor=J.+Fuauthor=J.+N.+Huardauthor=J.+Kaizermanauthor=K.+S.+Keeganauthor=C.+Liauthor=K.+Liauthor=Y.+Liauthor=L.+Liangauthor=W.+Liuauthor=S.+E.+Livelyauthor=M.-C.+Loauthor=J.+Maauthor=D.+L.+McMinnauthor=J.+T.+Mihalicauthor=K.+Modiauthor=R.+Ngoauthor=K.+Pattabiramanauthor=D.+E.+Piperauthor=C.+Quevaauthor=M.+L.+Ragainsauthor=J.+Suchomelauthor=S.+Thibaultauthor=N.+Walkerauthor=X.+Wangauthor=Z.+Wangauthor=M.+Wanskaauthor=P.+M.+Wehnauthor=M.+F.+Weidnerauthor=A.+J.+Zhangauthor=X.+Zhaoauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Daiauthor=L.+R.+McGeeauthor=J.+C.+Medina&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+dual+kinase+inhibitor+with+preferential+affinity+for+the+activated+state+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0lgDCVBhyKt70w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DConnors%26aufirst%3DR.%2BV.%26aulast%3DDeGraffenreid%26aufirst%3DM.%26aulast%3DDeignan%26aufirst%3DJ.%2BT.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DHuard%26aufirst%3DJ.%2BN.%26aulast%3DKaizerman%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLively%26aufirst%3DS.%2BE.%26aulast%3DLo%26aufirst%3DM.-C.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DMihalic%26aufirst%3DJ.%2BT.%26aulast%3DModi%26aufirst%3DK.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPattabiraman%26aufirst%3DK.%26aulast%3DPiper%26aufirst%3DD.%2BE.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DRagains%26aufirst%3DM.%2BL.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWanska%26aufirst%3DM.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520dual%2520kinase%2520inhibitor%2520with%2520preferential%2520affinity%2520for%2520the%2520activated%2520state%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uras, I. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheicher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellutti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prchal-Murphy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tigan, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubicek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexl, V.</span></span> <span> </span><span class="NLM_article-title">Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">2890</span>– <span class="NLM_lpage">2902</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-11-683581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2015-11-683581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=27099147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ars7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=2890-2902&author=I.+Z.+Urasauthor=G.+J.+Walterauthor=R.+Scheicherauthor=F.+Belluttiauthor=M.+Prchal-Murphyauthor=A.+S.+Tiganauthor=P.+Valentauthor=F.+H.+Heidelauthor=S.+Kubicekauthor=C.+Schollauthor=S.+Fr%C3%B6hlingauthor=V.+Sexl&title=Palbociclib+treatment+of+FLT3-ITD%2B+AML+cells+uncovers+a+kinase-dependent+transcriptional+regulation+of+FLT3+and+PIM1+by+CDK6&doi=10.1182%2Fblood-2015-11-683581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6</span></div><div class="casAuthors">Uras, Iris Z.; Walter, Gina J.; Scheicher, Ruth; Bellutti, Florian; Prchal-Murphy, Michaela; Tigan, Anca S.; Valent, Peter; Heidel, Florian H.; Kubicek, Stefan; Scholl, Claudia; Froehling, Stefan; Sexl, Veronika</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2890-2902</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Up to 30% of patients with acute myeloid leukemia have constitutively activating internal tandem duplications (ITDs) of the FLT3 receptor tyrosine kinase.  Such mutations are assocd. with a poor prognosis and a high propensity to relapse after remission.  FLT3 inhibitors are being developed as targeted therapy for FLT3-ITD+ acute myeloid leukemia; however, their use is complicated by rapid development of resistance, which illustrates the need for addnl. therapeutic targets.  We show that the US Food and Drug Administration-approved CDK4/6 kinase inhibitor palbociclib induces apoptosis of FLT3-ITD leukemic cells.  The effect is specific for FLT3-mutant cells and is ascribed to the transcriptional activity of CDK6: CDK6 but not its functional homolog CDK4 is found at the promoters of the FLT3 and PIM1 genes, another important leukemogenic driver.  There CDK6 regulates transcription in a kinase-dependent manner.  Of potential clin. relevance, combined treatment with palbociclib and FLT3 inhibitors results in synergistic cytotoxicity.  Simultaneously targeting two crit. signaling nodes in leukemogenesis could represent a therapeutic breakthrough, leading to complete remission and overcoming resistance to FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsmyPMjz8SYLVg90H21EOLACvtfcHk0lgDCVBhyKt70w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ars7zP&md5=63ac18917c968342abf1600403eed3e9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-11-683581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-11-683581%26sid%3Dliteratum%253Aachs%26aulast%3DUras%26aufirst%3DI.%2BZ.%26aulast%3DWalter%26aufirst%3DG.%2BJ.%26aulast%3DScheicher%26aufirst%3DR.%26aulast%3DBellutti%26aufirst%3DF.%26aulast%3DPrchal-Murphy%26aufirst%3DM.%26aulast%3DTigan%26aufirst%3DA.%2BS.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26aulast%3DKubicek%26aufirst%3DS.%26aulast%3DScholl%26aufirst%3DC.%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DSexl%26aufirst%3DV.%26atitle%3DPalbociclib%2520treatment%2520of%2520FLT3-ITD%252B%2520AML%2520cells%2520uncovers%2520a%2520kinase-dependent%2520transcriptional%2520regulation%2520of%2520FLT3%2520and%2520PIM1%2520by%2520CDK6%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D2890%26epage%3D2902%26doi%3D10.1182%2Fblood-2015-11-683581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuzzo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minuzzo, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinazza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bresolin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Indraccolo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Accordi, B.</span></span> <span> </span><span class="NLM_article-title">Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">2750</span>– <span class="NLM_lpage">2761</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-05-784603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1182%2Fblood-2017-05-784603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=29101238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Cjur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=2750-2761&author=V.+Serafinauthor=G.+Capuzzoauthor=G.+Milaniauthor=S.+A.+Minuzzoauthor=M.+Pinazzaauthor=R.+Bortolozziauthor=S.+Bresolinauthor=E.+Porc%C3%B9author=C.+Frassonauthor=S.+Indraccoloauthor=G.+Bassoauthor=B.+Accordi&title=Glucocorticoid+resistance+is+reverted+by+LCK+inhibition+in+pediatric+T-cell+acute+lymphoblastic+leukemia&doi=10.1182%2Fblood-2017-05-784603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia</span></div><div class="casAuthors">Serafin, Valentina; Capuzzo, Giorgia; Milani, Gloria; Minuzzo, Sonia Anna; Pinazza, Marica; Bortolozzi, Roberta; Bresolin, Silvia; Porcu, Elena; Frasson, Chiara; Indraccolo, Stefano; Basso, Giuseppe; Accordi, Benedetta</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2750-2761</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Pediatric T-acute lymphoblastic leukemia (T-ALL) patients often display resistance to glucocorticoid (GC) treatment.  These patients, classified as prednisone poor responders (PPR), have poorer outcome than do the other pediatric T-ALL patients receiving a high-risk adapted therapy.  Because glucocorticoids are administered to ALL patients during all the different phases of therapy, GC resistance represents an important challenge to improving the outcome for these patients.  Mechanisms underlying resistance are not yet fully unraveled; thus our research focused on the identification of deregulated signaling pathways to point out new targeted approaches.  We first identified, by reverse-phase protein arrays, the lymphocyte cell-specific protein-tyrosine kinase (LCK) as aberrantly activated in PPR patients.  We showed that LCK inhibitors, such as dasatinib, bosutinib, nintedanib, and WH-4-023, are able to induce cell death in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC resistance, even at therapeutic drug concns.  This was confirmed by specific LCK gene silencing and ex vivo combined treatment of cells from PPR patient-derived xenografts.  Moreover, we obsd. that LCK hyperactivation in PPR patients upregulates the calcineurin/nuclear factor of activated T cells signaling triggering to interleukin-4 (IL-4) overexpression.  GC-sensitive cells cultured with IL-4 display an increased resistance to dexamethasone, whereas the inhibition of IL-4 signaling could increase GC-induced apoptosis in resistant cells.  Treatment with dexamethasone and dasatinib also impaired engraftment of leukemia cells in vivo.  Our results suggest a quickly actionable approach to supporting conventional therapies and overcoming GC resistance in pediatric T-ALL patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQm_rduInbzLVg90H21EOLACvtfcHk0lj6VyG28Mn6fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Cjur%252FL&md5=9103800c495bccdd2bac3a7f4496babb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-784603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-784603%26sid%3Dliteratum%253Aachs%26aulast%3DSerafin%26aufirst%3DV.%26aulast%3DCapuzzo%26aufirst%3DG.%26aulast%3DMilani%26aufirst%3DG.%26aulast%3DMinuzzo%26aufirst%3DS.%2BA.%26aulast%3DPinazza%26aufirst%3DM.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DBresolin%26aufirst%3DS.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DFrasson%26aufirst%3DC.%26aulast%3DIndraccolo%26aufirst%3DS.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DAccordi%26aufirst%3DB.%26atitle%3DGlucocorticoid%2520resistance%2520is%2520reverted%2520by%2520LCK%2520inhibition%2520in%2520pediatric%2520T-cell%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D2750%26epage%3D2761%26doi%3D10.1182%2Fblood-2017-05-784603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iriyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takei, M.</span></span> <span> </span><span class="NLM_article-title">Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation</span>. <i>Cancer Cell Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">37</span>, <span class="refDoi"> DOI: 10.1186/s12935-016-0314-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1186%2Fs12935-016-0314-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=27182202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVertbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=37&author=N.+Iriyamaauthor=B.+Yuanauthor=Y.+Hattaauthor=N.+Takagiauthor=M.+Takei&title=Lyn%2C+a+tyrosine+kinase+closely+linked+to+the+differentiation+status+of+primary+acute+myeloid+leukemia+blasts%2C+associates+with+negative+regulation+of+all-trans+retinoic+acid+%28ATRA%29+and+dihydroxyvitamin+D3+%28VD3%29-induced+HL-60+cells+differentiation&doi=10.1186%2Fs12935-016-0314-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation</span></div><div class="casAuthors">Iriyama, Noriyoshi; Yuan, Bo; Hatta, Yoshihiro; Takagi, Norio; Takei, Masami</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell International</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37/1-37/11</span>CODEN:
                <span class="NLM_cas:coden">CCIACC</span>;
        ISSN:<span class="NLM_cas:issn">1475-2867</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Lyn, an import member of Src family kinases (SFKs), is supposed to be implicated in acute myeloid leukemia (AML) pathogenesis and development by participation in AML differentiation, yet the details still remain incompletely understood.  The expression status of Lyn and its correlation with multiple clin. parameters including cell differentiation degree, different cytogenetic risk classification, and the activity of myeloperoxidase (MPO) were thus investigated.  To address the mechanisms underlying the involvement of Lyn in differentiation induction, the effects of dasatinib, an inhibitor for SFKs including Lyn, on the alterations of all-trans retinoic acid (ATRA)- or dihydroxyvitamin D3 (VD3)-induced differentiation, and c-Myc protein expression were investigated.  Methods: Primary AML blasts were obtained from 31 newly diagnosed AML patients with different French-American- British (FAB) subtypes.  The expression of phosphorylated and total Lyn, c-Myc, and CD11b, CD11c and CD15 was analyzed by flow cytometry.  The activation of Akt and Erk known to be involved in the regulation of c-Myc expression was investigated using western blotting.  Results: Significant higher expression levels of total Lyn were obsd. in AML patients with favorable cytogenetics, higher MPO activity and FAB M2 subtype.  A clear pos. correlation between the expression levels of Lyn and differentiation status of primary AML blasts was obsd.  Dasatinib inhibited the expression of phosphorylated Lyn, and further enhanced the differentiation-inducing activity of ATRA and VD3 in HL-60 cells.  Augmented downregulation of c-Myc protein expression was obsd. in the combination treatment with ATRA, VD3 and dasatinib compared to treatment with each reagent alone in HL-60 cells.  The suppression of the activation of Akt and Erk was also obsd. concomitantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4p0geTA5adbVg90H21EOLACvtfcHk0lj6VyG28Mn6fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVertbk%253D&md5=309998fa1ecd5d80bc459d0323a1bfeb</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1186%2Fs12935-016-0314-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12935-016-0314-5%26sid%3Dliteratum%253Aachs%26aulast%3DIriyama%26aufirst%3DN.%26aulast%3DYuan%26aufirst%3DB.%26aulast%3DHatta%26aufirst%3DY.%26aulast%3DTakagi%26aufirst%3DN.%26aulast%3DTakei%26aufirst%3DM.%26atitle%3DLyn%252C%2520a%2520tyrosine%2520kinase%2520closely%2520linked%2520to%2520the%2520differentiation%2520status%2520of%2520primary%2520acute%2520myeloid%2520leukemia%2520blasts%252C%2520associates%2520with%2520negative%2520regulation%2520of%2520all-trans%2520retinoic%2520acid%2520%2528ATRA%2529%2520and%2520dihydroxyvitamin%2520D3%2520%2528VD3%2529-induced%2520HL-60%2520cells%2520differentiation%26jtitle%3DCancer%2520Cell%2520Int.%26date%3D2016%26volume%3D16%26spage%3D37%26doi%3D10.1186%2Fs12935-016-0314-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawahara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oishi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witthuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">et, a.</span></span> <span> </span><span class="NLM_article-title">Functional activation of JAK1 and JAK3 by selective association with IL-2 receptor subunits</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>266</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1126/science.7973659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1126%2Fscience.7973659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=7973659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFyqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1994&pages=1045-1047&author=T.+Miyazakiauthor=A.+Kawaharaauthor=H.+Fujiiauthor=Y.+Nakagawaauthor=Y.+Minamiauthor=Z.+Liuauthor=I.+Oishiauthor=O.+Silvennoinenauthor=B.+Witthuhnauthor=J.+Ihleauthor=a.+et&title=Functional+activation+of+JAK1+and+JAK3+by+selective+association+with+IL-2+receptor+subunits&doi=10.1126%2Fscience.7973659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits</span></div><div class="casAuthors">Miyazaki, Takaaki; Kawahara, Atsuo; Fujii, Hodaka; Nakagawa, Yoko; Minami, Yasuhiro; Liu, Zhao-Jun; Oishi, Isao; Silvennoinen, Olli; Witthuhn, Bruce A.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue">5187</span>),
    <span class="NLM_cas:pages">1045-7</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The interleukin-2 receptor (IL-2R) consists of three subunits: the IL-2Rα, IL-2Rβ, and IL-2Rγ chains, the last of which is also used in the receptors for IL-4, IL-7, and IL-9.  Stimulation with IL-2 induces the tyrosine phosphorylation and activation of the Janus kinases Jak1 and Jak3.  Jak1 and Jak3 were selectively assocd. with "serine-rich" region of IL-2Rβ and the C-terminal region of IL-2Rγ, resp.  Both regions were necessary for IL-2 signaling.  Furthermore, Jak3-neg. fibroblasts expressing reconstituted IL-2R became responsive to IL-2 after the addnl. expression of Jak3 complementary DNA.  Thus, activation of Jak1 and Jak3 may be a key event in IL-2 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEJB1ra0tS_rVg90H21EOLACvtfcHk0lg1FNWeS-D_JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFyqs7s%253D&md5=3494ec6a9ee34fd16904fc5ef4bc3c56</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1126%2Fscience.7973659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.7973659%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DKawahara%26aufirst%3DA.%26aulast%3DFujii%26aufirst%3DH.%26aulast%3DNakagawa%26aufirst%3DY.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DOishi%26aufirst%3DI.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DWitthuhn%26aufirst%3DB.%26aulast%3DIhle%26aufirst%3DJ.%26aulast%3Det%26aufirst%3Da.%26atitle%3DFunctional%2520activation%2520of%2520JAK1%2520and%2520JAK3%2520by%2520selective%2520association%2520with%2520IL-2%2520receptor%2520subunits%26jtitle%3DScience%26date%3D1994%26volume%3D266%26spage%3D1045%26epage%3D1047%26doi%3D10.1126%2Fscience.7973659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Newen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaper, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeve, L.</span></span> <span> </span><span class="NLM_article-title">Interleukin-6-type cytokine signalling through the gp130/JAK/STAT pathway</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1042/bj3340297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1042%2Fbj3340297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=9716487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFOls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=1998&pages=297-314&author=P.+C.+Heinrichauthor=I.+Behrmannauthor=G.+Muller-Newenauthor=F.+Schaperauthor=L.+Graeve&title=Interleukin-6-type+cytokine+signalling+through+the+gp130%2FJAK%2FSTAT+pathway&doi=10.1042%2Fbj3340297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-6-type cytokine signaling through the gp 130/Jak/STAT pathway</span></div><div class="casAuthors">Heinrich, Peter C.; Behrmann, Iris; Muller-Newen, Gerhard; Schaper, Fred; Graeve, Lutz</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">297-314</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review with 225 refs.  The family of cytokines signaling through the common receptor subunit gp130 comprises interleukin (IL)-6, IL-11, leukemia inhibitory factor, oncostatin M, ciliary neurotrophic factor, and cardiotrophin-1.  These so-called IL-6-type cytokines are important in the regulation of complex cellular processes (gene activation, proliferation, and differentiation).  The authors focus here on the assembly of receptor complexes after ligand binding, the activation of receptor-assocd. kinases of the Janus family, and the recruitment and phosphorylation of transcription factors of the STAT family, which dimerize, translocate to the nucleus, and bind to enhancer elements of resp. target genes leading to transcriptional activation.  The important players in the signaling pathway, namely the cytokines and the receptor components, the Janus kinases Jak1, Jak2 and Tyk2, the signal transducers and activators of transcription STAT1 and STAT3 and the tyrosine phosphatase SHP2 are introduced and their structural/functional properties are discussed.  Furthermore, the authors discuss various mechanisms involved in the termination of the IL-6-type cytokine signaling, namely the action of tyrosine phosphatases, proteasome, Jak kinase inhibitors SOCS (suppressor of cytokine signaling), protein inhibitors of activated STATs (PIAS), and internalization of the cytokine receptors via gp130.  Although all IL-6-type cytokines signal through the gp130/Jak/STAT pathway, the comparison of their physiol. properties shows that they elicit not only similar, but also distinct, biol. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqmo0Vn2hFsbVg90H21EOLACvtfcHk0lg1FNWeS-D_JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFOls7c%253D&md5=46365a3d4092c7f3bdeb742795daaf94</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1042%2Fbj3340297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3340297%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DP.%2BC.%26aulast%3DBehrmann%26aufirst%3DI.%26aulast%3DMuller-Newen%26aufirst%3DG.%26aulast%3DSchaper%26aufirst%3DF.%26aulast%3DGraeve%26aufirst%3DL.%26atitle%3DInterleukin-6-type%2520cytokine%2520signalling%2520through%2520the%2520gp130%252FJAK%252FSTAT%2520pathway%26jtitle%3DBiochem.%2520J.%26date%3D1998%26volume%3D334%26spage%3D297%26epage%3D314%26doi%3D10.1042%2Fbj3340297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Groot, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenderman, L.</span></span> <span> </span><span class="NLM_article-title">Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">619</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1016/s0898-6568(98)00023-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1016%2Fs0898-6568%2898%2900023-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=9794243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFKqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=619-628&author=R.+P.+de%0AGrootauthor=P.+J.+Cofferauthor=L.+Koenderman&title=Regulation+of+proliferation%2C+differentiation+and+survival+by+the+IL-3%2FIL-5%2FGM-CSF+receptor+family&doi=10.1016%2Fs0898-6568%2898%2900023-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family</span></div><div class="casAuthors">De Groot, Rolf P.; Coffer, Paul J.; Koenderman, Leo</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">619-628</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 176 refs.  The receptors for the IL-3/IL-5/GM-CSF cytokine family are composed of a heterodimeric complex of a cytokine-specific α chain and a common β chain (βc).  Binding of IL-3/IL-5/GM-CSF to their resp. receptors rapidly induces activation of multiple intracellular signaling pathways, including the Ras-Raf-ERK, the JAK/STAT, the phosphatidylinositol 3-kinase PKB, and the JNK/SAPK and p38 signaling pathways.  This review focuses on recent advancements in understanding how these different signaling pathways are activated by IL-3/IL-5/GM-CSF receptors, and how the individual pathways contribute to the pleiotropic effects of IL-3/IL-5/GM-CSF on their target cells, including proliferation, differentiation, survival, and effector functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWTBwWW7K8iLVg90H21EOLACvtfcHk0lg1FNWeS-D_JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFKqt7Y%253D&md5=8efa49440eb6a80561ec7e1fa473eb74</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fs0898-6568%2898%2900023-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0898-6568%252898%252900023-0%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BGroot%26aufirst%3DR.%2BP.%26aulast%3DCoffer%26aufirst%3DP.%2BJ.%26aulast%3DKoenderman%26aufirst%3DL.%26atitle%3DRegulation%2520of%2520proliferation%252C%2520differentiation%2520and%2520survival%2520by%2520the%2520IL-3%252FIL-5%252FGM-CSF%2520receptor%2520family%26jtitle%3DCell.%2520Signalling%26date%3D1998%26volume%3D10%26spage%3D619%26epage%3D628%26doi%3D10.1016%2Fs0898-6568%2898%2900023-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plimack, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorusso, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, S. G.</span></span> <span> </span><span class="NLM_article-title">AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2013-0198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1634%2Ftheoncologist.2013-0198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=23847256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A280%3ADC%252BC3sfgtFelsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=819-820&author=E.+R.+Plimackauthor=P.+M.+Lorussoauthor=P.+McCoonauthor=W.+Tangauthor=A.+D.+Krebsauthor=G.+Curtauthor=S.+G.+Eckhardt&title=AZD1480%3A+a+phase+I+study+of+a+novel+JAK2+inhibitor+in+solid+tumors&doi=10.1634%2Ftheoncologist.2013-0198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors</span></div><div class="casAuthors">Plimack Elizabeth R; Lorusso Patricia M; McCoon Patricia; Tang Weifeng; Krebs Annetta D; Curt Gregory; Eckhardt S Gail</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">819-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD1480 is a novel agent that inhibits Janus-associated kinases 1 and 2 (JAK1 and JAK2).  The primary objective of this phase I study was to investigate the safety and tolerability of AZD1480 when administered as monotherapy to patients with solid tumors.  METHODS:  Thirty-eight patients with advanced malignancies were treated at doses of 10-70 mg once daily (QD) and 20-45 mg b.i.d.  RESULTS:  Pharmacokinetic (PK) analysis revealed rapid absorption and elimination with minimal accumulation after repeated QD or b.i.d. dosing.  Exposure increased in a dose-dependent manner from 10-50 mg.  Maximum plasma concentration (Cmax) was attained ∼1 hour after dose, and t1/2 was ∼5 hours.  Pharmacodynamic analysis of circulating granulocytes demonstrated maximum phosphorylated STAT3 (pSTAT3) inhibition 1-2 hours after dose, coincident with Cmax, and greater pSTAT3 inhibition at higher doses.  The average pSTAT3 inhibition in granulocytes at the highest dose tested, 70 mg QD, was 56% (standard deviation: ±21%) at steady-state drug levels.  Dose-limiting toxicities (DLTs) consisted of pleiotropic neurologic adverse events (AEs), including dizziness, anxiety, ataxia, memory loss, hallucinations, and behavior changes.  These AEs were generally reversible with dose reduction or treatment cessation.  CONCLUSIONS:  Whether the DLTs were due to inhibition of JAK-1/2 or to off-target effects is unknown.  The unusual DLTs and the lack of clinical activity led to discontinuation of development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0C-aojk4K4brIbt-tGZmxfW6udTcc2eazoNrmThH157ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfgtFelsA%253D%253D&md5=1fd650bdef456d9912cb84d7ae9970f1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2013-0198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2013-0198%26sid%3Dliteratum%253Aachs%26aulast%3DPlimack%26aufirst%3DE.%2BR.%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26aulast%3DMcCoon%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DKrebs%26aufirst%3DA.%2BD.%26aulast%3DCurt%26aufirst%3DG.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26atitle%3DAZD1480%253A%2520a%2520phase%2520I%2520study%2520of%2520a%2520novel%2520JAK2%2520inhibitor%2520in%2520solid%2520tumors%26jtitle%3DOncologist%26date%3D2013%26volume%3D18%26spage%3D819%26epage%3D820%26doi%3D10.1634%2Ftheoncologist.2013-0198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=21860433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=236-243&author=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=S.+Hartauthor=L.+C.+Ongauthor=Y.+K.+Lohauthor=A.+Cheongauthor=Y.+C.+Tanauthor=C.+Huauthor=R.+Jayaramanauthor=A.+D.+Williamauthor=E.+T.+Sunauthor=B.+W.+Dymockauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=F.+Burrowsauthor=J.+M.+Wood&title=TG02%2C+a+novel+oral+multi-kinase+inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+potent+anti-leukemic+properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span></div><div class="casAuthors">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A. D.; Sun, E. T.; Dymock, B. W.; Ong, K. H.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3.  It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs.  TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis.  Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02.  Comparison with ref. inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells.  In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling.  TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60).  These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clin. evaluation of TG02 in patients with advanced leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMelEE91r_BrVg90H21EOLACvtfcHk0ljhB1F-CSDCtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D&md5=30af7dc302f9c421924b5b0062e82655</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DTG02%252C%2520a%2520novel%2520oral%2520multi-kinase%2520inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520potent%2520anti-leukemic%2520properties%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D236%26epage%3D243%26doi%3D10.1038%2Fleu.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekonnen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomusange, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahaman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, S. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Highly potent, selective, and orally bioavailable 4-thiazol-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1892</span>– <span class="NLM_lpage">1915</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01670</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01670" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVers74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1892-1915&author=S.+Tadesseauthor=M.+Yuauthor=L.+B.+Mekonnenauthor=F.+Lamauthor=S.+Islamauthor=K.+Tomusangeauthor=M.+H.+Rahamanauthor=B.+Nollauthor=S.+K.+C.+Basnetauthor=T.+Teoauthor=H.+Albrechtauthor=R.+Milneauthor=S.+Wang&title=Highly+potent%2C+selective%2C+and+orally+bioavailable+4-thiazol-N-%28pyridin-2-yl%29pyrimidin-2-amine+cyclin-dependent+kinases+4+and+6+inhibitors+as+anticancer+drug+candidates%3A+design%2C+synthesis%2C+and+evaluation&doi=10.1021%2Facs.jmedchem.6b01670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation</span></div><div class="casAuthors">Tadesse, Solomon; Yu, Mingfeng; Mekonnen, Laychiluh B.; Lam, Frankie; Islam, Saiful; Tomusange, Khamis; Rahaman, Muhammed H.; Noll, Benjamin; Basnet, Sunita K. C.; Teo, Theodosia; Albrecht, Hugo; Milne, Robert; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1892-1915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin D dependent kinases (CDK4 and CDK6) regulate entry into S phase of the cell cycle and are validated targets for anticancer drug discovery.  Herein the authors detail the discovery of a novel series of 4-thiazolyl-N-(pyridin-2-yl)pyrimidin-2-amine derivs. as highly potent and selective inhibitors of CDK4 and CDK6.  Medicinal chem. optimization resulted in I, an orally bioavailable inhibitor mol. with remarkable selectivity.  Repeated oral administration of I caused marked inhibition of tumor growth in MV4-11 acute myeloid leukemia mouse xenografts without having a neg. effect on body wt. and showing any sign of clin. toxicity.  The data merit I as a clin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTYZFfCuD687Vg90H21EOLACvtfcHk0ljhB1F-CSDCtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVers74%253D&md5=9ce8385ba9c977b9dc8d6d5d03b077aa</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01670%26sid%3Dliteratum%253Aachs%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DMekonnen%26aufirst%3DL.%2BB.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DIslam%26aufirst%3DS.%26aulast%3DTomusange%26aufirst%3DK.%26aulast%3DRahaman%26aufirst%3DM.%2BH.%26aulast%3DNoll%26aufirst%3DB.%26aulast%3DBasnet%26aufirst%3DS.%2BK.%2BC.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DHighly%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%25204-thiazol-N-%2528pyridin-2-yl%2529pyrimidin-2-amine%2520cyclin-dependent%2520kinases%25204%2520and%25206%2520inhibitors%2520as%2520anticancer%2520drug%2520candidates%253A%2520design%252C%2520synthesis%252C%2520and%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1892%26epage%3D1915%26doi%3D10.1021%2Facs.jmedchem.6b01670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gucký, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Řezníčková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radošová
Muchová, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klejová, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malínková, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazgier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepšík, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divoký, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryštof, V.</span></span> <span> </span><span class="NLM_article-title">Discovery of <i>N</i><sup>2</sup>-(4-amino-cyclohexyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-(4-morpholin-4-ylmethyl-phenyl)-9<i>H</i>-purine-2,6-diamine as a potent FLT3 kinase inhibitor for acute myeloid leukemia with FLT3 mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3855</span>– <span class="NLM_lpage">3869</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01529</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01529" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVahsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3855-3869&author=T.+Guck%C3%BDauthor=E.+%C5%98ezn%C3%AD%C4%8Dkov%C3%A1author=T.+Rado%C5%A1ov%C3%A1%0AMuchov%C3%A1author=R.+Jordaauthor=Z.+Klejov%C3%A1author=V.+Mal%C3%ADnkov%C3%A1author=K.+Berkaauthor=V.+Bazgierauthor=H.+Ajaniauthor=M.+Lep%C5%A1%C3%ADkauthor=V.+Divok%C3%BDauthor=V.+Kry%C5%A1tof&title=Discovery+of+N2-%284-amino-cyclohexyl%29-9-cyclopentyl-N6-%284-morpholin-4-ylmethyl-phenyl%29-9H-purine-2%2C6-diamine+as+a+potent+FLT3+kinase+inhibitor+for+acute+myeloid+leukemia+with+FLT3+mutations&doi=10.1021%2Facs.jmedchem.7b01529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations</span></div><div class="casAuthors">Gucky, Tomas; Reznickova, Eva; Radosova Muchova, Tereza; Jorda, Radek; Klejova, Zuzana; Malinkova, Veronika; Berka, Karel; Bazgier, Vaclav; Ajani, Haresh; Lepsik, Martin; Divoky, Vladimir; Krystof, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3855-3869</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to std. cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3.  We present novel 2,6,9-trisubstituted purine derivs. with potent FLT3 inhibitory activity.  The lead compd. 7d displays nanomolar activity in biochem. assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive.  The MV4-11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis.  Addnl., a single dose of 7d in mice with s.c. MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect obsd. after administration of the ref. FLT3 inhibitor quizartinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ88Wx0YxwWLVg90H21EOLACvtfcHk0ljoWYxa4PNiOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVahsr0%253D&md5=cbc982a08f1905840e273e23c825a134</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01529%26sid%3Dliteratum%253Aachs%26aulast%3DGuck%25C3%25BD%26aufirst%3DT.%26aulast%3D%25C5%2598ezn%25C3%25AD%25C4%258Dkov%25C3%25A1%26aufirst%3DE.%26aulast%3DRado%25C5%25A1ov%25C3%25A1%2BMuchov%25C3%25A1%26aufirst%3DT.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DKlejov%25C3%25A1%26aufirst%3DZ.%26aulast%3DMal%25C3%25ADnkov%25C3%25A1%26aufirst%3DV.%26aulast%3DBerka%26aufirst%3DK.%26aulast%3DBazgier%26aufirst%3DV.%26aulast%3DAjani%26aufirst%3DH.%26aulast%3DLep%25C5%25A1%25C3%25ADk%26aufirst%3DM.%26aulast%3DDivok%25C3%25BD%26aufirst%3DV.%26aulast%3DKry%25C5%25A1tof%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520N2-%25284-amino-cyclohexyl%2529-9-cyclopentyl-N6-%25284-morpholin-4-ylmethyl-phenyl%2529-9H-purine-2%252C6-diamine%2520as%2520a%2520potent%2520FLT3%2520kinase%2520inhibitor%2520for%2520acute%2520myeloid%2520leukemia%2520with%2520FLT3%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3855%26epage%3D3869%26doi%3D10.1021%2Facs.jmedchem.7b01529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard
Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-methyl-1<i>H</i>-imidazole derivatives as potent JAK2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1021/jm401546n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401546n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=144-158&author=Q.+Suauthor=S.+Ioannidisauthor=C.+Chuaquiauthor=L.+Almeidaauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Blockauthor=T.+Howardauthor=S.+Huangauthor=D.+Huszarauthor=J.+A.+Readauthor=C.+Rivard%0ACostaauthor=J.+Shiauthor=M.+Suauthor=M.+Yeauthor=M.+Zinda&title=Discovery+of+1-methyl-1H-imidazole+derivatives+as+potent+JAK2+inhibitors&doi=10.1021%2Fjm401546n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors</span></div><div class="casAuthors">Su, Qibin; Ioannidis, Stephanos; Chuaqui, Claudio; Almeida, Lynsie; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Block, Michael; Howard, Tina; Huang, Shan; Huszar, Dennis; Read, Jon A.; Rivard Costa, Caroline; Shi, Jie; Su, Mei; Ye, Minwei; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-158</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure based design, synthesis, and biol. evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described.  Using the C-ring fragment from our first clin. candidate AZD1480 (I), optimization of the series led to the discovery of compd. II, a potent, orally bioavailable Jak2 inhibitor.  Compd. II displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells.  Compd. II demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczgU5RpFv1bVg90H21EOLACvtfcHk0ljoWYxa4PNiOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL&md5=88c57119ec77d084a91a1123fd9dea86</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm401546n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401546n%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DBlock%26aufirst%3DM.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DRivard%2BCosta%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25201-methyl-1H-imidazole%2520derivatives%2520as%2520potent%2520JAK2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D144%26epage%3D158%26doi%3D10.1021%2Fjm401546n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-chloro-<i>N</i><sup>2</sup>-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-<i>N</i><sup>4</sup>-(5-methyl-1<i>H</i>-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the JAK/STAT pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1021/jm1011319</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1011319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFarsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=262-276&author=S.+Ioannidisauthor=M.+L.+Lambauthor=T.+Wangauthor=L.+Almeidaauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=B.+Pengauthor=M.+Suauthor=H.-J.+Zhangauthor=E.+Hoffmannauthor=C.+Rivardauthor=I.+Greenauthor=T.+Howardauthor=H.+Pollardauthor=J.+Readauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Yeauthor=D.+Huszarauthor=M.+Zinda&title=Discovery+of+5-chloro-N2-%5B%281S%29-1-%285-fluoropyrimidin-2-yl%29ethyl%5D-N4-%285-methyl-1H-pyrazol-3-yl%29pyrimidine-2%2C4-diamine+%28AZD1480%29+as+a+novel+inhibitor+of+the+JAK%2FSTAT+pathway&doi=10.1021%2Fjm1011319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway</span></div><div class="casAuthors">Ioannidis, Stephanos; Lamb, Michelle L.; Wang, Tao; Almeida, Lynsie; Block, Michael H.; Davies, Audrey M.; Peng, Bo; Su, Mei; Zhang, Hai-Jun; Hoffmann, Ethan; Rivard, Caroline; Green, Isabelle; Howard, Tina; Pollard, Hannah; Read, Jon; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Ye, Min-Wei; Huszar, Dennis; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">262-276</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematol. malignancies characterized by clonal expansion of one or more myeloid lineages.  The discovery of the Jak2 V617F gain of function mutation highlighted Jak2 as a potential therapeutic target in the MPNs.  Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor.  9E inhibits signaling and proliferation of Jak2 V617F cell lines in vitro, demonstrates in vivo efficacy in a TEL-Jak2 model, has excellent phys. properties and preclin. pharmacokinetics, and is currently being evaluated in Phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMG6RQUv4HqbVg90H21EOLACvtfcHk0lhI2Hu2t3iG8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFarsr%252FN&md5=c8141c5b0e25a007e68b6e2567a576fe</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm1011319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1011319%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.-J.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DGreen%26aufirst%3DI.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DPollard%26aufirst%3DH.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25205-chloro-N2-%255B%25281S%2529-1-%25285-fluoropyrimidin-2-yl%2529ethyl%255D-N4-%25285-methyl-1H-pyrazol-3-yl%2529pyrimidine-2%252C4-diamine%2520%2528AZD1480%2529%2520as%2520a%2520novel%2520inhibitor%2520of%2520the%2520JAK%252FSTAT%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D262%26epage%3D276%26doi%3D10.1021%2Fjm1011319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasarskis, A.</span></span> <span> </span><span class="NLM_article-title">Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 ″Gatekeeper″ F691L mutation with PLX3397</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-15-0060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=10.1158%2F2159-8290.cd-15-0060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=25847190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=668-679&author=C.+C.+Smithauthor=C.+Zhangauthor=K.+C.+Linauthor=E.+A.+Lasaterauthor=Y.+Zhangauthor=E.+Massiauthor=L.+E.+Damonauthor=M.+Pendletonauthor=A.+Bashirauthor=R.+Sebraauthor=A.+Perlauthor=A.+Kasarskis&title=Characterizing+and+overriding+the+structural+mechanism+of+the+quizartinib-resistant+FLT3+%E2%80%B3Gatekeeper%E2%80%B3+F691L+mutation+with+PLX3397&doi=10.1158%2F2159-8290.cd-15-0060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397</span></div><div class="casAuthors">Smith, Catherine C.; Zhang, Chao; Lin, Kimberly C.; Lasater, Elisabeth A.; Zhang, Ying; Massi, Evan; Damon, Lauren E.; Pendleton, Matthew; Bashir, Ali; Sebra, Robert; Perl, Alexander; Kasarskis, Andrew; Shellooe, Rafe; Tsang, Garson; Carias, Heidi; Powell, Ben; Burton, Elizabeth A.; Matusow, Bernice; Zhang, Jiazhong; Spevak, Wayne; Ibrahim, Prabha N.; Le, Mai H.; Hsu, Henry H.; Habets, Gaston; West, Brian L.; Bollag, Gideon; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">668-679</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PLX3397 inhibits the growth of quizartinib-resistant FLT3-ITD+ AML cells expressing the gatekeeper F691L mutation in vitro and in vivo, but not cells expressing kinase domain mutations in the FLT3 activation loop.  Tyrosine kinase domain mutations are a common cause of acquired clin. resistance to tyrosine kinase inhibitors (TKI) used to treat cancer, including the FLT3 inhibitor quizartinib.  Mutation of kinase "gatekeeper" residues, which control access to an allosteric pocket adjacent to the ATP-binding site, has been frequently implicated in TKI resistance.  The mol. underpinnings of gatekeeper mutation-mediated resistance are incompletely understood.  We report the first cocrystal structure of FLT3 with the TKI quizartinib, which demonstrates that quizartinib binding relies on essential edge-to-face arom. interactions with the gatekeeper F691 residue, and F830 within the highly conserved Asp-Phe-Gly motif in the activation loop.  This reliance makes quizartinib critically vulnerable to gatekeeper and activation loop substitutions while minimizing the impact of mutations elsewhere.  Moreover, we identify PLX3397, a novel FLT3 inhibitor that retains activity against the F691L mutant due to a binding mode that depends less vitally on specific interactions with the gatekeeper position.  Significance: We report the first cocrystal structure of FLT3 with a kinase inhibitor, elucidating the structural mechanism of resistance due to the gatekeeper F691L mutation.  PLX3397 is a novel FLT3 inhibitor with in vitro activity against this mutation but is vulnerable to kinase domain mutations in the FLT3 activation loop.  Cancer Discov; 5(6); 668-79. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9oYwTJ6cznrVg90H21EOLACvtfcHk0lhI2Hu2t3iG8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D&md5=7e76b2892a49a6e4701f534fce212ca4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.cd-15-0060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.cd-15-0060%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMassi%26aufirst%3DE.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DBashir%26aufirst%3DA.%26aulast%3DSebra%26aufirst%3DR.%26aulast%3DPerl%26aufirst%3DA.%26aulast%3DKasarskis%26aufirst%3DA.%26atitle%3DCharacterizing%2520and%2520overriding%2520the%2520structural%2520mechanism%2520of%2520the%2520quizartinib-resistant%2520FLT3%2520%25E2%2580%25B3Gatekeeper%25E2%2580%25B3%2520F691L%2520mutation%2520with%2520PLX3397%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D668%26epage%3D679%26doi%3D10.1158%2F2159-8290.cd-15-0060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4','PDB','2XA4'); return false;">PDB: 2XA4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7','PDB','4RT7'); return false;">PDB: 4RT7</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i75"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01348">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_27143"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b01348">10.1021/acs.jmedchem.9b01348</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Binding affinities of <b>18e</b> with 100 protein kinases; antiproliferative activity of <b>18e</b> against a panel of human tumor cell lines; antiproliferative activity of <b>18e</b> against a panel of human normal cell lines; 50 ns molecular dynamics simulation result of <b>18e</b>; histogram data of flow cytometry after cytokine stimulation in the presence of <b>18e</b>; western blot analysis of STAT phosophorylation after treatment with <b>18e</b> in different cells (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Details of various compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_002.csv">CSV</a>)</p></li><li><p class="inline">PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a> was used for modeling docking in JAK2 of <b>18e</b>. The authors will release the atomic coordinates and experimental data upon article publication (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_003.pdb">PDB</a>)</p></li><li><p class="inline">PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a> was used for modeling docking in FLT3 of <b>18e</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Molecule A-FLT3-4RT7 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Molecule A-JAK2-2XA4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_006.pdb">PDB</a>)</p></li><li><p class="inline">Molecule B-FLT3-4RT7 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_007.pdb">PDB</a>)</p></li><li><p class="inline">Molecule B-JAK2-2XA4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_008.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_001.pdf">jm9b01348_si_001.pdf (819.59 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_002.csv">jm9b01348_si_002.csv (4.32 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_003.pdb">jm9b01348_si_003.pdb (504.91 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_004.pdb">jm9b01348_si_004.pdb (742.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_005.pdb">jm9b01348_si_005.pdb (502.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_006.pdb">jm9b01348_si_006.pdb (736.61 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_007.pdb">jm9b01348_si_007.pdb (502.99 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01348/suppl_file/jm9b01348_si_008.pdb">jm9b01348_si_008.pdb (741.02 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01348%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01348" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797992bd33193d","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
